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Abstract 
 
Leishmania infantum is a parasite that maintains its life cycle by alternating between 
an extracellular flagellated promastigote in the gut of phlebotomine insects and an 
intracellular non-flagellated amastigote inside the macrophages of mammalian hosts. This 
protozoan causes visceral leishmaniasis in children and immunosuppressed individuals, a 
disease to which there are no adequate means of prevention and treatment. Hence, the 
improvement of our knowledge on the mechanisms of host resistance to L.infantum is 
imperative to contribute to the development of novel therapeutic strategies.  
Recent studies have evidenced the key role played by iron metabolism in the host-
pathogen interplay. Both the host and pathogen require iron to perform the most basic 
cellular functions, but are vulnerable to iron-induced toxicity. In this work, we studied the 
effects of iron supplementation or deprivation on the in vivo growth of L.infantum. We 
found that dietary iron deficiency did not affect L.infantum growth, whereas iron overload 
decreased its proliferation in the liver and spleen of a susceptible mouse strain. The anti-
leishmanial action of iron was abrogated in mice genetically deficient in the NADPH 
oxidase or nitric oxide synthase 2, the phagocytic enzyme complexes responsible for the 
generation of microbicidal reactive oxygen and nitrogen species (ROS and RNS), 
respectively. This suggested that iron inhibited the growth of L.infantum in the mouse 
tissues via interaction with ROS and RNS. Iron overload did not significantly influence the 
mouse adaptive immune response to L.infantum. We also described that iron inhibited, in 
a dose dependent manner, the growth of axenic cultures of L.infantum promastigotes and 
amastigotes. So, from these results, we inferred that iron synergizes with the host’s 
oxidative mechanisms of defense against L.infantum.  
Such observations prompted us to further characterize the relative contribution of 
those antimicrobial mechanisms to the control of L.infantum infection in the mouse. We 
established that NADPH oxidase, and hence ROS, were critical to restrain the initial 
establishment of L.infantum in the spleen and to control late infection in the liver. 
Contrariwise, nitric oxide synthase 2 and RNS did not confer protection against the 
parasite in both tissues at any stage of the infection. Hence, we provided evidence that 
ROS, but not RNS, are the critical host effector molecules involved in the restrain of 
L.infantum in the murine model.  
In this connection, drugs that act by inducing the generation of pernicious ROS in 
target pathogens, such as the anti-malarial primaquine (PQ) and its analogues, might be 
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efficacious agents against L.infantum. Although PQ exhibits activity against visceral 
Leishmania species, it is not used in the clinical setting of visceral leishmaniasis. This is, 
in part, ascribed to the propensity of the aliphatic amine of PQ to undergo oxidative 
deamination in vivo, which consequently causes its inactivation. Such limitation can be 
overcome by the protection of the PQ’s aliphatic amine with a peptidomimetic 
(imidazolidin-4-one) or organometallic (ferrocene) moiety. Here in, we tested the activity of 
PQ derivatives containing such substituents against both life stages of L.infantum. One of 
the peptidomimetic (3c) and one of the organometallic (7a) derivatives of PQ were active 
against the disease-causing intramacrophagic amastigote stage of the parasite. 
Furthermore, 3c and 7a were less cytotoxic towards host cells than reference drugs 
sitamaquine or miltefosine. Therefore, both these PQ derivatives constitute candidate 
leads for the development of new and safer anti-leishmanials.  
In summary, the work presented in this PhD dissertation might contribute to a better 
understanding of the mechanisms of host resistance to L.infantum and to the development 
of improved therapeutic agents for the treatment of visceral leishmaniasis. 
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Resumo 
 
Leishmania infantum é um parasita que mantém o seu ciclo de vida alternando 
entre a forma extracelular promastigota, presente no sistema digestivo de insectos 
flebotomíneos, e a forma intracelular amastigota, que reside em macrófagos dos 
hospedeiros mamíferos. Este protozoário causa leishmaniose visceral em crianças e 
indivíduos imuno-suprimidos, uma doença para a qual não existem meios adequados de 
prevenção e tratamento. Conhecer os mecanismos de resistência do hospedeiro à 
infecção por L.infantum poderá contribuir para o desenvolvimento de novas estratégias 
terapêuticas.  
Estudos recentes têm evidenciado o papel crucial do metabolismo do ferro na 
relação entre os hospedeiros e os patogénios. Tanto o hospedeiro como o patogénio 
necessitam de ferro para executarem as suas funções celulares básicas, sendo no 
entanto vulneráveis à toxicidade induzida por este metal. Neste trabalho, estudámos os 
efeitos de suplementar ou privar o hospedeiro de ferro no crescimento de L.infantum no 
modelo ratinho. Verificámos que a deprivação de ferro não afetou o crescimento de 
L.infantum, enquanto que a sobrecarga de ferro diminuiu a proliferação deste parasita no 
fígado e no baço de uma estirpe de ratinho suscetível à infeção. O efeito inibitório da 
sobrecarga de ferro foi abolido em ratinhos geneticamente deficientes na oxidase do 
NADPH ou sintase do óxido nítrico 2, que são complexos enzimáticos dos fagócitos 
responsáveis pela síntese de espécies reativas de oxigénio e azoto (ROS e RNS), 
respetivamente. Este facto sugeriu que o ferro inibiu o crescimento de L.infantum nos 
tecidos do ratinho através da interação com ROS e RNS. Adicionalmente, demonstrámos 
que a sobrecarga de ferro não influenciou significativamente a resposta imune adaptativa 
do ratinho à infeção por L.infantum. Também mostrámos que o ferro inibiu, de um modo 
dependente da dose, o crescimento de culturas axénicas de promastigotas e amastigotas 
de L.infantum. Assim, estes resultados permitiram-nos inferir que o ferro atua em sinergia 
com os mecanismos oxidativos do hospedeiro usados na defesa contra L.infantum. 
As observações anteriores incitaram-nos a caracterizar mais extensivamente a 
contribuição relativa destes mecanismos anti-microbianos para o controlo da infeção 
causada por L.infantum no ratinho. Estabelecemos que a oxidase do NADPH, e portanto 
as ROS, foram essenciais para restringir o estabelecimento da infeção por L.infantum no 
baço e para controlar a infeção tardia no fígado. Pelo contrário, a sintase do óxido nítrico 
2 e as RNS não conferiram proteção contra o parasita em qualquer fase da infeção nos 
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dois tecidos. Concluímos pois que as ROS, mas não as RNS, são as moléculas 
microbicidas envolvidas na restrição da infeção por L.infantum no hospedeiro murino.  
Tendo em conta esta conclusão, é possível que drogas que atuem nos patogénios 
alvo induzindo a formação de ROS, como é o caso do anti-malárico primaquina (PQ) e 
seus análogos, possam ser agentes eficazes contra L.infantum. Apesar de a PQ exibir 
atividade contra espécies viscerais de Leishmania, não é utilizada como tratamento da 
leishmaniose visceral. Isso deve-se, em parte, à propensão da amina alifática da PQ para 
sofrer oxidação desaminativa in vivo, o que conduz consequentemente à sua inativação. 
Esta limitação pode ser contornada através da proteção da amina alifática da PQ com um 
grupo péptido-mimético (imidazolidin-4-ona) ou organometálico (ferroceno). Neste 
trabalho, testámos a atividade de derivados da PQ, contendo estes substituintes, em 
ambas as fases de L.infantum. Observámos que um derivado da PQ péptido-mimético 
(3c) e um organometálico (7a) foram ativos contra a fase clinicamente relevante do 
parasita, o amastigota intramacrofágico. Observámos ainda, que os compostos 3c e 7a 
foram menos tóxicos para as células hospedeiras do que as drogas de referência 
sitamaquina ou miltefosina. Concluímos assim, que ambos os derivados da PQ poderão 
constituir estruturas-base para o desenvolvimento de novos agentes anti-Leishmania com 
reduzida toxicidade.  
Em suma, os resultados apresentados nesta dissertação de doutoramento poderão 
contribuir para a melhor compreensão dos mecanismos de resistência do hospedeiro à 
L.infantum e para a descoberta de agentes terapêuticos mais eficazes no tratamento da 
doença provocada por este protozoário. 
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Chapter I | General Introduction 
 
1. Leishmaniasis 
1.1. General considerations 
The leishmaniases are a complex of mammalian diseases characterized by distinct 
clinical manifestations: cutaneous (CL), mucocutaneous (MCL) and visceral leishmaniasis 
(VL). These are caused by protozoa of the genus Leishmania, that belong to the 
Trypanosomatidae family and Kinetoplastida order [1,2]. Natural transmission of the 
parasite occurs by the bite of female insects of the genera Phlebotomus (Old World) or 
Lutzomyia (New World), from the Psychodidae family and Diptera order [1,3]. The 
transmission of Leishmania parasites mediated by the sandfly may be zoonotic - from 
animal reservoir to humans - or anthroponotic - between humans without involvement of 
an animal reservoir. In the former, reservoir hosts include rodents, dogs and wild canids 
[1,4]. Leishmania parasites have a digenetic life cycle, alternating between the 
promastigote stage in the insect gut and the amastigote stage in macrophages of 
mammalian hosts [5]. 
The World Health Organization estimates that leishmaniasis is endemic in 98 
territories, where more than 350 million people are at risk of acquiring infection. Globally, 
the incidence of the disease is 2 million new cases per year, with 0.5 and 1.5 million cases 
of VL and CL, respectively [4]. VL alone is responsible for nearly 50,000 annual deaths, a 
rate exceeded only by malaria amongst parasitic diseases [4]. However, these figures are 
largely underestimated since official notification of the disease is not compulsory in many 
endemic countries and the disease is often either undiagnosed or misdiagnosed [6,7]. 
Leishmaniasis is generally regarded as a neglected tropical disease, being strongly 
associated to poverty. Within many endemic areas, increased infection risk is due to poor 
housing and sanitation conditions, household crowding and lack of personal protective 
measures. Migration driven by economic reasons or military conflicts can expose 
susceptible individuals to infected sandflies [8]. In addition, undernourishment [9,10] and 
co-infection with the human immunodeficiency virus (HIV) [11] increases the probability of 
developing clinically expressed VL. Lastly, diagnosis and treatment are expensive and 
often delayed due to difficult access to health care facilities [8].  
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1.2. Clinical presentations  
CL is characterized by the appearance of skin lesions at the sites of parasite 
inoculation, which slowly evolve from papules to nodules and in some circumstances to 
ulcers. The latter have a central depression and an indurated border that heals 
spontaneously but leaves permanent disfiguring scars [2,4]. Numerous nodular or 
ulcerated lesions can also be found in disseminated CL [4]. While in the Old World, CL is 
caused by L.tropica, L.major and L.aethiopica (L.infantum and L.donovani are also 
implicated), in the New World it is caused by L.mexicana, L.braziliensis, L.panamensis, 
L.guyanensis, L.amazonensis, L.peruviana or L.infantum [2,4]. However, new papules can 
appear in the vicinity of healed lesions typically caused by L.tropica, a condition known as 
leishmaniasis recidivans [2,4]. Moreover, non-ulcerative and non-healing lesions are 
spread throughout the body in diffuse CL (DCL), with frequent relapses occurring after 
treatment [4,6]. This form of CL is caused by L.aethiopica in the Old World and 
L.mexicana and L.amazonensis in the New World [4]. Most CL cases occur in Central and 
West Asia, North and East Africa, as well as in South America [4,6,12]. 
MCL is caused by lymphatic or hematogenous dissemination of the parasite from 
the skin to the oral, nasal and pharyngeal cavities, resulting in their severe mutilation and 
destruction [2,4,6]. This form of the disease seldom heals spontaneously and is mainly 
caused by L.braziliensis, L.guyanensis and L.panamensis, present in the New World. 
Most MCL cases are reported in South America [4]. In the Old World, MCL is rare but can 
be caused by L.infantum, L.donovani, L.major and L.tropica [4,6].  
VL is a systemic infection, nearly always fatal if left untreated. The disease may be 
asymptomatic, oligosymptomatic or fully established. Active VL comprises a wide range of 
clinical symptoms characterized by undulating fever, diarrhoea, severe cachexia, 
hepatosplenomegaly, lymphadenopathy, hypergammaglobulinaemia, pancytopenia and 
hypoalbuminaemia [2,4,13]. Moreover, a dermal manifestation termed post kala-azar 
dermal leishmaniasis (PKDL) may develop after treatment of VL. Patients with PKDL may 
constitute reservoirs for VL because their skin lesions contain numerous parasites 
[2,6,13]. In the Old World, VL is caused by L.donovani and L.infantum, whereas in the 
New World it is caused by L.infantum (synonymous to L.chagasi [14,15]) [4]. L.infantum 
affects mostly children (< 5 years) and immunosuppressed adult individuals, whereas 
L.donovani affects all age groups (median, 13-23 years) [4]. The majority of VL cases 
occur in the Indian Subcontinent, East Africa, Mediterranean Basin, Middle East, West 
Asia and South America [4,6,13].  
Canine leishmaniasis is a systemic disease manifested by non-specific clinical 
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signs, including loss of weight, cutaneous and mucosal lesions, lymphadenopathy, 
splenomegaly, fever, vomiting, polyuria, chronic renal failure, hyperglobulinemia, 
pancytopenia, hypoalbuminemia and ocular, vascular and neurological disorders. It is 
usually caused by L.infantum and can be present in the Mediterranean Basin, Africa, Asia 
and the American continent [16].   
In Portugal, the dog is considered a host and a major reservoir of L.infantum [1], the 
prevalence of canine leishmaniasis being estimated at up to 20% in endemic regions 
[17,18]. In this country, the number of reported cases of human leishmaniasis is estimated 
at 15 cases per year [18,19,20]. Though human VL in Portugal has been considered 
predominantly an infantile disease, since the advent of HIV, a tendency to decrease 
children cases and increase infection in adults has been observed [17].  
 
1.3. Diagnosis 
The classical diagnosis method of leishmaniasis is microscopic visualization of 
Leishmania amastigotes in Giemsa stained samples (spleen, bone marrow and lymph 
node aspirates or skin). The more sensitive parasite culture from these samples is time-
consuming and expensive, with contamination risks associated. In addition, the collection 
and management of biological samples demands well-equipped facilities and technical 
expertise and may be painful or life threatening for the patients [12,21,22]. Thus, non-
invasive methods are more suited for routine diagnosis.  
Serological diagnosis can be performed by indirect fluorescence antibody test, 
enzyme linked immunosorbent assay and western blot. These tests detect antibodies 
present in blood or serum, which can recognize a variety of Leishmania antigens with high 
sensitivity and specificity; yet, their application requires laboratory settings [13,21]. To 
overcome such drawback, freeze-dried or fast agglutination tests and the rK39 
immunochromatographic strip test have been adapted to easily and rapidly diagnose VL in 
field conditions [23]. Nonetheless, serological tests are unreliable in CL patients due to 
their low or undetectable antibody levels [12,24]. Moreover, these tests do not readily 
discriminate between active, asymptomatic or past VL infection, since anti-leishmanial 
antibodies are easily detected in these three conditions [13,25,26]. This limitation can be 
theoretically overcome by antigen detection tests, which directly correlate antigen levels 
with parasite load or disease progression [21]. The latex agglutination test employs latex 
beads coated with antibodies to detect a leishmanial glycoconjugate antigen in the urine 
of VL patients with good specificity, but this test requires sensitivity improvement [23,27].  
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The intradermal or Montenegro skin test consists in the injection of Leishmania 
antigen or killed intact parasites into the patients’ forearm and measurement of the local 
induration of the skin 48 or 72 hours later [12,28]. This test is negative in acute cases of 
VL due to impaired T cell mediated immunity, but is positive after cure, allowing the 
identification of people previously exposed to the parasites [28]. Such distinction is 
problematic in CL patients because T cell mediated immunity usually also develops during 
active infection [12,24]. 
Polymerase chain reaction based techniques, which amplify Leishmania DNA, can 
be used in the diagnosis of all forms of leishmaniasis. They are sensitive, specific and 
allow rapid parasite load quantification and species identification in diverse samples 
[12,21,22]. High cost and technical complexity restrict its use to laboratories, but field 
application is being developed [21,22]. 
Combination or improvement of available diagnostic tests should permit an accurate 
diagnosis of leishmaniasis and prompt initiation of therapy. New tests are needed and 
they ought to be rapid, simple, affordable, field applicable, sensitive and specific, allowing 
discrimination between current, subclinical and past infections [13,21,22]. 
 
1.4. Treatment 
1.4.1. Current therapeutic modalities 
Priority has been given to the development and clinical implementation of drugs to 
treat VL, due to the associated high mortality rates of this form of leishmaniasis [21]. 
Although not fatal, CL is treated to hasten cure, decrease scar advance and to prevent 
parasite spreading or relapse [12].  
The pentavalent antimonials (SbV) have been used in the treatment of VL, CL and 
MCL for more than 60 years [12,21]. They are affordable and highly effective in many 
endemic areas, but their use was discontinued in the Indian Bihar State due to escalating 
L.donovani resistance [29], a problem attributed to drug misuse. Besides, SbV present 
several disadvantages such as painful intramuscular or intravenous administration, 
prolonged treatment and toxicity (cardiac arrhythmias and pancreatitis) [21]. It is accepted 
that SbV are pro-drugs that require reduction to trivalent antimonials (SbIII) to become 
active. They act, in part, by interfering with the antioxidant defense system of both stages 
of L.donovani: SbIII induce efflux of reduced trypanothione (T(SH)2, the major thiol in 
Leishmania) and inhibit trypanothione reductase (TR), thus favouring intracellular 
accumulation of oxidized trypanothione (TS2) [30,31]. Consequently, uncontrolled 
oxidative metabolism leads to an apoptotic-like cell death of the parasite [32]. Therefore, it 
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is not surprising that resistance to SbIII correlates with increased levels of T(SH)2 [33], TR 
[34] and enzymes involved in the T(SH)2 biosynthetic pathway [35,36] and ROS 
detoxification [37]. Finally, other mechanisms such as decreased drug uptake or 
increased efflux/sequestration of the drug may be involved in SbIII resistance [38,39]. 
Pentamidine, an aromatic diamidine, is used only as a second line treatment for VL, 
CL and DCL [39] due to its serious adverse effects (insulin-dependent diabetes mellitus, 
shock, hypoglycaemia and death), high cost and declined efficacy over the years [21]. 
This drug induces alkalization of acidocalcisomes [40] and accumulates in mitochondria 
[41], causing collapse of membrane potential [42] and fragmentation of kinetoplastid DNA 
[43]. Resistance correlates with reduced pentamidine uptake and accumulation in the 
mitochondria, as well as with increased drug efflux from L.mexicana promastigotes [41].  
Amphotericin B (AmB), a polyene macrolide antibiotic, is used as a first-line drug in 
areas of high unresponsiveness to SbV. Although AmB is affordable and highly effective, it 
requires lengthy intravenous administration, hospitalization and causes infusion-related 
side effects (fever, chills, nephrotoxicity and hypokalemia) [21]. The safer lipid 
formulations of AmB are the drugs of choice for VL treatment in developed countries, 
though elevated cost precludes their use in poor countries [21]. Infusion of these 
formulations delivers AmB to tissue macrophages [21,44]. There, AmB binds to ergosterol 
present in Leishmania surface membrane and forms transmembrane channels, which 
affect membrane-bound enzymes and allow permeability to cations, water and glucose 
[45]. Although resistance to AmB is rarely reported [38], L.donovani promastigotes are 
able to resist its action by substituting membrane ergosterol by one of its precursors [46]. 
The aminoglycoside antibiotic paromomycin is effective against CL and VL [39], well 
tolerated and inexpensive, but requires intramuscular administration [47]. This molecule 
induces mitochondrial membrane depolarization and inhibits cytoplasmic and 
mitochondrial protein synthesis in Leishmania promastigotes [48], by binding to and 
interfering with the ribosome function [49]. Such effects together with drug uptake are less 
pronounced in L.donovani resistant promastigotes [48]. 
Miltefosine (hexadecylphosphocoline) is the only highly effective oral drug for the 
treatment of VL and CL [50], including cases unresponsive to SbV. Although miltefosine is 
relatively safe, it exhibits teratogenic potential [21,51]. This molecule causes mitochondrial 
membrane depolarization, decreases oxygen consumption and ATP cytosolic levels and 
inhibits mitochondrial cytochrome c oxidase in L.donovani promastigotes [52]. Besides, it 
alters the phospholipid and sterol content of promastigote membranes [53]. Despite 
miltefosine’s high efficacy, major concerns on the development of resistance have been 
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raised because of drug misuse, its long half-life and easiness to experimentally induce 
resistance [21]. The decreased drug internalization by resistant L.donovani parasites 
[54,55] is due to defects in the function of the miltefosine translocation machinery, which is 
normally present at the plasma membrane [56,57]. In addition, resistant promastigotes 
can change the lipid composition of the surface membrane to impede miltefosine binding 
[58] or they can efflux the drug through the action of ABC-like transporters [59,60]. 
The treatment of CL and MCL can also be achieved, with variable efficacy, by the 
use of azoles, azithromycin, allopurinol, dapsone, rifampicin or imiquimod, either by 
parenteral or topical administration [12]. 
 
1.4.2. Developing new chemotherapeutics for VL: primaquine derivatives 
The abovementioned drugs present several drawbacks, such as parasite resistance, 
specific toxicities, elevated costs, prolonged treatment regimens and painful 
administration routes that lead to treatment rejection by the patients. Hence, alternative 
drugs with improved therapeutic effectiveness and strategies to preserve the efficacy of 
the available ones are urgently required [21,38,61]. Many classes of compounds are being 
recently developed for the treatment of VL, including 2-quinolines, buparvaquone, 
alternative AmB formulations and 8-aminoquinolines (8-AQs) [21,50]. The latter are a 
promising class of drugs for the oral treatment of malaria, Pneumocystis jirovecii 
pneumonia, trypanosomiasis and leishmaniasis [62].  
One of the 8-AQ members, sitamaquine, is currently being tested for the oral 
treatment of VL (completed phase IIb clinical trials). However, this drug presents variable 
efficacy and serious side effects (dyspepsia, vomiting, abdominal pain, headache, 
nephrotoxicity, cyanosis and methemoglobinemia) [63,64,65,66,67]. Sitamaquine crosses 
the L.donovani promastigote plasma membrane via electrostatic and hydrophobic 
interactions with phospholipids [68,69]. Then, it rapidly accumulates in and alkalizes the 
acidocalcisomes [40], although this process appears to be unrelated to its lethal action 
[70]. Moreover, sitamaquine inhibits mitochondrial succinate dehydrogenase and causes 
respiratory dysfunctions, which consequently trigger oxidative stress that leads to 
apoptosis-like death of L.donovani promastigotes [42,71]. Resistance to sitamaquine can 
be experimentally induced in both parasite stages [72] and is possibly owed to drug efflux 
by an ABCG-like transporter [59]. 
Primaquine (PQ, A in Figure 1), a well known anti-malarial 8-AQ, also displays 
activity against visceral Leishmania species in culture medium [73], macrophages 
[74,75,76] or animal infection models [76,77,78]. However, it is not used in the VL clinical 
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context since it exhibits lower efficacy than VL reference drugs [73], low oral bioavailability 
and considerable toxicity (methemoglobinemia and hemolytic anemia) [79]. Such 
disadvantages can probably be overcome by PQ encapsulation or direct modification of its 
structure. In fact, encapsulation in liposomes or nanoparticles enhances PQ activity 
against L.donovani in macrophages [74,75,76] and animal models of infection [76,77]. On 
the other hand, the modification of PQ structure has already led to the finding of other 8-
AQs with excellent activity against experimental VL: tafenoquine [80], NPC1161B [81] and 
sitamaquine [78,81], which is already in clinical trials as mentioned earlier.  
The modification of PQ structure can be accomplished by introduction of 
substituents on the quinoline moiety and/or modification of the terminal aliphatic amino 
group [79]. The latter approach intends to reduce PQ conversion into inactive 
carboxyprimaquine (carboxyPQ, B in Figure 1), the major metabolic process underlying 
PQ’s low oral bioavailability [79]. In particular, the terminal aliphatic amino group of PQ 
can be blocked by N-acylation with amino acids or peptides (C in Figure 1). However, this 
produces structures susceptible to premature proteolytic cleavage that yield PQ (and 
consequently allow its conversion into carboxyPQ) before it can reach target cells. Hence, 
these structures require extra protection of the peptide moiety [79]. This can be achieved 
by condensing the N-aminoacyl derivatives of PQ with carbonyl compounds, leading to 
the formation of an imidazolidin-4-one ring (D in Figure 1) [82], a classical strategy to 
protect peptide drugs from early degradation by amino- or endo-peptidases [83,84,85,86]. 
The imidazolidin-4-one approach has been applied to amino acid derivatives of PQ, 
yielding novel compounds which displayed superior stability in physiological buffer and 
human plasma [82,87], while retaining PQ’s activity against Plasmodium and 
Pneumocystis [87,88]. Furthermore, higher stability and moderate activity could also be 
obtained by further N1-acylation of the imidazolidin-4-one ring with an additional amino 
acid residue (E in Figure 1) [89,90]. Such procedure aimed at (i) completely supressing 
the hydrolysis of the imidazolidin-4-one ring, (ii) increasing the aqueous solubility of the 
entire compound and finally, (iii) increasing the therapeutic activity due to the addition of a 
basic amino group, a feature indispensible for anti-malarial activity [79,89]. These 
strategies may also prove useful to increase the anti-leishmanial activity of PQ.  
To further improve efficacy against Plasmodium [91] and Pneumocystis [92], PQ 
and its amino acid derivatives were also coupled to a ferrocene (Fc) moiety by reaction 
with ferrocenecarboxylic acid (F in Figure 1). It is known that the Fc structure [93] and PQ 
induce the generation of reactive oxygen species (ROS) toxic to several pathogens [79]. 
Hence, their junction might have anti-leishmanial activity as well, since Leishmania are 
sensitive to ROS action [94]. Accordingly, the PQ analogues sitamaquine [71] and 
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tafenoquine [95] inhibit the activity of the mitochondrial succinate dehydrogenase and 
cytochrome c reductase, respectively, a process that leads to the production of ROS and 
culminates in Leishmania cell death. 
Apart from the modifications referred to above, many others can be made to the PQ 
structure to try to improve its anti-leishmanial activity, but only the ones described are the 
focus of this thesis. 
 
 
Figure 1 | Chemical structures of primaquine and some derivatives modified at the terminal aliphatic 
amino group. The low oral bioavailability of primaquine (PQ, A) is a consequence of its metabolic conversion 
to carboxyprimaquine (carboxyPQ, B), a process that can be reduced by blocking PQ’s terminal aliphatic 
amino group with amino acids or peptides (C), an imidazolidin-4-one ring (D) N1-acylated with an additional 
amino acid residue (E) or a ferrocene moiety (Fc, F). Adapted from [89,91,92]. 
 
1.5. Control and prevention 
All forms of leishmaniasis should be ideally controlled and prevented, but more 
attention has been given to VL on this matter due to its associated mortality [2]. Prompt 
diagnosis and treatment of human cases is extremely important to avoid or decrease the 
transmission of anthroponotic VL [13,96]. In addition, it has been advised that the control 
of canine leishmaniasis ought to involve removal and humane destruction of seropositive 
and/or infected canines [13,96]. Chemotherapy represents an alternative to this ethically 
questionable procedure, though relapses are very frequent [13,96]. Hence, it has been 
suggested that vector control and vaccination should constitute the proper measures to 
prevent leishmaniasis [96]. The former approach encompasses the protection of human 
residences and animal shelters by indoor insecticide spraying and inclusion of insecticide 
treated nets [97]. Moreover, canine protection can be achieved by treatment with topical 
repellents and use of insecticide-impregnated collars [98]. Despite many efforts to develop 
a vaccine against human leishmaniasis, no formulation has been registered so far [99]. 
Conversely, the canine vaccines Leishmune® and Leish-Tec® (Brazil) or CaniLeish® 
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(Europe) have already been licenced [96]. In fact, canine vaccination with Leishmune®, 
which revealed protective [100] and transmission blocking [101] effects, has been 
reported to decrease VL incidence in both dogs and humans [102]. 
 
2. Leishmania-host interactions 
2.1. Life cycle of Leishmania 
The life cycle of Leishmania (Figure 2) can be initiated when a female sandfly 
ingests free amastigotes or infected macrophages during a bloodmeal on the skin of a 
vertebrate host. In the insect posterior midgut, macrophages disintegrate and released 
amastigotes experience a decrease in temperature and increase in pH that triggers their 
transformation into flagellated procyclic promastigotes (weakly motile and highly 
replicative stage). Then, they undergo a series of replication and differentiation events that 
culminate in their migration to the anterior midgut/foregut as infective metacyclic 
promastigotes (highly motile, non-dividing forms) [3,103]. When the sandfly takes another 
bloodmeal, around 1000 metacyclic promastigotes are regurgitated into the skin of a 
mammalian host together with sandfly saliva [104] and promastigote secretory gel [105], 
both potent enhancers of promastigote infectivity in mammalian hosts.  
In the host dermis, metacyclic promastigotes are internalized by resident dendritic 
cells (DCs) [106], macrophages or rapidly infiltrating neutrophils [107]. Additional 
monocytes and neutrophils can be attracted to the bite site by the chemokines CCL2 and 
CXCL1, respectively, which are secreted by infected macrophages [108]. Although, 
Leishmania can infect diverse host cells, there is only evidence for replication and long-
term survival within mononuclear phagocytes [5]. Promastigote attachment to the 
receptors of complement (CR1 and CR3), fibronectin and mannose [109,110] triggers 
actin-dependent phagocytosis that leads to Leishmania enclosure within a phagosome. 
This vesicle matures over time through fusion/fission events with early and late 
endosomes and lysosomes to form a phagolysosome-like compartment, known as the 
parasitophorous vacuole (PV) [111]. This acidic compartment is highly enriched in 
lysosomal proteases (cathepsins B, D, H and L) and its membrane is characterized by the 
presence of lysosomal-associated membrane proteins (LAMP) 1 and 2, the small GTPase 
Rab7p, macrosialin (CD68) and major histocompatibility complex (MHC) class II 
molecules [111,112]. However, promastigotes are able to delay phagosomal maturation 
[113,114] and acidification [115], possibly to allow time for differentiation into the non-
flagellated amastigote, a process predominantly driven by the increased temperature of 
the host [116]. Once established, amastigotes are capable of surviving and proliferating 
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either in small PVs containing single amastigotes or in large PVs that can contain 
numerous amastigotes (L.mexicana complex species) [117]. Excessive amastigote 
replication may cause rupture of the macrophage and this allows re-infection of other local 
phagocytes [111]. Alternatively, the replicated amastigotes may be released from the 
macrophage by an exocytosis-like process [118]. Amastigotes may enter macrophages 
through the Fcγ, fibronectin, complement (CR3) or phosphatidylserine receptors [109,110] 
and do not delay phagosomal maturation [119]. In the case of visceral species of 
Leishmania, proliferation is paralleled by dissemination from the bite site in the skin to 
visceral organs (liver, spleen and bone marrow) [120,121]. Once dissemination or 
establishment of infection has been achieved, parasites must maintain a delicate balance 
between increasing the chance of transmission to the vector through proliferation and 
avoiding detection by the host immune system [111]. The transmission cycle of 
Leishmania is completed when infected phagocytes or free amastigotes are taken up by a 
sandfly during a blood meal from an infected host [3,103]. 
vertebrate host
sandfly
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Figure 2 | Life cycle of Leishmania parasites. Inside the sandfly midgut, Leishmania amastigotes (1) 
transform into flagellated procyclic promastigotes (2). In turn, these undergo differentiation and replication 
events (3-4), ultimately converting to infective flagellated metacyclic promastigotes (5), which can be 
encountered at the foregut ready for transmission. During blood feeding, the sandfly introduces metacyclic 
promastigotes into the dermis of a mammalian host (5). Then, metacyclic promastigotes are phagocytosed by 
diverse cell types found in the local environment (6). However, only macrophages constitute the definitive host 
cell. After establishing intracellularly, metacyclic promastigotes differentiate into non-flagellated amastigotes 
(7). Amastigote replication (8) eventually leads to rupture of the host cell, which allows reinfection of local 
phagocytes (9). Alternatively, amastigotes may exit the macrophage by an exocytosis-like process (9). The 
transmission cycle completes when another sandfly ingests infected phagocytes or free amastigotes during a 
blood meal (10). 
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2.2. Host immune response to Leishmania 
The type of immune response developed against Leishmania in mouse models is 
influenced by the host genetic background, the infecting parasite species and strain, the 
mode and site of parasite inoculation, as well as the inoculum size [122,123].  
Neutrophils are one of the first cells to be recruited to sites of parasite inoculation 
[107] and they are involved in the resolution or aggravation of L.major lesions in resistant 
or susceptible mice, respectively [124,125,126]. In the former, resolution of L.major 
infection is linked to the secretion of neutrophil elastase [124] and IL-12 [127]. In addition, 
neutrophils are clearly involved in the early control of L.infantum and L.donovani growth 
[128,129,130]. Apart from the capacity to kill Leishmania through the release of ROS or 
neutrophil extracellular traps [131], neutrophils can also promote the development of 
protective immunity [128] and assist macrophages in parasite killing [124,132].  
Monocytes also accumulate at the L.major inoculation site and may differentiate into 
dendritic cells (DCs) [133], which can capture amastigotes and activate CD4+ and CD8+ T 
cells [133,134]. These cells may also be activated by non-infected (bystander) DCs 
following exposure to L.braziliensis [135] and L.donovani [136], respectively.  
Furthermore, the secretion of IL-12 by DCs is required for the early activation of 
natural killer (NK) cells in mice infected with L.infantum [137] and L.major [138]. Activated 
NK cells release IFNγ in order to (i) induce nitric oxide (NO•)-mediated killing of 
L.infantum by macrophages [139] and (ii) drive the differentiation of Th1 cells in the 
draining lymph nodes (dLNs) of L.major resistant mice [140]. In turn, CD4+ T cells secrete 
IL-2 that synergizes with DC-derived IL-12 to activate NK cells early after L.major infection 
[138,140]. 
All the cell types described above are involved in the early immune response to 
Leishmania and subsequent development of T cell responses. It is consensual that the 
development of T helper (Th) 1 immunity correlates with murine resistance to several 
cutaneous and visceral Leishmania species. In this case, IL-12 derived from antigen 
presenting cells drives the differentiation and proliferation of CD4+ Th1 cells capable of 
secreting IFNγ, which induces parasite killing by macrophages via NO• production 
[122,123,141,142]. By contrast, in mouse models of CL caused by L.major, susceptibility 
is generally associated with an IL-4-driven expansion of CD4+ Th2 cells and secretion of 
IL-4, IL-13 and IL-10 [122,123]. However, the association of Th2 responses with 
susceptibility to visceralizing Leishmania is not so clear. Although IL-10 overproduction is 
also related to susceptibility in mouse models of VL [122,143], IL-4 [144] and IL-13 [145] 
seem to promote the hepatic control of L.donovani growth.  
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Apart from Th1 and Th2 cells, other CD4+ T cell subsets also intervene in the 
immune response to Leishmania. The accumulation of CD4+CD25+Foxp3+ T regulatory 
(Treg) cells in skin lesions of resistant mice induces long-term persistence of L.major. 
These cells are able to supress Th1 responses, in part, by secreting IL-10 [146]. 
Conversely, Tregs protect susceptible mice against L.major infection by restraining the early 
production of IL-4 and the ensuing development of Th2 responses [147]. Non-healing 
L.major infection appears, instead, to correlate with IL-10 release by IFNγ-secreting CD4+ 
T cells and not by Tregs [148]. Similarly, VL progression is linked to IL-10 production by 
regulatory DCs [149], NK cells [150] and CD4+ T cells that co-express or not IFNγ [151].   
Th17 is another CD4+ T cell subset that produces cytokines of the IL-17 family [123]. 
Neutrophil recruitment mediated by IL-17 contributes to CL progression in susceptible 
mice [152] and likely promotes tissue inflammation and injury in MCL patients [153]. By 
contrast, IL-17 production correlates with resistance to human VL. The secretion of IL-17 
by Th17 cells can be induced by exposure of peripheral blood mononuclear cells from 
healthy donors to L.donovani. Key cytokines required for the induction and maintenance 
of Th17 responses, namely IL-1β, IL-6 and IL-23, are also detected in such cultures [154].  
The control of infection caused by L.major in skin lesions [155,156] and by 
L.donovani in the liver [157] also depends on the presence of IFNγ-secreting CD8+ T cells. 
Still, L.donovani is able to evade CD8+ T cell responses in the spleen by supressing their 
proliferation and inducing their cell death [158]. Intriguingly, cytolytic CD8+ T cells have 
also been associated with lesion progression in L.braziliensis-infected humans [159].  
Finally, the role of B cells in regulating immunity to CL is controversial. B cell-derived 
immunoglobulin Gs (IgGs) appear to mediate L.major uptake by DCs, resulting in 
activation of the latter and stimulation of T cells to produce IFNγ that leads to parasite 
killing by macrophages [160]. However, contradictory findings indicate that B cells are not 
involved in the development of either Th1 or Th2 responses during L.major infection [161]. 
In experimental VL, early B cell expansion (persistent throughout infection) and secretion 
of IgG and IgM have been implicated in the exacerbation of L.infantum infection [162]. 
This is supported by the fact that resolution of L.donovani infection is accelerated in the 
absence of B cells [129]. 
 
2.2.1. Organ-specific immunity in VL  
The mouse liver is a site for initial multiplication of visceralizing Leishmania that 
eventually controls infection by forming cellular infiltrates around parasitized Kupffer cells 
(KCs), known as granulomas [120,121,163]. These structures start developing when 
 31 
infected KCs secrete chemokines - like CCL3, CCL2 or CXCL10 - that recruit monocytes 
and neutrophils to encircle them (1 – 7 days) [164]. At this early stage, some infected KCs 
fuse to form multinucleated cells [165]. Such steps are then followed by the recruitment of 
CD4+ and CD8+ T cells to form a mature granuloma (7 – 30 days), a process dependent 
on the presence of IL-12, IFNγ, TNF, IL-2 [163], IL-4 [144] and IL-13 [145]. In this milieu, 
IFNγ activates infected KCs to eliminate intracellular amastigotes (30 days onward) [166]. 
Although several mature granulomas devoid of parasites - sterile granulomas - can be 
found in the hepatic parenchyma, sterile cure is never achieved [163]. It is likely that low 
parasite persistence in the liver, induced by IL-10, accounts for its resistance to re-
infection [146]. Moreover, IL-10 secretion in developing granulomas may also counteract 
excessive pro-inflammatory responses and tissue injury [143]. 
Contrary to the liver, the spleen becomes chronically infected and a site of parasite 
persistency [120,121]. Leishmania are removed from the circulation in the spleen by 
macrophages located in the marginal zone (MZ) and red pulp. In the MZ, DCs acquire the 
parasite or its antigens, mature and migrate into the periarteriolar lymphoid sheaths 
(PALS). This recruitment occurs in response to CCL19 and CCL21, both chemokines 
produced by gp38+ stromal cells of the PALS. Once in the PALS, DCs secrete IL-12 and 
present Leishmania antigens to CD4+ T cells, leading to the generation of Th1 responses 
[167]. Hence, protective immunity occurs in the spleen during the acute phase of 
L.donovani infection. Still, infection progresses and causes disruption of the splenic 
architecture that is characterized by (i) loss of follicular DCs, (ii) remodelling of the MZ and 
(iii) changes in chemokine expression and cell migration [163]. Though the mechanism 
accounting for loss of follicular DCs is unknown, the other effects are primarily mediated 
by TNF and IL-10. Excessive TNF production causes the loss of MZ macrophages [168] 
and gp38+ stromal cells [169], with concomitant reduction of CCL19 and CCL21 
expression. In addition, DCs become unresponsive to these chemokines due to down-
regulation of CCR7 expression induced by IL-10. Consequently, DCs fail to migrate and 
interact with T cells in the PALS [169]. 
 
2.3. Host antimicrobial oxidative mechanisms  
As previously mentioned, macrophages can be activated to eliminate intracellular 
Leishmania. Two of the most important antimicrobial systems of macrophages (and other 
phagocytes) are the NADPH oxidase and the nitric oxide synthase 2 (NOS2), which are 
the enzyme complexes responsible for the generation of superoxide (O2•-) and nitric oxide 
(NO•), respectively. These radicals may give rise to other more toxic intermediates 
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collectively known as reactive oxygen species (ROS) and reactive nitrogen species (RNS) 
that have the potential to kill intracellular pathogens [170,171].  
The reduced nicotinamide adenine dinucleotide phosphate (NADPH) oxidase [171] 
catalyses the transfer of one electron from NADPH to oxygen (O2) to yield O2•- (Equation 
1) [172]. NADPH oxidase activation can be elicited by microbial products (LPS), cytokines 
(IFNγ and IL-8) or by binding to phagocytosis receptors (Fcγ and complement receptors) 
[171,173]. Following activation by the mentioned stimuli, the cytosolic subunits (p40phox, 
p47phox, p67phox and Rac1 or 2) migrate towards the membrane-bound subunits (p22phox 
and gp91phox and Rap1A) in order to assemble a functional oxidase [171]. The membrane 
subunits form the catalytic core of the oxidase, containing binding sites for flavin adenine 
dinucleotide (FAD), NADPH and two heme groups [170]. Hence, when a microbe is 
phagocytosed, the active NADPH oxidase present in the phagosomal membrane pours 
high amounts of O2•- into the interior of the phagosome [171]. Then, O2•- is rapidly 
converted to other oxidant successors that may cause oxidative damage to the target. The 
moderately reactive O2•- is rapidly reduced to hydrogen peroxide (H2O2), either 
spontaneously or enzymatically by superoxide dismutase enzymes (SOD), particularly at 
acidic pH (Equation 2) [172,174,175]. In turn, H2O2 may give rise to the highly reactive 
and short-lived hydroxyl radicals (HO•) in the Fenton reaction, by reacting with ferrous 
iron (Fe2+, Equation 3). The latter is regenerated when ferric iron (Fe3+) reacts with O2•- 
(Equation 4) [172,175]. Moreover, the formation of HO• can also be achieved by the 
reaction of O2•- with hypochlorous acid (HOCl) (Equation 5). The latter molecule is 
generated by myeloperoxidase, an enzyme that catalyses the oxidation of halide ions to 
hypohalous acids (e.g. chloride to HOCl) at the expense of H2O2 (Equation 6) [172].  
(1) 2 O2 + NADPH à 2 O2•- + NADP+ + H+    
(2) 2 O2•-  + 2H+à H2O2 + O2     
(3) H2O2 + Fe2+ à HO• + HO- + Fe3+ 
(4) O2•-   + Fe3+ à Fe2+ + O2   
(5) O2•-   + HOCl à O2 + HO• + Cl-    
(6) H2O2 + Cl- à HOCl + HO- 
 
The NOS family of enzymes catalyse the oxidation of L-arginine to L-citrulline and 
NO•, in the presence of NADPH and O2 (Equation 7). They have an amino-terminal 
oxidase domain that contains a heme centre and binding sites for tetrahydrobiopterin and 
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L-arginine, linked by a calmodulin-binding domain to a carboxy-terminal reductase domain 
with binding sites for NADPH, FAD and flavin mononucleotide. Importantly, the production 
of NO• only occurs when NOS form a homodimeric structure [170,176,177,178]. The 
neuronal NOS (nNOS or NOS1) and endothelial NOS (eNOS or NOS3) are constitutively 
expressed and produce low levels of NO•, being their activity highly dependent on high 
intracellular calcium levels [176,177,178]. On the contrary, the inducible isoform (iNOS or 
NOS2) is the most widely distributed among cell types and its activity is not controlled by 
intracellular calcium concentrations [170,176,177,178]. Macrophages express the NOS2 
enzyme [179], that can be found either in the cytosol or associated with intracellular 
vesicles [180]. Unlike other isoforms, NOS2 is capable of producing large quantities of 
NO• when suitably stimulated [170,177,178]. Its transcription can be induced by LPS, IFNγ 
and TNF [170,177,179] or supressed by IL-4 [181]. However, the expression of NOS2 can 
also be regulated at the post-transcriptional and post-translational levels. TGFβ can 
decrease the stability and translation of NOS2 transcripts and enhance NOS2 protein 
degradation [182]. Moreover, NO• may regulate its own production by directly inactivating 
NOS2 [183]. Notwithstanding, when NOS2 is expressed and localized to the phagosome 
membrane [184] it likely favours the diffusion of NO• into the interior of the vesicle where 
its derivatives will cause deleterious effects on the phagocytosed target. Here, NO• 
undergoes successive oxidative degradation to form nitrite (NO2-), nitrogen dioxide (NO2•) 
and nitrate (NO3-) [185]. Furthermore, NO• has a propensity to react with other free 
radicals, particularly with O2•- resulting in the formation of the strong oxidant peroxynitrite 
(ONOO-) (Equation 8), which can further react with CO2 to yield NO2• and carbonate 
radical (CO3•-) [172,175]. 
(7)  L-arginine + 1.5NADPH + 2O2 à L-citrulline + 1.5NADP+ + 2H2O + NO•  
(8)  NO• + O2•- à ONOO- 
Several of the mentioned ROS and RNS are capable of inducing oxidative stress to 
microbes. This can be defined as a disturbance in the pro-oxidant and anti-oxidant 
equilibrium in favour of the former. Such state may lead to oxidative damage, that is, to 
molecular damage caused by the action of reactive species (RS) on DNA, lipids and 
proteins [172]. Damage to DNA affects its replication, gene expression and cell division. 
Several RS such as HO•, CO3•-, HOCl, ONOO- can cause DNA strand breakage and/or 
chemical modifications to DNA bases or the deoxyribose sugar [172]. In addition, 
oxidative damage to polyunsaturated fatty acids tends to decrease the fluidity and 
functioning of biological membranes. Lipid peroxidation initiated by a RS (HO• and NO2•) 
leads to the formation of a carbon radical (R•). Then, R• reacts with O2 to give a peroxyl 
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radical (RO2•), which can abstract hydrogen from an adjacent fatty acid side chain. This 
reaction yields a lipid hydroperoxide and a new R• that can react again with O2 and 
consequently propagate lipid peroxidation [172]. Finally, proteins may also suffer oxidative 
damage at both the protein backbone and on the amino acid side-chains, due to the 
attack of RS (RO2•, HO•, HOCl, ONOO-) or end products of lipid peroxidation. Protein 
damage may be reversible or irreversible and impair the function of receptors, signal 
transduction and transport proteins and enzymes [172]. 
 
2.3.1. Leishmania susceptibility to host derived oxidants 
ROS and RNS generated in the absence of a host cell have the potential to kill 
Leishmania. In this context, both parasite stages are sensitive to the action of O2•- 
[186,187] and H2O2 [187,188,189,190]. Amastigotes are notably more resistant than 
promastigotes to the effects of H2O2 [191,192], while infective promastigotes are more 
resistant than non-infective ones [193]. Presumably, H2O2 toxicity towards promastigotes 
is mediated by HO• and involves cessation of protein and RNA synthesis [193], which 
culminates in an apoptosis-like cell death [194,195]. Similarly, NO• or its derivatives 
decrease the viability of both Leishmania life stages [186,196,197,198,199,200,201], 
being amastigotes generally less sensitive to their action [198,199,202]. RNS interfere 
with the differentiation of amastigotes to promastigotes [199], inhibit the activity of cysteine 
proteinase [200], glyceraldehyde 3-phosphate dehydrogenase and aconitase [198,199] 
and eventually also induce an apoptotic-like cell death in amastigotes [203]. It has been 
suggested that ONOO- mediates the toxicity of NO• towards L.donovani promastigotes 
[190] and L.amazonensis amastigotes [204], but not L.major promastigotes [197].  
During internalization and establishment of infection in the host cell, Leishmania 
face a deleterious mixture of ROS and RNS. Infection of macrophages with promastigotes 
elicits the release of O2•- [186] and ensuing formation of H2O2 [189,205]. Promastigotes 
trigger the oxidative burst [195,206,207,208] more easily than amastigotes 
[188,191,205,209], explaining the former increased susceptibility to elimination by a 
mechanism reminiscent of apoptosis [195]. Importantly, the leishmanicidal activity of the 
host cell is compromised in the presence of ROS scavengers [186,189,210] or due to a 
genetic deficiency in the NADPH oxidase [191,205]. However, the fact that monocytes 
and macrophages deficient in ROS production are able to restrain the growth of 
L.donovani after IFNγ activation [205], indicates that other mechanisms intervene in the 
control of the parasite. Indeed, macrophage activation (IFNγ and LPS) enhances the 
production of RNS and leads to elimination of both parasite stages [196,197,211,212,213], 
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whereas inhibition of NOS2 activity [186,196,211,212] or a genetic deficiency in this 
enzyme [213,214] has the reverse effect. Moreover, activated macrophages from resistant 
mouse strains have higher capacity than those from susceptible strains to generate RNS 
and eliminate L.major [215] by an apoptotic-like process [203,216]. 
Several lines of evidence also support the notion that ROS and RNS are relevant to 
control Leishmania infection in animal models [217]. The healing of cutaneous lesions and 
life-long containment of persisting parasites correlate intimately with NOS2 expression in 
the L.major [196,213,214,218,219,220,221], L.amazonensis [204] and L.braziliensis [222] 
mouse models. However, unlike NOS2, NADPH oxidase is not required to control 
L.amazonensis [217] or L.braziliensis [222] infections. Still, its activity is required to clear 
L.major from the spleen and to prevent late parasite visceralization [214,223]. In contrast 
to what is observed in most mouse models of CL, resolution of lesions caused by 
L.guyanensis depends solely on the induction of NADPH oxidase activity [195,217]. This 
seemingly clear scenario is, however, not observed in animal models of VL. A first report 
showed that both NADPH oxidase and NOS2 acted in concert to control early L.donovani 
replication in the mouse liver, whereas NOS2 alone was required and sufficient to resolve 
late infection [166]. Contradictorily, a subsequent study demonstrated that neither of these 
antimicrobial mechanisms influenced the outcome of L.donovani infection in the mouse 
liver, though NOS2 exerted moderate protective effects in the spleen at late phases of 
infection [223]. To further complicate this picture, NOS2 deficiency appears to be the 
cause of unrestrained growth of L.donovani in the hamster’s liver, spleen and bone 
marrow. These animals have an intrinsic defect in the NOS2 promoter, whose 
responsiveness to activating stimuli (IFNγ and LPS) is reduced. As a consequence, NOS2 
transcription and NO• production are impaired in the hamster’s macrophages [224,225]. 
 
2.3.2. Leishmania resistance to host derived oxidants  
Despite the importance of ROS and RNS generated by the macrophage as 
leishmanicidal molecules, complete elimination of the parasite is seldom attained [219]. 
Naturally acquired [226,227] or experimentally induced [187,201] resistance to oxidative 
stress increases Leishmania infectivity and capacity to multiply or persist in the host. This 
highlights the parasite’s capacity to subvert the production of oxidants or avoid their 
toxicity through its antioxidant defense and repair systems [94].  
Concerning the first situation, both L.donovani parasite stages interfere with the 
assembly of a functional NADPH oxidase by preventing the recruitment of p47phox and 
p67phox subunits to the phagosomal membrane [228,229]. Such effect is attributed to 
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lipophosphoglycan (LPG) in the case of promastigotes [228]. Other surface membrane 
molecules of Leishmania can also inhibit the oxidative burst of macrophages 
(metalloprotease Gp63) [230] or decrease NOS2 expression and activity 
(glycoinositolphospholipids [231] and LPG [232]). In particular, L.amazonensis 
promastigotes and L.mexicana amastigotes can decrease NO• synthesis by LPS-
stimulated macrophages [233] and DCs [234], respectively. Besides, amastigotes can 
impair NO• synthesis by inducing TGFβ release from the macrophage [235] or by 
attenuating the IFNγ-induced activation of the Jak1/2-Stat1 pathway (Janus kinases 1/2 – 
signal transducer and activator of transcription 1) [236]. 
In addition to modulating the capacity of the host cell to generate oxidants, 
Leishmania also possess an antioxidant defense system that allows them to withstand 
oxidative stress. Leishmania surface LPG and related phosphoglycans [237,238,239], 
reduced pterins [240] and the reduced thiols ovothiol A, glutathione and trypanothione 
[241] are non-enzymatic scavengers of ROS/RNS.  
In addition, the parasite actively detoxifies ROS and RNS through complex 
enzymatic machineries. Leishmania possess iron-containing SODs involved in O2•- 
detoxification mainly in the mitochondria and glycosomes [242,243,244]. However, this 
enzyme converts O2•- to the more toxic H2O2, which can be reduced by a variety of 
peroxidases that use electrons derived from reduced trypanothione, by the intermediate of 
tryparedoxin or ascorbate [94]. The L.infantum cytosolic 2-cysteine peroxiredoxin (2-cys 
PRX) is capable of detoxifying H2O2, t-butyl hydroperoxide (t-bOOH), ONOO- or NO• and 
its overexpression enhances parasite survival in macrophages [245,246]. In contrast, the 
mitochondrial 2-cys PRX appears to protect L.infantum from exposure to t-bOOH, but not 
H2O2 [245]. Another class of peroxidases are the non-selenium glutathione peroxidase-like 
enzymes (nsGPX). The L.major nsGPX1 displays slightly less affinity for H2O2 and is less 
abundant than 2-cys PRX [247]. Nevertheless, L.major also possesses a mitochondrial 
ascorbate peroxidase that confers resistance to H2O2 [248]. In addition, the L.major 
eukaryotic elongation factor 1B (eEF1B) exhibits trypanothione S-transferase and 
peroxidase activity [249]. This enzyme localizes to the endoplasmic reticulum and displays 
activity against hydrophobic hydroperoxides, but not H2O2, suggesting its participation in 
resistance to lipid peroxidation [249]. Finally, the presence of a NOS enzyme in 
L.donovani promastigotes, suggests that this parasite might have mechanisms to detoxify 
endogenously produced NO• that could offer resistance against exogenous NO• [250].  
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3. Iron and Leishmania-host interplay 
3.1. Iron properties and functions 
Iron is the fourth most abundant element of the earth’s crust and the most abundant 
transition metal in living organisms. Cells of virtually all forms of life are dependent on 
adequate quantities of iron for survival and proliferation [251,252]. The dynamic capacity 
to alternate between oxidation states (ferric iron, Fe3+ or ferrous iron, Fe2+) and to form 
coordination complexes with organic ligands, enables iron to participate in critical 
biological functions like oxygen binding and transport, electron transfer, NO• sensing, 
transcriptional regulation, structural stabilization or catalysis [252,253]. Whereas Fe3+ is 
virtually insoluble under aerobic conditions at physiological pH, Fe2+ is soluble and may 
readily catalyse the formation of pernicious radicals [172,252]. In fact, excessive 
accumulation of iron in tissues is strongly associated with DNA damage, lipid peroxidation, 
protein tyrosine nitration and oxidation [254,255,256]. In addition, iron-induced oxidative 
damage has been proposed to contribute to the pathology of several human disorders 
[257]. To reduce the threat of oxidative stress or damage in biological systems, iron is 
found associated to proteins in a variety of complexes [252,253].  
 
3.2. Iron and infection 
Both the host and invading pathogens require iron for survival and must have 
refined mechanisms for its acquisition and management. The vertebrates’ innate immune 
response to infection includes numerous mechanisms of iron restriction, which the 
pathogen attempts to circumvent to gain access to iron [258,259,260]. Data from humans 
and animal models indicate that the host iron status greatly influences susceptibility to 
infection. In most instances, iron availability favors the replication of pathogens, whereas 
iron deprivation hinders their growth [258,261,262].  
 
3.2.1. Host iron homeostasis 
The organism of an adult individual normally possesses 3000 to 4000 mg of iron, of 
which approximately 1-2 mg is lost per day, due to desquamation of skin and urinary cells, 
sloughing of intestinal epithelial cells, bleeding or sweat. In mammals, there is no 
regulated excretion of iron, hence the replenishment of such losses and consequent 
maintenance of iron balance occurs at the level of intestinal absorption. Dietary iron, 
inorganic or bound to heme, is absorbed at the brush border of enterocytes lining the 
proximal portion of the duodenum [263,264,265,266].  
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In order to be absorbed, Fe3+ must be previously reduced to Fe2+ by the 
ferrireductase duodenal cytochrome b (DCYTB or CYBRD1) present in the apical 
membrane of enterocytes [267] or alternatively by STEAP ferrireductases [268,269]. 
Subsequently, Fe2+ is transported across the membrane by the divalent metal transporter 
1 (DMT1, also known as DCT1, NRAMP2 or SLC11A2) [270,271,272], a process requiring 
proton co-transport [271]. Heme iron absorption is poorly understood, as the nature of its 
importer remains uncertain [273,274]. Notwithstanding, internalized heme is likely 
degraded by heme-oxygenase to yield Fe2+ [264]. Then, cytosolic Fe2+ is transported to 
circulation by the basolateral membrane exporter ferroportin (FPN, also known as IREG1, 
MTP1 or SLC40A1) [275,276,277] and is oxidized to Fe3+ by the multicopper ferroxidase 
hephaestin, the intestinal homologue of the abundant plasma protein ceruloplasmin [278].  
Soon after release from the enterocyte, Fe3+ is captured by transferrin (TF). This 
abundant high-affinity plasma iron transport protein distributes iron to cells containing the 
transferrin receptor 1 (TFR1), which is ubiquitously expressed [265]. Upon binding, the 
TF-TFR1 complex is internalized by clathrin-dependent endocytosis. Subsequent 
acidification (pH 5.5) of early endosomes through active proton influx causes dissociation 
of iron from the complex [279]. Free Fe3+ is then reduced by the ferrireductase STEAP3 
[280] and transported across the endosomal membrane by DMT1 into the cytosol 
[270,271,272,281]. Finally, empty TF and TFR1 are recycled to the cell surface to initiate 
further cycles of iron sequestration and internalization [279]. In particular, erythroid 
precursors, early lymphoid and neuroepithelial cells are strictly dependent on iron uptake 
by the TF-TFR1 pathway for normal development [282,283].  
Erythropoiesis requires approximately 25 mg of iron per day to produce 200 billion 
new erythrocytes [284]. Such demands cannot be met by diet and iron must therefore 
come from erythrophagocytosis. This process is most active in the spleen, where 
senescent or damaged erythrocytes are phagocytosed by macrophages of the 
reticuloendothelial system [263]. Hydrolytic enzymes of the macrophage phagolysosome 
lyse engulfed erythrocytes and freed hemoglobin (HB) then suffers proteolytic digestion to 
liberate heme [263]. Moreover, macrophages can take up HB and heme present in 
circulation due to intravascular hemolysis. HB-haptoglobin and heme-hemopexin 
complexes formed in the plasma are internalized, respectively, by CD163- [285] and 
CD91- [286] mediated endocytosis. Intracellular heme is either exported intact by the 
feline leukemia virus subgroup C cellular receptor (FLVCR) [287] or catabolized by heme-
oxygenase 1 to biliverdin, carbon monoxide and Fe2+ [288]. The latter can be exported by 
FPN [275,276,289] and oxidized to Fe3+ by the multicopper ferroxidase ceruloplasmin in 
order to facilitate incorporation in TF [290].  Iron that is either not exported or used for 
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metabolic reactions is stored within the core of ferritin (FT). Degradation of the cytosolic 
(and ubiquitous) FT and concomitant iron release helps mobilize iron for cellular utilization 
[264,265]. Also, it is presumed that mitochondrial FT is involved in the protection of this 
organelle against iron-mediated toxicity [291].  
Systemic iron homeostasis encompasses regulation of intestinal iron absorption, 
erythropoiesis, erythrophagocytosis and iron storage by hepatocytes and macrophages 
[264]. The regulation of these processes is the responsibility of hepcidin, a small peptide 
primarily synthesized by hepatocytes and secreted into circulation [292,293,294,295], that 
can also be produced by macrophages, monocytes and neutrophils [296,297,298]. 
Hepcidin production is subjected to regulation by systemic iron availability, among other 
factors. Its transcription is elevated in response to iron overload [295] and reduced in 
conditions of iron deficiency [299,300]. It acts by targeting cell surface FPN and eliciting its 
internalization and lysosomal degradation, thus leading to reduced intestinal iron 
absorption and macrophage iron export [301].  
Intracellular iron balance is controlled by the interaction of cytosolic iron regulatory 
proteins (IRPs) with iron responsive elements (IREs). The latter are sequences present in 
the 5’ or 3’ untranslated regions (UTR) of mRNAs encoding proteins of iron metabolism. 
The formation of IRE/IRP complexes on the 5’UTR of FT mRNA [302,303] represses 
translation initiation [304], whereas such interactions in the 3’UTR of TFR1 mRNA [305] 
preclude its endonucleolytic cleavage and subsequent degradation [306]. IRPs bind IREs 
with high affinity in iron-depleted cells and with low affinity in iron-replete cells 
[307,308,309,310,311]. Hence, when cellular iron levels are low, more TFR1, but not FT, 
protein can be produced. The opposite is observed when cells are iron replete [264].  
  
3.2.2. Host mechanisms of iron withholding 
Several mechanisms of innate immunity are involved in the restriction of iron 
availability to microbes. These can function constitutively or be induced in response to 
infection [258,259,260].  
Lactoferrin (LF) is a high affinity Fe3+ chelator (at acidic pH) present in milk, saliva, 
tears, semen and secondary granules of neutrophils, being involved in the withholding of 
iron from invading pathogens at extracellular compartments [312,313]. Still, numerous 
microbes also secrete Fe3+ chelators, known as siderophores, to effectively scavenge iron 
from their niches within the host. The host counteracts this microbial iron uptake system 
through the release of lipocalin-2 (also designated siderocalin, neutrophil gelatinase-
associated lipocalin or 24p3) from neutrophils, macrophages and epithelial cells. 
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Lipocalin-2 acts by sequestering diverse Fe3+-containing siderophores, hence preventing 
their acquisition by microbes [260,314]. Its importance for host defense is clearly shown 
by the enhanced susceptibility of lipocalin-2 deficient mice to infection by Escherichia coli 
[315] and Mycobacterium tuberculosis [316]. 
Other iron withholding strategies include the reduction of iron delivery to the infected 
host cell or the induction of iron efflux from the cellular compartments where microbes 
replicate [258,259]. The internalization of TF by monocytes can be blocked by decreasing 
the surface expression of TFR1 upon IFNγ activation, thus limiting the availability of iron 
for the growth of bacteria such as Legionella pneumophila [317,318]. Moreover, IFNγ can 
also induce the transcription of natural resistance associated macrophage protein 1 
(NRAMP1 or SLC11A1) [319], which functions as a divalent metal-proton symporter [320] 
in phagosomal membranes of professional phagocytes [321]. This protein acts by 
depleting iron from phagosomal compartments [322], in this way starving pathogens like 
M.bovis, Salmonella typhimurium and L.donovani of this essential nutrient [323]. Similarly, 
FPN over-expression stimulates iron export from macrophages and consequently limits 
the growth of S.typhimurium [324,325], Chlamydia and L.pneumophila [326]. By contrast, 
FPN degradation mediated by hepcidin binding, blocks iron efflux from macrophages and 
results in increased availability of iron for these pathogens [324,326].  
Although the host’s iron deprivation mechanisms are important to contain microbial 
growth, many pathogens are capable of counteracting their action [260]. Leishmania 
parasites are not only capable of subverting the host’s iron uptake systems, as they are 
also proficient in the acquisition of iron by their own mechanisms [327,328].  
 
3.2.3. Leishmania iron acquisition  
Since both Leishmania life stages lack critical enzymes of the heme biosynthetic 
pathway [329], they have to be cultured in medium supplemented with inorganic salts of 
iron, heme-containing compounds or heme alone [330]. This molecule is acquired through 
the Leishmania heme response 1 (LHR1) importer present in the plasma membrane and 
lysosomes of L.amazonensis promastigotes [331,332]. Other physiological iron sources 
such as HB [333,334], TF and LF [335], but not FT, may also promote the growth of this 
parasite stage. However, their uptake occurs by quite distinct mechanisms. The HB 
protein is acquired by endocytosis after its attachment to a high affinity receptor, a 
hexokinase present in the flagellar pocket of L.donovani promastigotes [333,334]. 
Subsequently, the degradation of internalized HB in the late endosomes/lysosomes 
releases heme that is possibly trafficked to the mitochondria by Leishmania ATP-binding 
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cassette, sub-family G, member 5 (LABCG5). The latter is an intracellular ATP-binding 
cassette (ABC) protein present in the membranes of a vesicular network of L.donovani 
promastigotes [336]. Instead, TF and LF bind to a common surface receptor in L.infantum 
promastigotes, after which Fe3+ is presumably released from them and converted to Fe2+ 
by the action of a Fe3+ reductase before internalization by an yet unidentified transporter 
[337,338,339]. Accordingly, this Fe3+ reductase activity is detectable on the promastigote 
surface of different Leishmania species [340]. Consistent with promastigote studies, the 
growth of axenic amastigotes of L.infantum or L.amazonensis can also be supported by 
iron derived from HB and hemin [341] or TF [342], respectively. The uptake of heme by 
intramacrophagic L.amazonensis amastigotes is again mediated by LHR1 [331]. 
Furthermore, intracellular L.amazonensis also possesses a Fe3+ reductase, the LFR1, 
[340] which provides soluble Fe2+ for transport across the parasite plasma membrane by 
the Fe2+ iron transporter LIT1 [343,344]. Lastly, apart from the mechanisms of direct iron 
internalization, Leishmania parasites can also subvert the host’s iron uptake systems for 
their own profit. In fact, L.amazonensis amastigotes can obtain TF by forcing the fusion of 
TF-containing endosomes with the PVs [342]. Alternatively, L.donovani is capable of 
decreasing the macrophage labile iron pool, a process that triggers an increased surface 
expression of TFR1 and internalization of TF, thus permitting a continuous provision of 
iron to the parasite [345].  
In sum, the abovementioned variety of iron sources and acquisition mechanisms 
used by Leishmania parasites reflects the plasticity of their growth requirements and 
ability to survive in the diverse environments of the hosts encountered during their life 
cycle [327,328]. 
 
3.2.4. Host iron status and Leishmania infection 
Most clinical and experimental evidence indicates that excessive iron levels in the 
host, owing to nutritional, hereditary or therapeutic reasons, favours the multiplication of 
pathogens and worsens the outcome of infections. Conversely, iron deprivation tends to 
hinder the multiplication of pathogens and improve the outcome of infections [258,261]. 
Experimental studies on the relationship between the host iron status and infection by 
Leishmania indicate that these parasites might be an exception to such tenet. So far, 
studies in this regard have never been conducted in humans. 
The fact that Leishmania are equipped with diverse iron acquisition mechanisms 
and are capable of utilizing various iron sources, has led to the suggestion that iron 
deprivation could be an effective strategy to control leishmanial infections [327,328]. Such 
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hypothesis is supported by the finding that the iron chelators desferrioxamine (DFO) and 
hydroxypyridin-4-ones moderately inhibit the multiplication of L.major and L.infantum 
promastigotes in culture medium [346]. However, DFO has shown either no effect [347] or 
an inhibitory effect on the intramacrophagic growth of L.donovani [345,348] and 
L.amazonensis [342]. Moreover, treatment of mice with DFO reduces the hepatic and 
splenic growth of L.infantum [349], but does not affect the development of skin lesions 
caused by L.major [350]. Overall, Leishmania parasites do not seem to be particularly 
sensitive to iron chelation. 
On the other hand, iron supplementation appears to mediate in vivo resistance to 
Leishmania, though such effect has not been reproduced in vitro. Iron treatment either 
favours the intramacrophagic growth of L.donovani [345] and L.amazonensis [342] and 
reverses the capacity of activated macrophages to eliminate L.enriettii [212] or has no 
influence on both effects [347]. By contrast, iron administration to susceptible mice leads 
to early containment of L.major in the skin and delays its dissemination to the dLNs, liver 
and spleen [350,351,352]. The control of this infection correlates with an early and 
sustained oxidative burst mediated primarily by neutrophils [351] and with the 
development of a Th1-type immune response [350]. The protective immune response to 
L.major displayed by iron overloaded mice is characterized by (i) an increased ability of 
splenic cells to present L.major-derived peptides, (ii) increased levels of IFNγ and NOS2 
and decreased levels of IL-4 and IL-10 transcripts at the lesion site and (iii) reduced levels 
of serum IgE and IgG1 and increased levels of IgG2a [350]. Finally, iron overloaded mice 
are resistant to re-infection with L.major, which is linked to an enhanced proliferation of 
IFNγ-secreting CD4+ T cells in the dLNs [352]. The development of these cells and 
concomitant resistance to L.major is regulated by the transcription factor NF-κB [353]. In 
fact, the cellular activation and nuclear translocation of NF-κB is detectable in the dLNs of 
iron overloaded mice, during primary and secondary infections with L.major [352]. The 
abovementioned reports highlight the role of iron in mediating host protection against 
L.major infection. Clearly, more studies are needed to ascertain the role of iron during the 
course of infection with other Leishmania species. 
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Chapter II | Definition Of Objectives 
 
Iron is an essential nutrient for the growth and survival of the host and the pathogen. 
It is generally acknowledged that iron chelation decreases and iron excess increases the 
growth of most pathogens [258,261]. However, this principle does not seem to apply to 
Leishmania for two main reasons. First, iron chelation does not consistently reduce the 
growth of Leishmania in macrophages [342,345,347,348] and in mouse models [349,350]. 
Second, the proliferation of L.major in the mouse is impaired by the host’s iron overload, 
an effect correlated to an enhanced oxidative burst [350,351,352]. In fact, it is well 
established that ROS and RNS can inhibit the replication of Leishmania in culture medium 
and inside macrophages [94]. However, their relevance to the control of these parasites in 
the mouse model has not been well defined [166,217,223]. Moreover, several lines of 
evidence indicate that visceralizing Leishmania are vulnerable to chemotherapeutics that 
act on the parasites by inducing the generation of ROS, as is the case of analogues of PQ 
[71,95]. Although PQ displays activity against visceral Leishmania, its aliphatic amine is 
prone to undergo oxidative deamination in vivo, which consequently causes PQ 
inactivation [79]. This drawback may be overcome by blocking PQ’s aliphatic amine with a 
peptidomimetic (imidazolidin-4-one) or organometallic (ferrocene) moiety. Indeed, 
optimization of PQ structure has already led to the development of potent anti-leishmanial 
compounds [78,80,81].  
Given these facts, the key objectives of this PhD thesis were to: 
1| Clarify the effect of modulating the host iron status on the growth of L.infantum in 
the mouse model (chapter III);  
2| Define the relative contribution of ROS and RNS to the control of L.infantum 
infection in the mouse model (chapter IV); 
3| Explore the anti-leishmanial potential of peptidomimetic and organometallic 
derivatives of PQ, with higher resistance to proteolytic degradation and oxidative 
deamination (chapter V). 
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Chapter III | Iron Overload Favors The Elimination Of 
Leishmania infantum From Mouse Tissues Through 
Interaction With Reactive Oxygen and Nitrogen Species 
 
1. Abstract 
Iron plays a central role in host-parasite interactions, since both intervenients need 
iron for survival and growth, but are sensitive to iron-mediated toxicity. Host’s iron 
overload is often associated with susceptibility to infection. However, it has been 
previously reported that iron overload prevented the growth of Leishmania major, an agent 
of cutaneous leishmaniasis, in BALB/c mice. 
In order to further clarify what is the impact of iron modulation on the growth of 
Leishmania in vivo, we studied the effects of iron supplementation or deprivation on the 
growth of L.infantum, the causative agent of Mediterranean visceral leishmaniasis, in the 
mouse model. We found that dietary iron deficiency did not affect the protozoan growth, 
whereas iron overload decreased its replication in the liver and spleen of a susceptible 
mouse strain. The fact that the iron-induced inhibitory effect could not be seen in mice 
deficient in NADPH dependent oxidase or nitric oxide synthase 2 suggests that iron 
eliminates L.infantum in vivo through the interaction with reactive oxygen and nitrogen 
species. Iron overload did not significantly alter the mouse adaptive immune response 
against L.infantum. Furthermore, the inhibitory action of iron towards L.infantum was also 
observed, in a dose dependent manner, in axenic cultures of promastigotes and 
amastigotes.  
In conclusion, externally added iron synergizes with the host’s oxidative 
mechanisms of defense in eliminating L.infantum from mouse tissues. Additionally, the 
direct toxicity of iron against Leishmania suggests a potential use of this metal as a 
therapeutic tool or the further exploration of iron anti-parasitic mechanisms for the design 
of new drugs. 
 
2. Introduction 
Leishmania are trypanosomatid protozoans that alternate between two forms: the 
extracellular motile promastigote in the gut of phlebotomine insects and the intracellular 
non-motile amastigote inside the macrophages of mammalian hosts. These parasites 
cause leishmaniasis, a spectrum of human diseases that range from self-healing 
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cutaneous ulcers to fatal visceralizing infection. Every year, approximately 2 million people 
develop symptomatic disease (0.5 million of them the visceral form) [4]. In Europe, 
visceral leishmaniasis (VL) is caused almost exclusively by L.infantum, which is 
transmitted as a zoonosis. The domestic dog is one of the main reservoirs of this parasite 
and canine leishmaniasis is an important veterinary problem in European Mediterranean 
countries [1]. 
There are currently no effective vaccines to prevent human leishmaniasis [99]. 
Therefore, management of the disease relies on chemotherapy. However, available drugs 
are highly toxic and the frequency of resistant parasite strains is increasing worldwide 
[21,38]. The improvement of our knowledge on the mechanisms of host resistance to 
Leishmania is important to contribute to the development of new therapeutic strategies. 
The important role played by iron metabolism in the interaction between host and 
pathogens is being increasingly highlighted by recent research [259,260]. Both the host 
and the pathogens absolutely need iron for survival and must have efficient mechanisms 
for its acquisition together with adequate mechanisms of cell defense to avoid iron toxicity. 
Data obtained in human patients, as well as in different animal infection models indicate 
that in most cases iron availability favors the multiplication of pathogens, whereas iron 
deprivation impairs their growth [258,261]. Interestingly, the vertebrates innate immune 
response to infection includes several mechanisms of iron with-holding such as lactoferrin, 
hepcidin, Nramp1 or lipocalin2 [258,259]. Still, adequate concentrations of iron are 
required to support macrophage killing mechanisms during infection [354,355]. Contrary to 
what happens with most pathogens, the growth of Brucella abortus inside macrophages 
[356] and that of L.major in the mouse [350,351,352] are decreased by host’s iron 
overload. In both cases, killing was correlated to oxidative burst [351,356]. These 
examples highlight that iron can be exploited, in some cases, by the host to strengthen its 
antimicrobial defense mechanisms.  
Our group has previously shown that the infection by Mycobacterium avium, an 
intramacrophagic pathogen, is clearly exacerbated by host’s iron overload, either 
genetically determined [357] or caused by iron-dextran injection [358,359]. Furthermore, 
we have also demonstrated that iron chelation can be used to inhibit the growth of 
M.avium [360]. In the present work, we evaluated the effect of iron on the growth of 
L.infantum, the agent of European VL. We found that iron consistently inhibited the 
replication of L.infantum both by a direct effect and through the activity of the host’s 
macrophage.  
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3. Materials & Methods 
3.1. Animals and ethics statement | BALB/c and C57BL/6 mice were purchased 
from Charles River (Madrid, Spain). Mice deficient on the p47 subunit of the NADPH 
oxidase complex, on a C57BL/6 background (p47phox-/-), were bred at IBMC from a 
breeding pair purchased from Taconic (Lille Skensved, Denmark). The p47phox-/- mice 
were administered trimethoprimsulfamethoxazole (Bactrim; 600 mgl-1) in the drinking 
water, as prophylactic treatment against bacterial infection. This treatment was ceased 
when infection experiments began. Mice deficient in the nitric oxide synthase 2, on a 
C57BL/6 background (NOS2-/-), were bred at IBMC from a breeding pair kindly provided 
by Drs. J. Mudgett, J. D. MacMicking and C. Nathan (Cornell University, New York, USA). 
Mice deficient in HFE, on a C57BL/6 background (Hfe-/-) were bred at IBMC from a 
breeding pair obtained from Centre Nationale de la Recherche Scientifique. All animals 
were housed at IBMC facilities under specific pathogen free conditions and fed ad libitum, 
except for the diet experiments indicated below. All animals were used at 8 to 16 weeks of 
age. Only female mice (average 20 – 25 g) were used for in vivo experiments. Mice were 
euthanized by isofluorane anesthesia followed by cervical dislocation and tissues were 
collected in aseptic conditions. The experimental animal procedures were approved by the 
Local Animal Ethics Committee of IBMC and licensed by the Portuguese General 
Directory of Veterinary (DGV, Ministry of Agriculture, Rural Development and Fishing), in 
May 18, 2006 with reference 520/000/000/2006. All animals were handled in strict 
accordance with good animal practice as defined by national authorities (DGV, Law 
nu1005/92 from 23rd October) and European legislation EEC/86/609.  
3.2. Parasites | All experiments were performed with L.infantum strain 
MHOM/MA/67/ITMAP-263 (zymodeme MON-1). For each experiment, parasites were 
obtained from the spleens of infected mice. Promastigotes were differentiated from spleen 
amastigotes by culturing at 25ºC in complete Schneider’s medium (Sigma-Aldrich Co., St 
Louis, MO, USA) supplemented with 20% heat-inactivated fetal bovine serum (FBS), 100 
Uml-1 penicillin, 100 µgml-1 streptomycin (all from Gibco, Life Technologies, Carlsbad, CA, 
USA), 2% human urine, 5 µgml-1 phenol red (Sigma) and 5 mM HEPES sodium salt 
(Sigma) pH 7.4. Promastigote cultures were expanded at 25ºC, for a maximum of 5 
passages, in RPMI 1640 GlutaMAXTM-I medium (Gibco, Life Technologies), containing 
20% FBS, 50 Uml-1 penicillin, 50 µgml-1 streptomycin and 25 mM HEPES sodium salt pH 
7.4. Promastigote differentiation from the exponential to the stationary phase was 
promoted by culture at 25ºC, without medium renovation, for 4 to 5 days.  
Axenic amastigotes were derived from the above-mentioned L.infantum strain, by 
culture at 37ºC with 7% CO2 atmosphere, in a medium for axenic amastigotes 
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supplemented with 2 mM L-glutamine (GlutaMAXTM-I, Gibco, Life Technologies) and 20% 
FBS (MAA20 medium, adapted from [361]).  
3.3. Direct effect of iron on Leishmania promastigote and amastigote cultures | 
Promastigotes (2 × 106 / well) and amastigotes (4 × 105 / well) of L.infantum were cultured 
in complete RPMI (25ºC) or MAA20 (37ºC) medium, respectively, supplemented with iron-
dextran (Fe3+ hydroxide-dextran complex, Sigma), iron citrate (Fe3+, Sigma) and iron 
sulphate (Fe2+, Merck) in the concentrations of 0.018, 0.035, 0.070, 0.14, 0.28, 0.56, 1.1, 
2.2, 4.5, 9 and 18 mM (96 well plates). Equivalent concentrations of dextran (Sigma), tri-
sodium citrate (Merck) and magnesium sulphate (Merck) were used as controls. After 24h 
of culture, 20 µl of a 2.5 mM resazurin solution (freshly prepared and filtered in phosphate 
buffered saline, pH 7.4, Sigma) was added to each well. The fluorescence intensity 
(excitation at 560 nm and emission at 590 nm) was determined 24h (for amastigotes) or 
48h (for promastigotes) after resazurin addition to allow conversion to fluorescent 
resorufin, with a fluorometer SpectraMAX GeminiXS (Molecular Devices LLC, Sunnyvale, 
CA). In order to exclude a possible interference of iron with resazurin conversion to 
resorufin, appropriate controls were included without cells. No resazurin conversion was 
detected in the absence of parasites. Complete RPMI and MAA20 medium contains 
approximately 6 and 7.7 µM of iron, respectively, according to supplier´s information.  
3.4. Animal experimental infection and parasite burden quantification | Mice 
were injected in the lateral vein of the tail with 2 × 107 L.infantum stationary promastigotes 
in 200 µl of phosphate buffered saline (PBS) pH 7.4. At defined time points, the animals 
were euthanized and total livers and spleens were removed and homogenized, 
respectively, in 3.5 ml and 3 ml of complete Schneider’s medium. These suspensions 
were further diluted 1:100 (liver) or 1:10 (spleen). Four-fold serial dilutions of the 
homogenized tissue suspensions were performed in quadruplicate (96 well plates). After 7 
to 14 days at 25ºC, the wells were examined for viable promastigotes. The reciprocal of 
the highest dilution that was positive for parasites was considered to be the number of 
parasites per ml of suspension and was used to calculate the number of parasites per 
organ (parasite burden). 
3.5. Animal experimental iron overload | In the kinetics experiments, 1 mg of iron, 
as iron-dextran (Sigma), was administered every other day intraperitoneally (i.p.) to each 
mouse, from day -20 to day -2 of infection (a total of 10 mg of iron per mouse). Control 
mice received equivalent amounts of dextran (Sigma) by the same route. Parallel studies 
allowed us to verify that the administration of 10 mg of iron in a single injection produced 
the same effect in terms of outcome of Leishmania infection and also that dextran alone 
had no effect on the course of infection. Consequently, in subsequent experiments, iron 
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overload was achieved by one single i.p. injection with 10 mg of iron per mouse. Control 
animals were injected with saline solution pH 6.0. None of the iron-dextran doses tested 
were toxic to the mice, as treated but uninfected mice remained healthy. 
3.6. Animal experimental iron deprivation | Mice were fed iron-free chow 
(Mucedola, Milan, Italy), from weaning until the end of the experiment (24 weeks). Control 
mice were fed a chow that differed only at its iron content (180 mgKg-1, Mucedola, Milan, 
Italy). Chow was administered in plastic recipients to avoid metal contamination. Animals 
were allowed to drink deionized water. 
3.7. Tissue iron determination | Non-heme iron was measured in tissues by the 
bathophenanthroline method [362]. Briefly, tissue samples (30 – 100 mg) were weighted, 
placed in iron-free Teflon vessels (ACV-Advanced Composite Vessel, CEM Corporation, 
Matthews NC, USA) and dried in a microwave oven (MDS 2000, CEM Corporation). 
Subsequently, dry tissue weights were determined and samples digested in an acid 
mixture (30% hydrochloric acid and 10% trichloroacetic acid) for 20 h at 65ºC. After 
digestion, a chromogen reagent (5 volumes of deionised water, 5 volumes of saturated 
sodium acetate and 1 volume of 0.1% bathophenanthroline sulfonate/1% thioglycollic 
acid) was added to the samples in order to react with iron and obtain a colored product 
that was measured spectrophotometrically at 535 nm. The extinction coefficient for 
bathophenanthroline is 22.14 mM-1cm-1. Iron content in tissues was expressed as µg non-
heme iron/ organ. 
3.8. Cytokine quantification | Liver (100 mg) and spleen (50 mg) samples were 
lysed in Bio-plex cell lysis buffer containing 2mM phenylmethanesulfonyl fluoride (PMSF, 
Bio-Rad Laboratories Inc., CA, USA), sonicated for 5 min in a refrigerated bath and 
centrifuged at 4500g for 4 min at 4ºC to remove debris. Total protein was quantified in 
supernatants with the MicroBCA kit (Pierce, Thermo Fisher Scientific). Clear 
homogenates were diluted to 1.5 mgml-1 in PBS pH 7.4 containing 0.5% bovine serum 
albumin (BSA) and again centrifuged at 16000g for 10 min at 4ºC. Cytokine quantification 
in liver and spleen homogenates was performed following Bio-plex assay (Bio-Rad) 
instructions. 
3.9. Flow cytometry analysis | Spleen cells were obtained by teasing these organs 
gently with forceps and incubating them in ammonium chloride hemolytic buffer to lyse 
any remaining erythrocytes. Cell suspensions were then washed with HBSS and 
resuspended in DMEM / 10% FBS. For immunofluorescence staining, 106 splenic cells 
were incubated for 15 min at 4ºC, in a 96 well plate, with fluorescein isothiocyanate 
(FITC)-conjugated anti-DX5 (1:200), anti-Gr1 (1:800) or anti-CD19 (1:200) antibodies, 
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phycoerythrin (PE)-conjugated anti-CD3 (1:200), anti-CD11c (1:200) or anti-CD11b 
(1:400) antibodies and allophycocyanin (APC)-conjugated anti-mouse F4/80 (1:200) 
antibodies (BD Pharmingen, San Diego, CA, USA), in PBS / 1% FBS in order to analyze 
spleen cell populations during infection. The cells were washed twice with PBS / 1% FBS. 
The analysis of the cell populations was based on the acquisition of 10 000 events in a 
Becton Dickinson (BD, Franklin Lakes, NJ, USA) FACSCalibur equipped with BD 
CELLQuest and FlowJo (Tree Star Inc., Ashland, OR, USA) softwares. 
3.10. Histological analysis | Liver samples (50 mg) were fixated in 4% buffered 
paraformaldehyde pH 7.4 and embedded in paraffin. Tissue sections (5 µm) were stained 
with Perls' blue stain for iron (Fe3+) detection. Representative pictures were obtained with 
an Olympus CX31 light microscope equipped with a DP-25 camera (Imaging Software 
Cell^B, Olympus, Center Valley, PA, USA). 
3.11. Statistical analysis | Statistical analysis was carried out using GraphPad 
Prism 5.0 software (GraphPad Software Inc., La Jolla, CA, USA). Student’s t-test was 
used to estimate the statistical significance of the differences between groups. Multiple 
comparisons were performed with One-way ANOVA followed by Dunnett or Student 
Newman-Keuls post hoc test. Differences between groups were considered statistically 
significant when p value was less than 0.05 (*p<0.05; **p<0.01; ***p<0.001).  
 
4. Results 
4.1. Iron deprivation does not affect L.infantum growth in mouse tissues 
Iron withdrawal has been suggested as a means of controlling the growth of several 
unrelated pathogens [261,262]. To evaluate the effect of iron deprivation on the growth of 
L.infantum, BALB/c mice were fed normal or iron-deficient chow for the first 120 days of 
life. They were subsequently infected and kept in the respective diets for the next 60 days, 
before being euthanized. Non-heme iron quantification in the liver and spleen confirmed 
that mice kept on an iron-deficient diet had less than half the amount of iron found in 
controls (Figure 1A). However, no differences in parasite load were observed between 
groups fed control or iron-deficient diets (Figure 1B), indicating that a mild iron deficiency 
has no impact on L.infantum replication in mouse tissues.  
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Figure 1 | Effect of iron deprivation or overload on the growth of L.infantum in the mouse. A. B. BALB/c 
mice were kept on a control or iron deficient diet for 120 days prior to their intravenous (i.v.) infection with 2 × 
107 stationary promastigotes of L.infantum. Mice were sacrificed 60 days after infection. A. Non-heme iron 
content of liver and spleen was quantified in mice fed the control (white bars) or iron deficient diet (black bars). 
The graph shows the average + standard deviation of the non-heme iron content, expressed as µg / organ 
(n=6). B. The parasite burden in the liver and spleen of groups fed the control (white bars) or iron deficient 
(black bars) diet was quantified by limiting dilution. The graph shows the average + standard deviation of the 
log10 number of parasites per organ (n=6). C. BALB/c mice were i.p. injected with 1 mg of iron (given as 
dextran), in 10 alternate days, from day -20 to day -2 of infection (a total of 10 mg of iron per animal). Control 
mice received equivalent amounts of dextran by the same route. Mice were infected i.v. with 2 × 107 stationary 
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promastigotes of L.infantum and were sacrificed at 7, 15, 30 and 60 days of infection. The parasite burden in 
the liver and spleen of control (white circles) or iron overloaded (black circles) groups was quantified by 
limiting dilution (n=5). D. Non-heme iron content in the liver and spleen was quantified in control (white bars) 
and iron overloaded (black bars) groups at 60 days after infection (n=4-5). Student’s t-test was performed to 
determine the statistical significance of the differences between groups (**p<0.01; ***p<0.001). E. F. G. H. 
Perl´s blue staining was performed in liver sections of uninfected (E), uninfected iron overloaded (F), 60 days-
infected (G) and 60 days-infected iron overloaded (H) mice. Black bar corresponds to 50 µm. The results of 
one representative experiment are shown. Two experiments were performed with similar results. 
 
4.2. Iron overload decreases the growth of L.infantum in mouse tissues 
Iron overload correlates with increased susceptibility to a great variety of pathogens 
[261,262]. In order to determine the effect of host’s iron overload on the infection by 
L.infantum, BALB/c mice were injected with 10 mg of iron-dextran or an equivalent 
amount of dextran before infection. Parasite burdens were determined in the livers and 
spleens at 7, 15, 30 and 60 days after infection. The growth of L.infantum in the liver and 
spleen of non-treated mice followed kinetics similar to that previously reported [120,121]. 
During the first 30 days of infection, the parasite numbers increased significantly in both 
organs, returning to baseline levels in the liver thereafter, while continuing to grow in the 
spleen (Figure 1C). Conversely, parasite load was significantly lower in both organs of 
iron-overloaded mice throughout the experiment period (Figure 1C).  
Non-heme iron quantification confirmed that iron-overloaded animals had 8 and 3 
times more iron, respectively, in the liver and spleen than control mice at 60 days after 
infection (Figure 1D). Iron distribution was analyzed in the liver, by Perl’s staining. In those 
animals that were not injected with iron-dextran, iron deposition was very rarely seen 
(Figure 1E, G), the exception being the faint staining of some cell infiltrates (Figure 1G). 
The administration of iron to non-infected mice led to its accumulation predominantly in 
Kupffer cells (Figure 1F, black arrows), as expected from previous reports [253,363]. 
Infection with L.infantum, lead to the appearance of heavily iron-loaded macrophages 
inside cell infiltrates, the areas presumed to correspond to parasite containment (Figure 
1H) [163,165].  
In order to investigate whether the in vivo anti-leishmanial effect of iron could be 
attributed to a generalized host tissue oxidative damage, we measured DNA cleavage and 
lipid peroxidation in the hepatic parenchyma through the immunofluorescence staining for 
TUNEL (Terminal deoxynucleotidyl transferase dUTP nick end labeling) and 4-hydroxy-
nonenal, respectively. Moreover, we assessed the formation of protein carbonyl groups in 
liver protein lysates by western blotting. However, we could not find any differences 
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between control and iron-treated mice (data not shown), indicating that iron 
supplementation in our model did not cause a generalized oxidative damage to the tissue.   
These experiments revealed that the accumulation of iron inside macrophages at 
L.infantum infection foci correlates with reduced parasite´s multiplication, but not to 
generalized tissue damage. 
	  
4.3. High concentrations of iron inhibit the axenic growth of L.infantum 
In order to clarify the mechanisms by which iron exerts its anti-leishmanial effect in 
our model, we first asked whether iron could be exerting a toxic effect directly on the 
parasites. Axenic promastigotes (Figure 2A-C) or amastigotes (Figure 2D-F) of L. 
infantum were grown in the presence of increasing concentrations of iron (0.018 – 18 mM) 
in the form of either dextran (A,D) or citrate (B,E) complexes or sulphate (C,F) salt. 
L.infantum viability was measured, based on the parasite’s capacity to metabolize the dye 
resazurin.  
 
 
Figure 2 | Effect of different forms of iron on the axenic growth of L.infantum pro- and amastigotes: 
Promastigotes in the exponential phase of growth (2 × 106 / well; A, B, C) or amastigotes (4 × 105 / well; D, E, 
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F) were incubated in RPMI (25ºC) or MAA20 (37ºC) medium, respectively, with iron-dextran (A, D), iron citrate 
(B, E) and iron sulphate (C, F) (black circles) in the concentrations of 0.018, 0.035, 0.070, 0.14, 0.28, 0.56, 
1.1, 2.2, 4.5, 9 and 18 mM. Equivalent concentrations of dextran (A, D), tri-sodium citrate (B, E) and 
magnesium sulphate (C, F) were used as controls (white circles). Resazurin dye was added after 24h of 
culture. The fluorescence was measured 24h (for amastigotes) or 48h (for promastigotes) after resazurin 
addition. The results show the average ± standard deviation of the percentage viability in relation to the non-
treated control (n=3). One-way ANOVA, followed by a Newman-Keuls multiple comparison post-hoc test, was 
performed to determine the statistical significance of the differences between control (white circles) and iron 
treated (black circles) groups (*p<0.05, **p<0.01; ***p<0.001). The results of one representative experiment 
are shown. Three experiments were performed with similar results. 
 
Iron concentrations below 0.56 mM had no effect on the multiplication of the 
parasites (Figure 2). Amastigotes seemed to be more susceptible to iron toxicity, as iron 
decreased the viability of these parasites in a dose dependent manner from 0.56 to 18 
mM irrespective of its molecular form (Figure 2D-F). Promastigotes were inhibited by iron-
dextran (Fe3+) at 0.56 mM or above (Figure 2A), while iron citrate (Fe3+) and iron sulphate 
(Fe2+) were active against promastigotes only above 4.5 mM (Figure 2B, C). 
Promastigotes exposed to 9 – 18 mM of iron in any form displayed oval shape, atrophied 
cell body and reduced motility (not shown), changes which are characteristic of stress 
situations [364]. The results obtained by resazurin reduction were confirmed by the visual 
microscopic quantification of the parasites in a Neubauer chamber, on selected samples 
(not shown). Overall, these results indicate that iron can inhibit the growth or even kill 
L.infantum promastigotes and amastigotes, although the concentrations needed to 
achieve that effect are relatively high. 
	  
4.4. Iron overload does not affect the capacity of the L.infantum infected mice 
to induce expansion of splenic cell populations or expression of key 
cytokines  
Since previous studies had suggested that host’s iron-overload interfered with the 
development of a protective immune response [350], we evaluated the impact of iron-
overload on the induction of protective cytokines and specific splenic cell populations in 
our VL model. 
BALB/c mice were treated with 10 mg of iron (given as iron-dextran) or saline 
solution 15 days prior to infection. They were infected with L.infantum and sacrificed 60 
days later. Groups of non-infected mice were kept as controls. We performed a cytometric 
analysis of the number of splenic CD3+ (T cells), CD3-DX5+ (NK cells), CD19+ (B cells), 
CD11c+ (DCs), CD11b+F4/80+ (Macrophages) and CD11b+Gr1++ (Neutrophils) cells. The 
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infection with L.infantum resulted in a significant increase in the numbers of CD19+ and 
CD11c+ cells, while other splenic cell sub-sets remained unaltered (Figure 3). More 
importantly, the number of cells belonging to each of the abovementioned populations 
was the same in control and iron overloaded groups (Figure 3).  
Additionally, the in situ production of a number of cytokines was measured, using a 
multiplex assay. The results of this screening revealed that infection with L.infantum did 
not have a dramatic impact on cytokine production. Only IL-1β, IL-6, TNF and IL-4 were 
significantly induced by infection in the spleen (the latter also in the liver, Figure 4), while 
the production of IL-12p70 and IL-13 decreased with infection, in the liver (Figure 4). No 
significant differences were found between iron overloaded and control infected animals in 
any of the cytokines tested (Figure 4). The determination of cytokine mRNA expression in 
the tissues at earlier time-points did not reveal any differences between iron-overloaded 
and control infected mice (not shown). 
Overall, these experiments indicate that the inhibitory effect of iron on the growth of 
L.infantum in the mouse does not result from an improvement of the activation of 
protective cells or increased production of protective cytokines. 
 
 
Figure 3 | Effect of iron overload on the capacity of the mouse to induce the expansion of splenic cell 
populations. BALB/c mice were i.p. injected with saline solution or 10 mg of iron (-dextran, in a single dose) 
and were infected 15 days later by the i.v. route, with 2 × 107 L.infantum stationary promastigotes (inf) or were 
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left uninfected (non-inf). Mice were sacrificed 60 days later and the spleen was collected. The levels of CD3+, 
CD3-DX5+, CD19+, CD11c+, CD11b+F4/80+ and CD11b+GR1++ cells were quantified in the spleen of mice 
without (white bars) or with (black bars) iron overload. The results express the average + standard deviation of 
the total number of cells in the spleen (n=3-5). One-way ANOVA, followed by a Newman-Keuls multiple 
comparison post-hoc test, was performed to determine the statistical significance of the differences between 
all groups (*p<0.05). The results of one representative experiment are shown. Two experiments were 
performed with similar results. 
 
 
Figure 4 | Effect of iron overload on the capacity of the mouse to induce the production of key 
cytokines. BALB/c mice were i.p. injected with saline solution or 10 mg of iron (-dextran, in a single dose) and 
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were infected 15 days later by the i.v. route, with 2 × 107 L.infantum stationary promastigotes (inf) or were left 
uninfected (non-inf). Mice were sacrificed 60 days later and liver (100 mg) and spleen samples (50 mg) were 
collected and homogenised in protein lysis buffer with 2mM PMSF (Bio-plex Cell Lysis Kit, Biorad). The levels 
of IL-1β, IL-2, IL-4, IL-6, IL-10, IL-13, IL-12p70, IFNγ, TNF and IL-17 were quantified in liver and spleen 
homogenates of mice without (white bars) or with (black bars) iron overload, accordingly to 10-Plex assay 
instructions (Biorad). The results express the average + standard deviation of the cytokine levels, expressed in 
pg / mg of protein (n=3-5). Student’s t-test was performed to determine the statistical significance of the 
differences between the different groups (*p<0.05; **p<0.01). The results of one representative experiment are 
shown.  
 
4.5. High iron doses and administration prior to infection are necessary for the 
inhibitory effect of iron 
In order to further understand the mechanisms of the iron inhibitory effect on 
L.infantum, we tested the importance of different experimental parameters. First, we 
decided to assess if the same protective effect could be obtained with lower iron doses. 
BALB/c mice were injected with different amounts of iron (given as iron-dextran complex) 
prior to infection with L.infantum. Parasite loads were determined 30 days after infection. 
A significant inhibitory effect on the growth of L.infantum in the liver and spleen was seen 
only in mice that received 10 mg of iron (Figure 5A). The administration of lower iron 
doses (0.4, 1 and 4 mg) tended to decrease the parasite growth in the liver, but not to a 
statistically significant level (Figure 5A).  
Next, we asked whether iron would still have an inhibitory effect on L.infantum 
growth when given after infection. We administered 10 mg of iron (-dextran) or saline 
solution to BALB/c mice, 1 or 15 days after infection. Parasite loads were determined 60 
days post-infection. In the liver, similar levels of growth inhibition were seen when iron 
was given either before, 1 day after or 15 days after infection (Figure 5B). However, in the 
spleen and in contrast with iron pre-loading, no significant reduction on the growth of 
L.infantum was detected when the administration of iron was done after infection (Figure 
5B). 
These results suggested that high amounts of iron present in the host prior to 
infection favor the decrease of the multiplication of L.infantum. In the model used, iron 
accumulation is observed in macrophages. To assess the relevance of the cellular 
location of iron deposition at the time of infection, we used HFE-deficient mice which are 
used as a model of human hemochromatosis and accumulate iron in parenchymal cells 
rather than inside macrophages [365,366]. We infected Hfe-/- mice with L.infantum and 
evaluated the parasite load and iron content in the livers and spleens at 60 days after 
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infection. HFE-deficient mice had around 3 times more iron in the liver than controls and 
normal amounts of iron in the spleen (Figure 6A). As expected, in non-infected Hfe-/- mice, 
iron was found predominantly in the hepatic parenchyma (Figure 6D). However, in 
L.infantum-infected mice, strong iron staining was found inside cell infiltrates both in wild-
type mice and (more intensely) in Hfe-/- mice (Figure 6E,F) showing that infection re-
routed iron between the two cell types. Interestingly, the parasite loads in wild-type and 
Hfe-/- mice were the same (Figure 6B). 
Overall, these results indicate that a decrease in the growth of L.infantum is 
observed when high amounts of iron are found inside the host’s macrophages, with a 
stronger effect when this occurs before the infection. 
 
 
Figure 5 | Effect of different iron doses and periods of administration on the growth of L.infantum. A. 
BALB/c mice were injected i.p. with 0.4, 1, 4 or 10 mg of iron (-dextran), in a single dose, 12 days before the 
infection. B. BALB/c mice were injected i.p. with 10 mg of iron (-dextran), in a single dose, 15 days before or 1 
and 15 days after the infection (-15, +1 and +15 days, respectively). A. B. Control mice received saline 
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solution by the same route. Mice were sacrificed 30 (A) or 60 (B) days after the i.v. infection with 2 × 107 
stationary promastigotes of L.infantum. The parasite burden in the liver and spleen of mice without (white bar) 
and with (gray - black bars) iron administration was determined by limiting dilution. The data shows the 
average + standard deviation of the log10 number of parasites per organ (n=4-5). One-way ANOVA, followed 
by a Dunnett’s multiple comparison post-hoc test, was performed to determine the statistical significance of 
the differences between each of the iron treated groups and control group (*p<0.05; **p<0.01; ***p<0.001). 
The results of one representative experiment are shown. Two experiments were performed with similar 
results. 
 
 
Figure 6 | Effect of genetically determined iron overload on the growth of L.infantum in mice.  A. B. 
Wild-type (WT) and Hfe-/- mice were i.v. infected with 2 × 107 stationary promastigotes of L.infantum and were 
sacrificed 60 days after infection. A. Non-heme iron content in both organs was quantified in WT (white bars) 
and Hfe-/- (black bars) groups. The data shows the average + standard deviation of the non-heme iron content, 
expressed in µg / organ (n=4-6). Student’s t-test was performed to determine the statistical significance of the 
differences between WT and Hfe-/- groups (***p<0.001). B. The parasite burden in the liver and spleen of WT 
(white bars) and Hfe-/- (black bars) mice was determined by limiting dilution (n=5-6). C. D. E. F. Perl´s blue 
staining was performed in liver sections of uninfected (C) and infected (E) WT and uninfected (D) and infected 
(F) Hfe-/- mice. Black bar corresponds to 50 µm. The results of one representative experiment are shown. Two 
experiments were performed with similar results. 
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4.6. Host production of reactive oxygen and nitrogen species is necessary for 
the inhibitory effect of iron overload on L.infantum growth 
Iron concentrations necessary to inhibit L.infantum growth in axenic conditions are 
relatively high. So, we hypothesised that iron synergizes with antimicrobial mechanisms of 
macrophages, such as the production of reactive oxygen species (ROS) by the NADPH 
oxidase (respiratory burst) and reactive nitrogen species (RNS) by the nitric oxide 
synthase 2 (NOS2) to decrease Leishmania viability in the mouse tissues.  
 
 
Figure 7 | Effect of iron overload on the growth of L.infantum in mice: role of NADPH oxidase and 
NOS2. Wild-type (WT) and p47phox-/- (A, C) or NOS2-/- (B, D) mice were i.p. injected with saline solution or 10 
mg of iron (-dextran, in a single dose) 15 days before i.v. infection with 2 × 107 stationary promastigotes of 
L.infantum and were sacrificed 15 days later. The liver (A, B) and spleen (C, D) were removed and the 
parasite burden in mice without (white bars) or with (black bars) iron overload was quantified by limiting 
dilution. The results express the average + standard deviation of the log10 number of parasites per organ (n=3-
8). One-way ANOVA, followed by a Newman-Keuls multiple comparison post-hoc test, was performed to 
determine the statistical significance of the differences between all groups (*p<0.05; **p<0.01; ***p<0.001). 
The results of one representative experiment are shown. At least two experiments were performed with similar 
results. 
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Mice genetically deficient in the p47phox subunit of NADPH oxidase (p47phox-/-) 
and in the NOS2 enzyme (NOS2-/-) were used to test this hypothesis. Animals were 
treated with 10 mg of iron (-dextran) or saline solution and 15 days later were infected with 
L.infantum. Mice were sacrificed 15 days after infection and the parasite load was 
determined in the liver and spleen. Iron overload decreased L.infantum growth in wild-type 
but not in knock-out mice in the liver (Figure 7A, B) and spleen (Figure 7C, D), indicating 
that the mechanism through which iron exerts its inhibitory effect is dependent on the 
production of ROS and RNS by the host. A similar experiment in which animals were 
sacrificed 30 days after infection gave identical results (data not shown). 
	  
5. Discussion 
Iron is a central element in host-parasite interaction and several iron-depriving 
mechanisms are used by the host to inhibit pathogen proliferation [259,260]. In contrast, 
previous work has shown that host’s iron overload prevented the growth of L.major in 
BALB/c mice [350,351,352]. In those studies, it is shown that iron overload correlates with 
increased production of ROS upon L.major infection [351]. In the present work, we treated 
mice with iron-dextran and infected them with L.infantum. We observed iron-loaded 
macrophages inside hepatic infiltrates, the areas of parasite containment, concomitantly 
with the decrease of tissue parasite loads. Such iron-associated decrease did not occur in 
p47phox- or NOS2-deficient mice, suggesting that iron exerts its effects through the 
combination with ROS and/or RNS produced by the macrophage. In fact, superoxide (O2•-
) and nitric oxide (NO•), synthesized by the phagocytic NADPH oxidase and the NOS2, 
respectively, have been implicated in the elimination of Leishmania by the host’s 
macrophages [166,195,204,214,217,218,220,222,225]. Moreover, both macrophagic 
NADPH oxidase and NOS2 require iron for proper function [170].  
The fact that the anti-parasitic effect of iron is lost in mice deficient in only one of the 
two enzymes, either NOS2 or NADPH oxidase, suggests that both ROS and RNS are 
simultaneously required for iron to exert its anti-leishmanial effect. Iron can possibly favour 
the formation of peroxynitrite (ONOO-), a strong oxidizing species formed by the reaction 
of NO• with O2•- [172]. Since we could not find evidences of tissue oxidative damage 
(DNA damage, lipid peroxidation and protein oxidation) in iron-treated mice, we suggest 
that this formation of ROS and RNS in combination with iron has a highly localized 
activity, inside the macrophage. 
It was somewhat surprising that Hfe-/- mice, which have spontaneous iron overload, 
predominantly in the liver, had tissue parasite loads similar to those of wild-type mice, 
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when infected with L.infantum. This could be justified by the fact that Hfe-/- mice develop 
spontaneous iron overload predominantly in hepatocytes, keeping macrophages relatively 
iron depleted [365,366,367]. When Hfe-/- mice were infected with L.infantum, we could see 
iron accumulation inside macrophages at the infection foci. However, as suggested by the 
experiments in which we treated mice with iron-dextran after infection, the inhibitory effect 
of iron is best accomplished when the macrophages are iron-loaded prior to infection. 
Another hypothesis to explain the lack of an impact of Hfe-/- iron overload on the growth of 
L.infantum is the level of iron overload in the tissues. Indeed, Hfe-/- mice had tissue iron 
levels that were significantly lower than those found in iron-dextran-injected mice. The fact 
that even with iron-dextran injection, we needed high iron doses to decrease the parasite 
burden in tissues, argues for this hypothesis.  
In the mouse model of CL, iron-induced respiratory burst at the onset of L.major 
infection is coupled to later activation of the nuclear transcription factor NF-κB [352] and to 
the display of a protective immune response [350]. Iron and ROS can modulate the 
activation of NF-κB signaling pathways [368], known to regulate several genes involved in 
immune and inflammatory responses [369]. In the case of L.major infection, mouse 
resistance is clearly related to an IL-12-driven, IFNγ-dominated Th1 immune response, 
whereas susceptibility correlates with an IL-4-driven Th2 response [122,123,141,370]. 
Experimentally iron overloaded BALB/c mice, infected with L.major, exhibited a Th1-type 
immune response, with increased levels of IFNγ and NOS2 and decreased levels of IL-4 
and IL-10 transcripts compared to untreated mice [350]. In accordance, supplementation 
of rats with iron-dextran [371] or saccharated colloidal iron [372] potentiated the induction 
of hepatic NOS2 and the production of NO• by LPS. However, the decrease of NO• 
production has also been observed in mice [373] and macrophages [374] treated with 
different iron sources. Additionally, delayed Th1 immune responses and Th2 phenotypes 
have been observed in response to iron supplementation in mice infected with 
Cryptoccocus neoformans [375] and Candida albicans [376], indicating that each 
particular host-pathogen interaction responds differently to iron overload. 
In the case of VL, an efficient control of infection is also dependent on Th1 
responses, although a mixed Th1/Th2 cytokine profile is detected during the course of 
infection [120,121,141,377]. So, iron supplementation in our model, besides exerting a 
direct toxic effect on parasites in conjunction with ROS and RNS, could be improving the 
host’s capacity to control the infection, by modulating the adaptive immune response. 
When we evaluated the cytokine response to L.infantum infection, we saw a discrete 
induction of IL-4 both in the liver and the spleen of infected mice, together with increases 
in the splenic expression of the pro-inflammatory cytokines, IL-1β, IL-6 and TNF. 
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However, iron overload did not significantly alter the immune response profile induced by 
infection, leading us to conclude that the modulation of the adaptive immune response 
does not contribute significantly to the protective effect of iron.  
Most studies indicate that iron deficiency impairs the growth of pathogens 
[258,261,262]. In our model, feeding mice with an iron deficient diet did not affect 
L.infantum growth. Observations regarding the effects of iron chelators on Leishmania 
growth are contradictory. Treatment of mice with desferrioxamine (DFO) led to the 
decrease of L.infantum proliferation [349] but not that of L.major [350]. Also, in in vitro 
models of macrophage infection, DFO has shown either no effect [347] or an inhibitory 
effect [342,345] on Leishmania growth. Finally, when tested on Leishmania promastigotes 
growing in culture medium, hydroxypiridinone-derived chelators showed some inhibitory 
effect, which was higher than that of DFO [346]. Thus, overall, Leishmania do not seem to 
be particularly sensitive to iron deprivation. In our model of nutritional iron deficiency, the 
low levels of iron in tissue stores were probably sufficient to maintain the growth of 
Leishmania and not low enough to impact on the host’s capacity to control the infection. 
In addition to the results obtained in vivo and discussed above, we found axenic 
cultures of L.infantum to be sensitive to the direct toxicity of iron. In this regard, L.infantum 
promastigotes have been shown to accumulate iron in catalytically active forms, which 
contribute to their sensitivity to killing by hydrogen peroxide (H2O2) [193,335], possibly 
through the Fenton reaction. Upon exposure to high doses of this metal, L.infantum 
promastigotes exhibited impaired motility and morphological changes identical to those 
reported to occur after exposure to antimony (III) [364] (not shown). This metalloid, used 
for a long time as a first line treatment against leishmanial infections, was recently found 
to act through the induction of oxidative damage in L.donovani [31,364]. Interestingly, 
increased intracellular iron levels directly correlated to the parasite sensitivity to this drug 
[364].  
In conclusion, the present work discloses that iron overload decreases Leishmania 
proliferation and induces parasite death, probably by promoting oxidative reactions 
pernicious to the parasite. The further investigation of the molecular mechanisms of these 
effects will be fundamental to explore a potential utilization of iron itself as a therapeutic 
tool and also to understand and improve the mechanisms of action of other anti-
leishmanial drugs. 
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Chapter IV | Phagocyte NADPH Oxidase, But Not Nitric 
Oxide Synthase 2, Is Essential For The Control Of 
Leishmania infantum In The Mouse Tissues 
 
1. Abstract 
Reactive oxygen and nitrogen species generated by the phagocyte NADPH oxidase 
and the nitric oxide synthase 2 (NOS2) respectively, are of crucial importance for host 
resistance to numerous microbial pathogens. However, their contribution to host defense 
against visceralizing species of Leishmania in the mouse model has not been clearly 
defined. To help elucidate this subject, we investigated the capacity of mice genetically 
deficient in the p47phox subunit of NADPH oxidase (p47phox-/-) and nitric oxide synthase 
2 (NOS2-/-) to combat an infection with L.infantum, a causative agent of visceral 
leishmaniasis. We found that NADPH oxidase is essential to restrain the initial 
establishment of L.infantum in the spleen and to inhibit late infection in the liver. In 
contrast, NOS2 does not confer protection against the parasite in none of the organs nor 
at any stage of the infection. Relevantly, NADPH oxidase deficiency did not impair the 
expression of NOS2. 
In sum, our results demonstrate that NADPH oxidase, not NOS2, is the critical host 
effector mechanism involved in the control of L.infantum in the mouse model. 
 
2. Introduction 
Leishmania parasites maintain their life cycle by alternating between flagellated 
promastigotes in the gut of phlebotomine insects and non-flagellated amastigotes inside 
macrophages of mammalian hosts [3,5]. These protozoa cause leishmaniasis, a complex 
of mammalian diseases whose clinical symptoms range from self-healing cutaneous 
lesions to the more severe visceralizing infection [2]. Human visceral leishmaniasis (VL) 
results from infection with L.donovani and L.infantum and is usually fatal if left untreated, 
accounting for more than 50 000 deaths per year [4,13].  
In the macrophage, Leishmania parasites have to overcome several microbicidal 
mechanisms in order to survive and replicate. Two of the most important antimicrobial 
systems of these cells, as well as of other phagocytes, are based on the activity of 
NADPH oxidase and nitric oxide synthase 2 (NOS2), which are the enzyme complexes 
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responsible for the generation of superoxide (O2•-) and nitric oxide (NO•), respectively. 
These radicals can give rise to other more toxic intermediates collectively known as 
reactive oxygen species (ROS) and reactive nitrogen species (RNS) [170,171].  
There is plenty of evidence indicating that ROS and RNS inhibit the multiplication of 
visceral species of Leishmania in axenic cultures as well as inside macrophages 
[186,187,188,189,190,191,192,193,194,199,201,205,206,207,209,210]. However, their 
relevance to the control of infections caused by visceralizing Leishmania in mouse models 
has not been thoroughly characterized. The two available studies have been performed 
exclusively with L.donovani and have yielded conflicting results [166,223]. The first report 
demonstrated that both NADPH oxidase and NOS2 acted in concert to control early 
L.donovani replication in the liver, whereas NOS2 on its own was sufficient to resolve late 
infection [166]. Contrasting with these data, a subsequent study showed that none of 
these antimicrobial mechanisms influenced the growth of L.donovani either in the early or 
late stages of hepatic infection, although NOS2 exerted moderate protective effects in the 
spleen at late phases of infection [223].  
In this work, we sought to explore the contribution of ROS and RNS to the control of 
L.infantum infections in vivo. We found that NADPH oxidase and ROS, but not NOS2 or 
RNS, are critical to restrain L.infantum infection in the mouse liver and spleen. 
 
3. Materials and Methods 
3.1. Animals and ethics statement | C57BL/6 mice were purchased from Charles 
River (Madrid, Spain). Mice deficient in the p47 subunit of the NADPH oxidase complex, 
on a C57BL/6 background (p47phox-/-), were bred at IBMC from a breeding pair 
purchased from Taconic (Lille Skensved, Denmark). The p47phox-/- mice were 
administered trimethoprimsulfamethoxazole (Bactrim; 600 mgl-1) in the drinking water, as 
prophylactic treatment against bacterial infection. This treatment was ceased when 
infection experiments began. Mice deficient in the nitric oxide synthase 2, on a C57BL/6 
background (NOS2-/-), were bred at IBMC from a breeding pair kindly provided by Drs. J. 
Mudgett, J. D. MacMicking and C. Nathan (Cornell University, New York, USA). All 
animals were housed at IBMC facilities under specific pathogen free conditions and fed ad 
libitum. Only female mice (average 20 – 25 g) were used at the age of 8 to 16 weeks. 
Mice were euthanized by isofluorane anesthesia followed by cervical dislocation and 
tissues were collected in aseptic conditions. The experimental animal procedures were 
approved by the Local Animal Ethics Committee of IBMC and licensed by the Portuguese 
General Directory of Veterinary (DGV, Ministry of Agriculture, Rural Development and 
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Fishing), in May 18, 2006 with reference 520/000/000/2006. All animals were handled in 
strict accordance with good animal practice as defined by national authorities (DGV, Law 
nu1005/92 from 23rd October) and European legislation EEC/86/609.  
3.2. Parasites | All experiments were performed with L.infantum strain 
MHOM/MA/67/ITMAP-263 (zymodeme MON-1). For each experiment, parasites were 
obtained from the spleens of infected mice. Promastigotes were differentiated from spleen 
amastigotes by culturing these at 25ºC in complete Schneider’s medium (Sigma-Aldrich 
Co., St Louis, MO, USA) supplemented with 20% heat-inactivated fetal bovine serum 
(FBS), 100 Uml-1 penicillin, 100 µgml-1 streptomycin (all from Gibco, Life Technologies, 
Carlsbad, CA, USA), 2% human urine, 5 µgml-1 phenol red (Sigma) and 5 mM HEPES 
sodium salt (Sigma) pH 7.4. Promastigote cultures were expanded at 25ºC, for a 
maximum of 5 passages, in RPMI 1640 GlutaMAXTM-I medium (Gibco, Life Technologies), 
containing 20% FBS, 50 Uml-1 penicillin, 50 µgml-1 streptomycin and 25 mM HEPES 
sodium salt pH 7.4. Promastigote differentiation from the exponential to the stationary 
phase was promoted by maintaining the cultures without medium renovation for 4 to 5 
days at 25ºC.  
3.3. Animal experimental infection and parasite burden quantification | Mice 
were injected in the lateral vein of the tail with 2 × 107 L.infantum stationary promastigotes 
in 200 µl of phosphate buffered saline (PBS) pH 7.4. At defined time points, the animals 
were euthanized and total livers and spleens were removed and homogenized, 
respectively, in 3.5 ml and 3 ml of complete Schneider’s medium. These suspensions 
were further diluted 10- to 100-fold accordingly to the time point being assessed. Four-fold 
serial dilutions of the homogenized tissue suspensions were performed in quadruplicate. 
After 7 to 14 days at 25ºC, the wells were examined for viable promastigotes. The 
reciprocal of the highest dilution that was positive for parasites was considered to be the 
number of parasites per ml of suspension and was used to calculate the number of 
parasites per organ (parasite burden). 
3.4. Indirect immunofluorescence assay | Liver and spleen samples were fixated 
in 4% buffered paraformaldehyde pH 7.4 and embedded in paraffin. Tissue sections (5 
µm) were adhered to poly-L-lysine treated slides, deparaffinised in xylol and re-hydrated. 
Tissues were permeabilized for 5 min with the working solution PBS-TritonX-100 0.1%–
Tween20 0.1% and antigen retrieval was performed in 10 mM citrate buffer pH 6.0 for 30 
min at 96ºC. After blocking with a rat purified anti-mouse CD16/CD32 (2.4G2, BD 
Pharmingen, San Diego, CA, USA) diluted 1:100 in working solution-BSA 5% for 30 min at 
room temperature (RT), the tissues were incubated overnight (ON) at RT with a rabbit 
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polyclonal anti-mouse NOS2 antibody (M-19, Santa Cruz Biotechnology, Santa Cruz, CA, 
USA) diluted 1:100 in working solution. Then, tissues were washed in PBS and 
subsequently incubated for 3h at RT with Alexa Fluor 568 goat anti-rabbit IgG (A-11036, 
Molecular Probes, Eugene, OR, USA) diluted 1:500 in working solution. After washing in 
PBS for 3h at 4ºC, the tissues were incubated for 15 min in a solution of 0.2 µg/mL DAPI 
(Sigma-Aldrich Co., St Louis, MO, USA) and were mounted with VectaShield (Vector 
Laboratories Ltd., UK). The images were obtained with a Zeiss AxioImager Z1 epi-
fluorescence microscope and analysed with the Zeiss AxioVision Rel. 4.8.2 software (Carl 
Zeiss Microscopy GmbH, Germany). Background was subtracted with Photoshop CS5 
(Adobe Systems Inc., San Jose, CA, USA). No significant signal was observed in the 
negative controls (no antibodies; no primary antibody; both antibodies in NOS2-/- mice).  
3.5. Statistical analysis | Differences between groups were estimated with 
Student’s t-test and considered significant when p value was less than 0.05 (*p<0.05; 
***p<0.001). 
 
4. Results 
The role of ROS and RNS in the control of infection caused by visceralizing 
Leishmania species in mouse models is not clearly defined [166,223]. In this study, we 
proposed to dissect how the production of ROS and RNS affects the outcome of 
L.infantum infection in the mouse. To address this issue, we followed the kinetics of the 
infection of mice genetically deficient in the p47phox subunit of the NADPH oxidase 
(p47phox-/-) and in the NOS2 enzyme (NOS2-/-). Both knock-out and wild-type mice were 
infected with L.infantum stationary promastigotes and the parasite load in the liver and 
spleen was estimated at 3 hours or 1, 7, 15, 30, 60 and 120 days after infection.  
Our results show that the parasite burden in the liver of wild-type and p47phox-/- 
mice is identical during the first 30 days of infection, but is increased in the knock-out mice 
at 60 and 120 days after infection (Figure 1A, left). Hence, NADPH oxidase is required to 
control L.infantum but only at late phases of infection in the liver. A different picture is 
observed in the spleen, where p47phox-/- mice have parasite loads significantly higher 
than wild-type animals as soon as 3 and 24h after infection (Figure 1B, right). This 1-
logarithmic difference in parasite burden is maintained at all other time points analyzed 
(Figure 1A, right) and, most likely, is a consequence of the early restrain of L.infantum 
infection by NADPH oxidase. 
 75 
 
Figure 1 | Role of NADPH oxidase and NOS2 on the control of L.infantum infection in the mouse. Wild-
type (WT) and p47phox-/- (A, B) or NOS2-/- (C) mice were i.v. infected with 2 × 107 L.infantum stationary 
promastigotes and sacrificed at 1, 7, 15, 30, 60 and 120 days after infection (A, C) or at 3 and 24 hours after 
infection (B). The parasite burden in the liver and spleen of WT (white bars) or knock-out (black bars) mice 
was quantified by limiting dilution. The data shows the average + standard deviation of the log10 number of 
parasites per organ (n=4-9). Student’s t-test was performed to determine the statistical significance of the 
differences between groups (*p<0.05; ***p<0.001).  
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In contrast to the results above, wild-type and NOS2-/- mice were equally susceptible 
to L.infantum infection at all time points assessed and in both organs (Figure 1C). 
Importantly, we confirmed that the NOS2 protein was expressed in the liver and spleen of 
wild-type and p47phox-/- mice at 30, 60 (not shown) and 120 days after infection (Figure 
2A), but not in NOS2-/- mice. We also observed that while the number of hepatic infiltrates 
expressing NOS2 was identical in both groups (Figure 2B), the number of splenic foci 
staining for this protein in p47phox-/- was clearly higher than in the wild-type (Figure 2A). 
Together, these results indicate that NOS2 expression in the mouse tissues analysed 
does not correlate with protection against L.infantum.  
In short, we conclude that the activity of NADPH oxidase, unlike that of NOS2, is 
critical for the control of L.infantum in vivo. 
 
 
Figure 2 | Expression of NOS2 protein in the hepatic and splenic tissue of L.infantum infected mice. 
Liver and spleen sections from wild-type (WT), p47phox-/- or NOS2-/- mice infected with 2 × 107 stationary 
promastigotes of L.infantum for 30, 60 and 120 days were stained for NOS2 protein (red). Nuclei were 
counterstained with DAPI (blue). A. It is only shown the NOS2 staining detected at 120 days after infection, as 
it is similar to that of other time points. White bar represents 20 µm (liver) or 100 µm (spleen). B. The 
expression of NOS2 in the liver was determined as the percentage (%) of the number of NOS2-positive 
 77 
infiltrates towards the total number of infiltrates, which were counted in 15 random microscopic fields per liver 
section (n=4-6). A similar quantification was not performed in the spleen, since no infiltrates were observed. 
No statistically significant differences were found.  
 
5. Discussion 
The present study shows that NADPH oxidase is a key factor controlling the initial 
establishment of L.infantum in the spleen and restricting late infection in the liver. In 
contrast, NOS2 does not confer protection against the parasite in none of these organs at 
any stage of the infection.  
The generation of ROS by the NADPH oxidase of professional phagocytes is known 
to be triggered by phagocytosis of Leishmania promastigotes 
[170,171,186,188,189,191,195,205,206,207,209]. Accordingly, we have observed that 
ROS restrain the onset of infection by L.infantum promastigotes in the mouse spleen, 
since mice deficient in the p47phox subunit of NADPH oxidase (p47phox-/-) have 
significantly higher parasite burdens than control mice at 3 and 24h after infection. 
Neutrophils [130] and macrophages, which produce high levels of ROS, are likely to play 
a decisive role in the early containment of L.infantum in the mouse spleen. Importantly, 
the same difference in splenic parasite burden between wild-type and p47phox-/- mice was 
seen throughout the entire course of infection, reinforcing that ROS were important to 
regulate the initial extent of L.infantum replication. Nevertheless, infection progression still 
occurs in both groups of mice, meaning that several parasites survive the early respiratory 
burst. Indeed, the spleen is a site of parasite persistency that becomes chronically 
infected in VL [120,121,163].  
In the liver, the role of NADPH oxidase appears to be different from the spleen as its 
activity is only apparent in the late phase of infection. The liver is a site of early 
multiplication for visceralizing Leishmania that spontaneously controls infection by forming 
granulomas [120,121,163]. It is assumed that infected Kupffer cells, comprised inside 
granulomas, are activated to eliminate Leishmania amastigotes through the production of 
ROS and RNS [163]. We hypothesize that Kupffer cells or recruited blood monocytes only 
produce ROS to eliminate L.infantum amastigotes when the granuloma becomes fully 
matured and the adequate activating stimuli are present [165]. Although granuloma 
formation is an asynchronous process, these structures tend to become mature around 30 
- 60 days upon infection with visceral Leishmania [163,165], which argues in favour of our 
hypothesis.  
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The fact that IFNγ-activation of human macrophages genetically deficient in the 
NADPH oxidase leads to eventual restrain of L.donovani growth, indicates that other 
effector mechanisms like NOS2 might intervene in the control of visceralizing Leishmania 
[205]. Contradictorily, we found that NOS2 is not essential to restrain the growth of 
L.infantum, since mice deficient in the NOS2 enzyme (NOS2-/-) and wild-type mice display 
identical parasite loads in both the liver and spleen. Of relevance, control and p47phox-/- 
mice developed progressive infection in the spleen, despite the high NOS2 protein 
expression. Thus, NOS2 expression and RNS generation do not correlate with protection 
against L.infantum infection. The latter observations have also been made in the spleen of 
mice chronically infected with L.major [214], L.infantum [121] and L.donovani [378]. 
Together, these results suggest that the strain of L.infantum studied in this work may be 
resistant to the action of RNS. Remarkably, NO•-resistant strains of L.infantum, which 
exhibit increased capacity to survive and multiply inside macrophages, have been isolated 
from infected humans and dogs [227]. Otherwise, L.infantum may have the capacity to 
locally subvert the expression of NOS2. In fact, we have spotted some infected cells in the 
hepatic parenchyma that were not expressing NOS2 (data not shown). However, we 
cannot exclude the possibility that NOS2 had not yet been activated in those parasitized 
cells, since this observation was made only at 30 days after infection.  
Finally, previous studies showed that NADPH oxidase and NOS2 had little or no 
influence on the control of L.donovani growth in the mouse liver and spleen [223] or that 
NOS2 alone was sufficient for the resolution of hepatic infection [166]. Our work clearly 
demonstrates that NADPH oxidase, not NOS2, is crucial for the control of L.infantum. The 
discrepancy between these experimental models of VL might be attributed to several 
factors. First, L.donovani and L.infantum might have distinct sensitivities to ROS and RNS 
in vivo. Second, we infected mice with L.infantum promastigotes, while the other studies 
used the L.donovani amastigote stage, which barely triggers the respiratory burst of 
macrophages [188,191,205,209]. Third, the genetic background of mice was different 
between these studies.  
In conclusion, understanding the host mechanisms that govern resistance to 
Leishmania may open new avenues to develop adequate therapeutic strategies. Our work 
discloses that the control of L.infantum in vivo is mediated by ROS and not by RNS.  
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Chapter V | Peptidomimetic And Organometallic Derivatives 
Of Primaquine Active Against Leishmania infantum 
 
1. Abstract 
The current treatment of visceral leishmaniasis is made difficult by the low efficacy, 
elevated costs, low bioavailability and high toxicity of many of the available drugs. 
Primaquine, an anti-malarial 8-aminoquinoline, displays activity against Leishmania spp. 
and several of its derivatives have been developed as potential anti-leishmanial drugs. 
However, primaquine exhibits low oral bioavailability due to oxidative deamination of its 
aliphatic chain. We have previously developed peptidomimetic and organometallic 
derivatives of primaquine with higher resistance to proteolytic degradation and oxidative 
deamination, which presented significant activity against primaquine-sensitive pathogens 
like Plasmodium or Pneumocystis. In light of these relevant findings, we decided to 
evaluate these compounds against both the promastigote and the intramacrophagic 
amastigote forms of Leishmania infantum, the agent of Mediterranean visceral 
leishmaniasis. We found that several of these compounds had significant activity against 
L.infantum. One of the peptidomimetic (3c) and one of the organometallic (7a) derivatives 
of primaquine were active against the clinically relevant intramacrophagic amastigote form 
of the parasite, causing more than 96% reduction in the number of amastigotes per 100 
macrophages at 60 and 40 µM respectively, while being less cytotoxic for host cells than 
reference drugs sitamaquine or miltefosine. Hence, 3c and 7a represent new entries 
towards the development of new anti-leishmanial leads. 
 
2. Introduction 
Leishmania are digenetic protozoa that alternate between motile promastigotes in 
the gut of the sand fly and non-motile amastigotes inside macrophage phagolysosomes of 
the mammalian host. These parasites are the causative agents of leishmaniasis, a 
disease with clinical symptoms that range in severity from self-healing cutaneous lesions 
to serious mucocutaneous disfigurement and fatal visceralizing infection. The World 
Health Organization estimates that more than 12 million people are currently infected, with 
2 million new cases occurring every year and 350 million people, in 98 different countries, 
at risk of acquiring the infection [4]. 
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Visceral leishmaniasis (VL) is the most severe form of the disease, fatal if left 
untreated, with an annual incidence estimated at 0.5 million cases, causing around 50 000 
deaths annually (a rate exceeded only by malaria among protozoan diseases) [4]. VL is 
caused by Leishmania donovani in East Africa and Indian subcontinent and L.infantum in 
Europe, North Africa and Latin America [13]. Active VL is characterized by weight loss, 
fever, weakness and hepatosplenomegaly, among other symptoms [2]. The increasing co-
infection HIV/Leishmania has raised the incidence of the disease, reduced the likelihood 
of a therapeutic response and greatly contributed to the probability of relapse [11].  
Since there are currently no effective vaccines to prevent Leishmania infections, 
management of VL relies on chemotherapy with first line drugs - pentavalent antimonials 
(sodium stibogluconate and meglumine antimoniate) - and second line drugs - 
pentamidine, paromomycin, amphotericin B or its lipid formulations and miltefosine [13]. 
However, these drugs present several problems, such as specific toxicities, elevated 
costs, prolonged treatment regimens, low patient compliance and parasite resistance [38]. 
Therefore, alternative drugs and combination regimens with improved therapeutic 
effectiveness are urgently needed to treat VL [61].  
8-Aminoquinolines (8-AQ) have been established as a promising class of drugs for 
the oral treatment of malaria, Pneumocystis jirovecii pneumonia, leishmaniasis and 
trypanosomiasis [62,89]. Primaquine (PQ, 1 in Figure 1), an anti-malarial 8-AQ, is known 
to exhibit activity against visceral Leishmania [73,74,75,76,77,78]. Since it leads to some 
adverse side effects and has a lower therapeutic index than VL reference drugs, PQ has 
currently no applicability in the VL clinical setting. The optimization of the PQ structure has 
already led to the discovery of three promising 8-AQ: NPC1161B [81], tafenoquine [80] 
and sitamaquine [78,81], which demonstrated high activity against experimental VL. 
Sitamaquine has completed phase IIb clinical trials by GlaxoSmithKline, although with 
variable results and unexpected cases of toxicity [63,64,65,66,67]. 
Interestingly, earlier works suggested that PQ encapsulation in liposomes or 
nanoparticles enhanced its leishmanicidal activity, either in infected macrophages 
[74,75,76] or in animal models of infection [76,77]. This enhanced effect may be due to 
the fact that encapsulation of PQ prevents it from undergoing metabolic inactivation to 
carboxyprimaquine (2, Figure 1) [79], thus increasing the drug’s bioavailability. Therefore, 
it is reasonable to expect that alternative strategies that prevent PQ conversion into its 
inactive metabolite, 2, will possibly contribute to the improvement of the drug’s activity 
against VL. 
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We have been working on the synthesis and biological evaluation of PQ 
derivatives where the aliphatic amine of the parent drug has been masked by acylation 
with a peptidomimetic (3, Figure 1) or organometallic moiety (5-10, Figure 2), as a 
strategy to (i) avoid premature oxidative deamination of PQ to 2 and (ii) confer resistance 
to proteolytic degradation, which affects PQ dipeptide derivatives such as 4 (Figure 1) 
[87,89,379,380]. Both compounds 3 and 5-10 have previously revealed remarkable 
activity against PQ-sensitive pathogens, namely Plasmodium (malaria) and Pneumocystis 
(pneumocystic pneumonia), in some cases with better performances than PQ at the 
activity and/or toxicity levels [88,89,91,92]. In view of this, and of the known anti-
leishmanial properties of 8-AQ analogues of PQ, as sitamaquine, the present work aimed 
to explore the activity of the peptidomimetic and organometallic PQ derivatives against 
L.infantum, the causative agent of Mediterranean VL. As presented forward, some of 
these compounds exhibited anti-leishmanial activity, which was stronger than that of PQ 
and comparable to reference anti-leishmanial drugs sitamaquine or miltefosine, while 
having lower cytotoxicity than the latter. These findings emphasize the importance of 
scrutinizing the activity of PQ derivatives or analogues against protozoan pathogens other 
than Plasmodia. 
	  
 
Figure 1 | Chemical structures of primaquine (1), its main metabolite carboxyprimaquine (2) and its 
peptidomimetic (3a-e) or dipeptidic (4a-i) derivatives. Cyt P450: cytochrome P450; MAO: monoamine oxidase. 
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Figure 2 | Chemical structures of primaquine’s organometallic derivatives 5-10. 
 
 
 
Figure 3 | Chemical structures of sitamaquine (11) and miltefosine (12). 
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3. Materials & Methods 
3.1. Chemical synthesis | Synthetic procedures and structural data have been 
reported elsewhere on compounds 3a-e [89] and 4b [380]. Other compounds of the PQ-
Pro-Xaa series, 4a,c-i, were synthesized as previously described for 4b [380], and 
spectroscopic data as well as HPLC traces are given as Supporting Information (Supp. 
Info.). Synthetic procedures and chromatographic/spectroscopic data were reported 
elsewhere for all compounds 5-10 [91,92], except 7h, for which relevant procedures and 
data are available in Supp. Info. 
3.2. Reagents | Sitamaquine was supplied by GlaxoSmithKline (Brentford, 
Middlesex, UK). Miltefosine was purchased from Cayman Chemical (Ann Arbor, Michigan, 
USA). All compounds used in this study were dissolved in dimethyl sulfoxide (DMSO) and 
stored at -20ºC. 
3.3. Parasites | Promastigotes of the L.infantum strain MHOM/MA/67/ITMAP-263 
(zymodeme MON-1) were differentiated at 25ºC in complete Schneider’s medium (Sigma-
Aldrich Co., St Louis, MO, USA) supplemented with 20% heat-inactivated fetal bovine 
serum (FBS), 100 Uml-1 penicillin, 100 µgml-1 streptomycin (all from Gibco, Life 
Technologies, Carlsbad, CA, USA), 2% human urine, 5 µgml-1 phenol red (Sigma) and 5 
mM HEPES sodium salt (Sigma) pH 7.4, from amastigotes present in the spleen of 
infected mice. Promastigote cultures were expanded at 25ºC, for a maximum of 5 
passages, in RPMI 1640 GlutaMAXTM-I medium (Gibco, Life Technologies), containing 
20% FBS, 50 Uml-1 penicillin, 50 µgml-1 streptomycin and 25 mM HEPES sodium salt pH 
7.4. Promastigote differentiation from the exponential to the stationary phase was 
promoted by culture at 25ºC, without medium renovation, for 4 to 5 days. 
3.4. Drug screening assay on promastigotes | Promastigotes (1 × 106 /well) were 
cultured at 25ºC in complete RPMI medium, supplemented with the various compounds at 
concentrations between 2.5 and 160 µM (200 µL total volume). After 24h of culture, 20 µL 
of a 2.5 mM resazurin solution (freshly prepared and filtered in phosphate buffered saline, 
pH 7.4, Sigma) was added to each well. The fluorescence intensity, corresponding to 
resazurin conversion to the fluorescent compound resorufin was determined 48h after 
resazurin addition (excitation wavelength of 560 nm and emission wavelength of 590 nm, 
with a fluorometer SpectraMAX GeminiXS, Molecular Devices LLC, Sunnyvale, CA). All 
experimental conditions were carried out in triplicate. The IC50 (µM) values were 
determined with GraphPad Prism 5.0 software (GraphPad Software Inc., La Jolla, CA, 
USA) from plots of percentages of parasite growth in relation to control versus inhibitor 
concentration.  
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3.5. Bone marrow derived macrophages | Macrophages were derived from the 
bone marrow of BALB/c mice as follows. Each femur was flushed with 5 ml of HBSS 
(Gibco). The resulting cell suspension was centrifuged and the cells re-suspended in 
complete DMEM (Gibco), containing 10% FBS, 2 mM L-glutamine, 1 mM sodium 
pyruvate, 50 Uml-1 penicillin, 50 µgml-1 streptomycin, 10 mM HEPES pH 7.4 and 10% 
L929 cell conditioned medium (LCCM), as a source of macrophage-colony stimulating 
factor. The cells were distributed in 24 or 96-well plates containing or not, sterile and LPS-
free microscopy slides and incubated at 37ºC in a 7% CO2 atmosphere. Three days after 
seeding, 100 µL of LCCM was added. On the 7th day of culture, the medium was renewed. 
3.6. Infection of bone marrow derived macrophages | On the 10th day of culture, 
completely differentiated macrophages adhered to microscopy slides (4 × 105 /well) were 
infected with stationary promastigotes of L.infantum at an approximate macrophage: 
parasite ratio of 1:10. After 4h at 37ºC in a 7% CO2 atmosphere, cells were washed with 
warm HBSS to remove non-internalized promastigotes and re-incubated in complete 
DMEM. Compounds were added after 24h of culture at the desired concentrations. Cells 
were fixed and stained with Hemacolor® (Merck KGaA, Darmstadt, Germany) 24 or 72h 
hours later. The slides were visually inspected under the light microscope to determine the 
number of parasites present inside macrophages. The “parasite index” was calculated as 
the number of amastigotes per 100 macrophages. Each experimental condition was run in 
triplicate wells. A minimum of 400 macrophages was counted per slide. Representative 
pictures of stained cells were obtained with an Olympus CX31 light microscope equipped 
with a DP-25 camera (Imaging Software Cell^B, Olympus, Center Valley, PA, USA).  
3.7. Drug cytotoxicity assay on bone marrow derived macrophages | On the 
10th day of culture, macrophages (8 × 104 /well) were treated with the various compounds 
at the desired concentrations (200 µL total volume). 24 or 72h later, 20 µL of a 1.25 mM 
resazurin solution was added to each well and the plates were re-incubated at 37ºC for 
another 3 h. The fluorescence intensity was determined as above-mentioned. All 
experimental conditions were carried out in triplicates. The CC50 (µM) values were 
determined with GraphPad Prism 5.0 software (GraphPad Software Inc., La Jolla, CA, 
USA) from plots of percentages of cell viability in relation to control versus inhibitor 
concentration. 
3.8. Statistical analysis | One-way ANOVA, followed by Bonferroni's multiple 
comparison post hoc test, was performed to determine statistical significance of the 
differences between vehicle and groups treated with the different compounds. 
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4. Results 
4.1. In vitro activity against L.infantum promastigotes 
Our first approach was to test PQ and its peptidomimetic, dipeptidic and 
organometallic derivatives on axenic cultures of L.infantum promastigotes. The 
promastigote stage of Leishmania is best suited to this purpose due to the simplicity of 
cultivation, allowing a fast and easy way to screen a large number of drugs. 
Results obtained for compounds of the 3 and 4 series (Figure 1) are depicted in 
Table 1. Two of these compounds, 3c and 4c, were as active as PQ (1) against 
L.infantum promastigotes, whereas all other derivatives from these series displayed lower 
or no activity. Although 3c and 4c are amongst the PQ derivatives with highest lipophilicity 
(3c ranks 1st) – there is no direct correlation between clogP and IC50 values (Table 1). 
This is clearly shown by the significantly different IC50 values obtained with 4d-4f, whose 
calculated clogP values are identical. It is interesting to notice, though, that β-ramification 
of the aminoacid (Xaa) residue may have a role in antimicrobial activity, as all PQ 
derivatives which displayed IC50<35 µM bear a β-ramified Xaa residue. Other structural 
features in Xaa, like presence/absence of ionizable (as in 4h) or of hydrogen-bonding (as 
in 4g or 4h) groups, as well as the bulkiness of the hydrocarbon aminoacid side chains in 
subsets 3a-c or 4a-f (expressed by the Charton’s steric factor ν [381] (Table 1)), do not 
seem to have any particular effect on compound’s activity against L.infantum. 
Since several reports indicate that iron potentiates the leishmanicidal activity of 
several drugs [364,382] and that we have previously shown that ferrocene (Fc) derivatives 
of PQ were active against Plasmodium [91] and Pneumocystis [92], we next tested a 
series of Fc derivatives of PQ for their activity against L.infantum promastigotes. The 
results obtained with compounds 5-10 (Figure 2) are shown in Table 2. The compounds of 
series 7, where PQ is linked to Fc through a variable amino acid spacer, were generally 
inactive or performed worse than parent PQ and reference drugs sitamaquine (11) or 
miltefosine (12) (Figure 3). Relevantly, removal of the amino acid spacer between PQ and 
Fc, to give compound 5, led to an increase in activity, which became higher than that of 
PQ, though lower than those of both reference drugs sitamaquine (11) and miltefosine 
(12). Compounds 9 and 10 were inactive, although the latter had shown the highest 
activity against Plasmodium [91]. Compound 10 was obtained by directly binding a 
hexylFc moiety to the PQ heteroaromatic core, 8-amino-6-methoxyquinoline. Interestingly, 
inserting the same hexylFc moiety of 10 on PQ itself led to compound 6, which exhibited a 
remarkably higher activity against promastigotes, being more potent than both reference 
drugs (11, 12). Finally, compound 8, whose structure encompasses an imidazolidin-4-one 
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and an Fc moiety, also showed a significant activity against L.infantum promastigotes, 
comparable to that of miltefosine (12). With the exception of compound 6, no other PQ 
derivative ranked better than sitamaquine (11). Nonetheless, toxicity issues with this drug 
(11), the fact that peptidomimetic derivatives of PQ are promising alternatives to PQ due 
to enhanced chemical and metabolic resistance [89,383] and the good activities 
demonstrated by the organometallic series of compounds, motivated us to further explore 
the potential of some of them in the amastigote form of Leishmania parasites. 
 
Table 1 | Anti-parasitic activity and macrophage toxicity of primaquine (1), its peptidomimetic (3a-e) 
and dipeptidic (4a-i) derivatives and reference drugs sitamaquine (11) and miltefosine (12), with estimated 
clogP values and Charton’s steric parameter (ν) for relevant hydrocarbon amino acid side chains. 
 
Compound R1 R2 R3 
L.infantum 
promastigotes 
(IC50 ± SD / µM; 
72h)  
Mouse bone 
marrow-derived 
macrophages 
(CC50 ± SD / µM; 
24h) 
clogPa ν  (R2 or R3)b 
1 - - - 32.2 ± 1.0 > 60 2.04 - 
3ad H H - 74.8 ± 1.7 - 1.82 0 
3b H Me - 64.4 ± 1.2 - 2.22 0.52 
3ce H iPr - 31.8 ± 1.0 > 60 3.03 0.76 
3d H (CH2)2SMe - > 80 - 2.40 - 
3e Me H - > 80 - 2.10 - 
4a - - H > 80 - 1.05 0 
4b - - Me > 80 - 1.45 0.52 
4ce - - iPr 31.6 ± 1.0 > 60 2.25 0.76 
4d - - sBu 37.6 ± 1.0 - 2.72 1.02 
4e - - iBu > 80 - 2.72 0.98 
4f - - Bzl 52.0 ± 1.4 - 2.72 0.70 
4g - - p-(OH)Bzl > 80 - 2.43 - 
4h - - (CH2)4NH2 62.9 ± 1.5 - 1.35 - 
4i - - (CH2)2SMe 43.3 ± 1.0 - 1.62 - 
11 - - - 7.4 ± 1.0 < 60 5.84c - 
12 - - - 14.4 ± 1.1 > 60 3.30 - 
 
aCalculated using the OSIRIS Property Explorer (http://www.organic-chemistry.org/prog/peo/); 
bTaken from reference [381];  
cExperimental value taken from reference [384]; 
dIn 3a to 4i, R stands for amino acid side chain; H, hydrogen; Me, methyl; iPr, isopropyl; iBu, isobutyl; sBu, sec-butyl; Bzl, 
benzyl. 
eβ-ramified amino acids 
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Table 2 | Anti-parasitic activity and macrophage toxicity of primaquine (1), its organometallic 
derivatives 5-10 and reference drugs sitamaquine (11) and miltefosine (12). 
 
Compound R 
L.infantum 
promastigotes 
(IC50 ± SD / µM; 
72h)  
Mouse bone 
marrow-derived 
macrophages 
(CC50 ± SD / µM; 
72h) 
1 − 26.5  ± 1.2 > 80 
5 − 22.7  ± 1.1 > 80 
6 − 4.9  ± 2.3 6.8 ± 1.2 
7aa H > 80 > 80 
7b Me 44.7  ± 1.1 −	  
7ce iPr > 80 −	  
7d iBu > 80 −	  
7e Bzl > 80 −	  
7f (CH2)4NH2 40.3  ± 2.5 −	  
7g CH2NH2 39.2  ± 6.2 −	  
7h CH(CH3)OH 63.3  ± 1.3 −	  
8 −	   11.5  ± 1.0 > 80 
9 −	   > 80 −	  
10 −	   > 80 −	  
11 −	   7.4 ± 1.0 −	  
12 −	   14.4  ± 1.1 24.7 ± 0.5 
 
aIn 7a to 7e, R stands for amino acid side chain; H, hydrogen; Me, methyl; iPr, isopropyl; iBu, isobutyl;  Bzl, benzyl. 
eβ-ramified amino acids 
 
4.2. In vitro activity against intramacrophagic L.infantum amastigotes 
In light of the observations made in the previous section, compounds 3c and 4c 
(Figure 1), as well as 5 and 8 (Figure 2) were selected for evaluation on intramacrophagic 
L.infantum amastigotes, the clinically relevant parasite stage. The high toxicity of 
compound 6 towards mouse bone marrow derived macrophages (Table 2) excluded it 
from further testing. Compound 7a was included in these studies for comparison with 8, of 
which it is the synthetic acyclic precursor. Moreover, PQ (1), sitamaquine (11) and 
miltefosine (12) were included as reference drugs. 
The anti-leishmanial activity of the peptidomimetic PQ derivative 3c was confirmed 
in this assay, as this compound was found to be more effective than PQ at eliminating 
intramacrophagic L.infantum (Table 3). Conversely, the dipeptide derivative 4c had no 
effect on the elimination of intramacrophagic L.infantum amastigotes (Table 3).  
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Table 3. Activity of PQ (1), 3c, 4c and sitamaquine (11) against intramacrophagic L.infantum.  
 
Compound Concentration / µM 
Nr amastigotes / 100 
macrophages ± SD (24h) 
% 
reduction 
Vehicle -­‐	   313.0 ± 18.3 -­‐	  
1 60 221.4 ± 29.5 29.3 
 30 235.0 ± 53.7 24.9 
3c 60 7.3 ± 1.8 97.7a 
 30 168.5 ± 35.9 46.2a 
4c 60 322.3 ± 57.1 - 3.0 
 30 320.5 ± 54.4 - 2.4 
11 60 8.7 ± 6.9 97.2a 
 30 84.1 ± 27.1 73.1a 
 
a p<0.001 
 
As shown in Table 4, among the organometallic derivatives, compound 5 showed 
no activity against amastigotes, while the activity of compound 8 was confirmed on this 
intramacrophagic form of the parasite (Table 4). Surprisingly, compound 7a also showed 
potent activity against amastigotes, revealing an efficacy at 40 µM that was comparable to 
that of miltefosine (12) at 20 µM (Table 4). Due to its high toxicity towards macrophages 
(Table 2 and Figure 4C), miltefosine (12) could not be used in these assays at 
concentrations higher than 20 µM.  
 
Table 4. Activity of PQ (1), 5, 7a, 8 and miltefosine (12) against intramacrophagic L.infantum.  
  
 
Compound Concentration / µM 
Nr amastigotes / 100 
macrophages ± SD (72h) 
% 
reduction 
Vehicle -­‐	   135.8 ± 27.5 -­‐	  
1 80 10.6  ± 5.1 92.2b 
 40 66.8  ± 23.6 50.8a 
5 80 127.8  ± 33.5 5.9 
 40 99.0  ± 32.2 27.1 
7a 80 3.7  ± 1.1 97.3b 
 40 5.3  ± 1.7 96.1b 
8 80 29.0  ± 5.4 78.6b 
 40 30.5  ± 3.3 77.6b 
12 20 5.0  ± 1.0 96.3b 
 
a p<0.05; b p<0.001 
 
 91 
Lastly, both 3c (Figure 4E and Table 1) and 7a (Figure 4F and Table 2) caused no 
significant toxicity towards macrophages in contrast with reference drugs 11 and 12 
(Figure 4B and 4C, Table 1 and 2). Reference drugs 11 (60µM) and 12 (20µM) clearly 
decreased the confluency and altered the morphology of infected macrophages as 
compared to vehicle, whereas compounds 1 (60µM), 3c (60µM) and 7a (80µM) did not 
significantly affect any of these parameters at the highest concentrations tested (Figure 4). 
 
 
Figure 4 | Micrographs of L.infantum infected bone marrow-derived macrophages exposed to: vehicle (A) and 
compounds 11 at 60 µM (B), 12 at 20 µM (C), 1 at 60 µM (D), 3c at 60 µM (E) and 7a at 80 µM (F). Black bar 
corresponds to 50 µm. 
 
5. Discussion 
Chemotherapy is currently the only option for the management of the life threatening 
VL. However, the limited number of available drugs and their serious drawbacks reinforce 
the urgent need for adequate therapies [13]. The ideal drug should be non-toxic, 
affordable, extremely effective and easily administered during a short period in the 
outpatient setting with no parasite resistance associated. To acquiesce with these criteria, 
the rational modification of known anti-parasitic molecules such as PQ is a valuable 
strategy.  
Structural modifications that involve the inclusion of imidazolidin-4-one 
(peptidomimetics 3) and Fc (organometallics 5 – 10) moieties into PQ improve its activity 
against Plasmodium and Pneumocystis and/or its safety [88,89,91,92]. The results here in 
disclosed show that peptidomimetic 3c and organometallic 7a derivatives of PQ were 
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more effective at eliminating intramacrophagic amastigotes of L.infantum than the parent 
drug and showed decreased toxicity when compared to sitamaquine and miltefosine. 
We tested 5 peptidomimetic and 9 dipeptidic derivatives of PQ for their activity 
against L.infantum promastigotes. Among these, 3c and 4c were the most active, with an 
IC50 close to that of PQ (1). It is remarkable that compounds 3c and 4c are closely related, 
as 3c is the imidazolidin-4-one peptidomimetic surrogate of PQ’s dipeptide derivative 4c. 
This is hardly coincidental and shows that the valine residue, common to the two, is 
beneficial for in vitro anti-leishmanial activity against promastigotes. Interestingly, when 
tested for anti-leishmanial activity inside macrophages, 3c was much more active than 4c. 
This is not surprising since 4c is more susceptible than 3c to proteolytic degradation [383], 
which could be aggravated by the fact that protease activity is increased in Leishmania-
infected macrophages [385]. Proteolytic degradation would cause cleavage of the 
dipeptide moiety in 4c, leading to PQ release. However, if this was the case, 4c would 
expectedly display an activity similar to that of the parent drug, which did not occur. 
Another possible explanation for the discrepant behavior of 1, 3c and 4c against either 
promastigotes or intracellular amastigotes could be the fact that the macrophage 
metabolizes 3c, but not 1 or 4c, to originate a compound which is more toxic to 
L.infantum. This lack of activity of 4c may also be due to the action of a macrophage efflux 
pump able to recognize dipeptide substrates as, e.g., multi-substrate transporters from the 
ABC super-family [386] or peptide/histidine transporters PHT1 and PHT2 [387]. It is likely 
that such transporters would not recognize the peptidomimetic imidazolidin-4-one moiety 
in 3c. The most remarkable finding on 3c, however, is the fact that this compound was as 
potent as sitamaquine (11) at the highest concentration tested, 60 µM (Table 3), with the 
further advantage that 3c is not cytotoxic at this concentration, whereas sitamaquine is 
(Table 1, Figure 4). Though sitamaquine (11) performed better than 3c at the lowest 
concentration tested, 30 µM, its high toxicity hampers its application in clinics, which urges 
the discovery of safer anti-leishmanial leads, like 3c.  
Moreover, this study allowed the drawing of some conclusions regarding structure-
activity relationships. β-ramification of the aminoacid (Xaa) residue may have a role in 
antimicrobial activity, as all PQ derivatives which displayed IC50<35 µM bear a β-ramified 
Xaa residue (Table 1). Possibly, this feature favors the uptake by L.infantum parasites, 
mediated by specific amino acid permeases or transmembrane peptide transporters [388], 
parallel to, e.g., the arginine-specific transporter previously reported for L.donovani [389]. 
Curiously, enhanced activity and uptake when β-ramified amino acids were present has 
been previously described, although with other compounds and pathogens [390,391]. 
Although the most active compounds had high lipophilicity, we found no direct correlation 
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between this parameter and anti-parasitic activity. Other structural features in Xaa do not 
seem to have any relevant effect on compound’s activity against L.infantum (Table 1). 
Concerning the Fc derivatives of PQ 5-10 (Figure 2), results obtained on 
promastigotes (Table 2) were very variable, reflecting the high structural diversity of these 
organometallic compounds. Series 7a-h, where PQ is linked to Fc through a variable 
amino acid spacer, was generally not very promising, while the removal of the amino acid 
spacer between PQ and Fc, to give 5, led to a substantial increase in activity. Also 
somewhat surprising was the fact that compound 10, the most promising as an anti-
malarial [91], was inactive against L.infantum promastigotes. Interestingly, compound 6, 
which has the same hexylFc moiety as 10, but linked to the PQ’s aliphatic amine group 
than directly bound to the aryl-amine group in 8-amino-6-methoxyquinoline (the 
heteroaromatic core of PQ), appeared remarkably active against promastigotes, being 
more potent than both sitamaquine (11) and miltefosine (12). The second most active 
compound against L.infantum promastigotes was 8, with an activity comparable to that of 
miltefosine (12). This is an interesting finding, as 8 includes both structural modifications 
pursued by our group over the past few years in order to improve PQ’s therapeutic 
properties [87,89,91,92]: it encompasses an imidazolidin-4-one and an Fc moiety, i.e., it 
can be seen as an organometallic surrogate of peptidomimetic compounds 3 (Figure 1). 
Since the intramacrophagic amastigote form of Leishmania is the most biologically 
relevant, the most promising organometallic PQ derivatives were also tested in this model. 
Unfortunately, compound 6, which had shown the highest activity against promastigotes, 
revealed a high toxicity towards bone marrow derived macrophages, which excluded it 
from further studies. The CC50 on macrophages was of about 7 µM, in agreement with the 
cytotoxicity previously displayed on Huh-7 human hepatoma cells [91]. On the contrary, 
compounds 5 and 8 (similarly to the peptidomimetics of the 3 and 4 series tested 
previously) had very low cytotoxicity and were selected for subsequent analysis on 
intramacrophagic amastigotes. Compound 7a, though inactive against promastigotes, was 
also taken further for such studies, as representative of the non-cytotoxic (Table 2) acyclic 
precursor of 8. In fact, compounds 5, 7a and 8 can be seen as sequential analogues of 
each other, i.e., 7a is the analogue of 5 where the simplest amino acid (glycine) has been 
introduced as spacer between the PQ and the Fc moiety; in turn, 8 is the derivative of 7a 
where an additional cyclization step introduced an imidazolidin-4-one ring. While 
compound 5 lost its activity inside macrophages, 8 revealed a significant activity on this 
setting. Yet, the most striking observation was that 7a had potent activity against 
amastigotes, not far from that of miltefosine (12) (Table 4). So, contrary to what was 
observed in the peptidomimetic series, the presence of an imidazolidin-4-one ring was not 
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necessary for intramacrophagic activity in the case of the organometallic derivatives. 
Eventually, joining the constrained cyclic imidazolidin-4-one motif with the bicyclic Fc 
moiety in 8 represents a structure too large or too stiff to easily enter the macrophage 
and/or the amastigote. By removing the imidazolidin-4-one ring, as in 7a, such problem 
might be minimized or eliminated, explaining the higher activity of 7a as compared to 8. 
Another clear fact is the key role of the amino acid residue: 7a differs from 5 only in the 
fact that the latter misses the glycine residue present in the former, yet this difference was 
enough to remove anti-leishmanial activity in 5. Curiously, both 7a and 5 were previously 
found to be inactive either against blood-stage Plasmodia or as malaria transmission-
blocking agents, while presenting very good activity against liver-stage malaria parasites 
[91,92]. This suggests stage-specific anti-parasitic activity, which might deserve further 
investigation in the future.  
Factors underlying the different activities described in this study remain to be 
determined. However, it is clear that the screening of a variety of PQ derivatives for anti-
leishmanial activity revealed two compounds with interesting (3c) or highly potent (7a) 
effects on the clinically relevant stage of L.infantum, with very low toxicity for host cells. 
This makes them worthy candidates as leads for the development of novel and safer PQ-
based anti-leishmanials and emphasizes the relevance of exploring the potential of PQ-
based structures against protozoan pathogens other than Plasmodia. 
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Chapter VI | General Discussion 
 
1. Relationship between the host iron status and Leishmania infection 
Iron is an indispensible nutrient for the survival and proliferation of nearly every 
living organism. The biological utility of iron originates from its capacity to readily undergo 
electron transfer reactions and to interact with numerous coordinating ligands, features 
that enable its participation in the most basic cellular functions. Yet, when redox active 
iron is present in excess it can promote oxidative reactions pernicious to biological 
systems [172,175,253,392]. Hence, organisms must have mechanisms to supply their 
own iron needs and avoid iron’s toxicity [258,264,265,266,327,328].  
Several studies show that vertebrates use an elaborate iron withholding system to 
restrict the access to iron by invading microbes [258,259,260]. So, when the host is iron 
overloaded by nutritional, therapeutic or hereditary reasons, the iron withholding system is 
overwhelmed and the growth of pathogens is favoured [258,261]. Intriguingly, L.major 
[350,351,352] and L.infantum (our work) parasites appear to be an exception to this tenet, 
as discussed below. It is currently unknown if the proliferation of other Leishmania species 
is also inhibited by the host’s iron overload, a subject worthy to explore in the future.  
 
1.1. Iron mediates host resistance to Leishmania: a role for ROS and RNS 
One of our most significant findings was that iron overload protected mice against 
L.infantum visceral infection (chapter III). By administering high iron doses via the 
parenteral route, we forced its accumulation in the mouse tissue macrophages, as 
previously reported [175,253,363,393]. Upon infection with L.infantum, we observed that 
iron-loaded macrophages were found inside hepatic infiltrates, which are structures of 
parasite containment [163,165]. This observation allied to the reduced tissue parasite 
proliferation led us to conclude that iron acted as a toxic insult to L.infantum and not as a 
growth factor. The fact that the anti-leishmanial effect of iron overload was abrogated in 
mice genetically deficient in the NADPH oxidase or NOS2, suggested that ROS and RNS 
generated by macrophages are the mediators of iron toxicity towards L.infantum. 
Likewise, treatment of mice with diphenyleneiodonium chloride, which is an inhibitor of 
both the NADPH oxidase and NOS2, reverted the protective effects of iron overload 
against L.major [351]. It is possible that the high iron levels inside macrophages increased 
the extent of the labile iron pool, which comprises iron in a form that can potentially 
engage in redox reactions and induce oxidative damage to biological structures [394]. 
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Moreover, the macrophage PVs were probably enriched in redox-active iron, since the 
mouse strains used in our studies do not express a functional NRAMP1 protein, whose 
role is to deplete iron from phagosomal compartments [320,321,322,323]. In the future, 
we could directly ascertain whether iron is enhancing the macrophage oxidative defense 
mechanisms against L.infantum. This could be achieved by quantifying the level of ROS 
and RNS released in response to L.infantum infection by macrophages treated or not with 
iron [208]. Alternatively, the detection of ROS and RNS could be performed ex vivo in 
macrophages isolated from the liver and spleen of iron overloaded mice infected with 
L.infantum [204,351]. 
Notably, we verified that L.infantum hepatic parasite burden was significantly 
reduced in iron overloaded mice early after infection, meaning that iron might have 
interacted with ROS and RNS during phagocytosis (chapter III). In agreement, iron 
overload significantly enhanced the respiratory burst of rat Kupffer cells (liver 
macrophages) in response to phagocytosis of inert particles [392,395]. In addition, iron 
overloaded mice exhibited increased levels of NADPH oxidase-mediated oxidative burst 
[351] and NOS2 transcripts [350] early after L.major inoculation in the skin. The iron-
induced effects on parasitemia were detected in the spleen only at later time-points 
(chapter III). This discrepancy between organs might be related to the initial iron 
distribution. A larger proportion of the injected iron is taken up by Kupffer cells in the liver. 
Although the spleen has a higher basal amount of iron per mg of tissue, this iron is 
probably distributed among cells that are not involved in the initial uptake of Leishmania 
parasites. The fact that iron overload does inhibit the growth of L. infantum in the spleen at 
later stages of infection, raises the hypothesis that iron may exert its effects during cell-to-
cell spread of the parasites or once parasites are proliferating inside an iron-loaded 
macrophage, by pathways unexplored in the present work. 
The ROS and RNS synthesized by NADPH oxidase and NOS2, respectively, have 
been implicated in the elimination of several other Leishmania species by the host’s 
macrophages [166,195,204,213,214,217,218,220,222,225]. However, we showed that 
ROS, but not RNS, are required to control L.infantum infection in the tissues of non-iron 
overloaded mice (chapter IV). Moreover, we hypothesize that L.infantum might be 
resistant to the action of RNS (chapter IV). So, it is conceivable that in an iron overloaded 
mouse, the generation or propagation of both ROS and RNS reaches a level that cannot 
be withstood by the parasite. On the other hand, iron might have promoted the formation 
of alternate reactive species to which the parasite displays no antioxidant defense 
capacity. For instance, the reaction of iron with peroxynitrite (ONOO-) yields nitronium ion 
(NO2+), a strong oxidizing species to which no detoxification system in Leishmania has 
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been reported [392,396]. Furthermore, L.infantum promastigotes were shown to contain 
iron in catalytically active forms, which contribute to their sensitivity to killing by ROS 
[193,335] and possibly also by RNS.  
Relevantly, both macrophagic NADPH oxidase and NOS2 require iron (as part of 
the heme co-factor) for proper function [170]. In a few models of macrophage infections 
with different bacteria, macrophages were shown to need iron to exert their antimicrobial 
activity. Iron increased the capacity of macrophages to eliminate or prevent the 
multiplication of B.abortus, by catalyzing the production of HO• [356] and iron loading of 
Staphylococcus aureus prior to infection enhanced bacterial killing by monocytes, most 
likely by promoting oxidative damage [397]. Also in the case of Listeria monocytogenes 
and S.typhimurium, iron seems to be needed for intramacrophagic killing of these bacteria 
[354,355]. However, several studies performed with macrophage infection models failed to 
reproduce the in vivo anti-leishmanial effect of iron. Indeed, treatment of macrophages 
with different iron sources either did not alter [347] or increased the multiplication and 
survival of several Leishmania species [212,342,345]. In these cases, iron doses were 
probably not sufficient to promote oxidative reactions pernicious to Leishmania. Instead, 
the in vivo effects of iron may also be mediated by other cell types, such as neutrophils, 
as has been previously proposed for the L.major model [351].  
The findings discussed above led us to question if genetically determined host iron 
overload would also inhibit L.infantum multiplication. To address this question, we used 
the HFE deficient mouse model, which mimics the human iron overload disorder 
hereditary hemochromatosis. This pathology is most often associated with mutations in 
HFE, a MHC class I-like molecule, and is characterized by increased serum TF saturation 
and iron deposition predominantly in the liver [264,265,365,366]. We observed that HFE-
deficient mice had tissue parasite loads comparable to those of wild-type mice. Such 
result did not corroborate our finding that iron-dextran administration inhibited L.infantum 
growth (chapter III). A possible explanation might be the fact that HFE-deficient mice 
develop spontaneous iron overload mainly in hepatocytes, while macrophages are 
relatively depleted of this metal [365,366]. Still, upon infection with L.infantum, we clearly 
detected high accumulation of iron inside macrophages of the hepatic infiltrates in HFE-
deficient mice. Notably, an identical observation has been previously reported in M.avium 
infection of this mouse model [357]. Redistribution of iron towards accumulation inside 
macrophages is likely a strategy of the host’s iron withholding system to decrease 
circulating iron levels in response to infection and/or inflammation [264]. Non-infected 
HFE-deficient mice have reduced hepatic hepcidin transcripts [264,398] and increased 
FPN expression in the liver and spleen [399,400], an expression pattern not consistent 
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with iron retention in macrophages. Although we ignore the mechanisms of macrophage 
iron retention in chronically infected HFE-deficient mice, it is possible that the 
hepcidin/FPN expression is altered to favor iron accumulation in this condition.  
Other justifications may then account for the absence of effect of iron overload, 
caused by HFE deficiency, on the growth of L.infantum. Firstly, the inhibitory effect of iron 
is best accomplished when the macrophages are iron-loaded prior rather than after 
infection. To validate this hypothesis, we could infect the flatiron mouse model, which has 
spontaneous iron loading in Kupffer cells due to a loss-of-function mutation in FPN [401]. 
In this mouse model, iron would be present in tissue macrophages before infection. 
Secondly, the function of NADPH oxidase and NOS2 may be compromised in HFE-
deficient mice. This is, however, unlikely since their expression is identical in the spleen of 
wild-type and HFE-deficient mice infected with S.typhimurium [399]. Thirdly, HFE-deficient 
mice had tissue iron levels that were considerably lower than those found in iron-dextran-
injected mice and were probably not enough to promote oxidative reactions pernicious to 
L.infantum. Supporting this hypothesis is the fact that in iron-dextran-injected mice, high 
iron doses had to be administered to significantly reduce the tissue parasite burden 
(chapter III). 
 
1.2. Influence of iron overload on the host immune response to Leishmania 
Mouse resistance or susceptibility to L.major infection is dependent on the 
development of Th1 or Th2 immunity, respectively [122,123,141,142,370]. Iron 
supplementation, besides enhancing the early oxidative burst [351], also promoted the 
development of a Th1-like immune response to L.major in a susceptible mouse strain 
[350]. Such a protective immune response in iron overloaded mice was characterized by 
(i) reduced levels of serum IgE and IgG1 and increased levels of IgG2a, (ii) an increased 
ability of spleen cells to act as antigen presenting cells, (iii) increased number of IL-12+ 
cells and decreased number of IL-4+ and IL-10+ cells at the inoculation site, and (iv) 
increased levels of IFNγ and NOS2 and decreased levels of IL-4 and IL-10 transcripts at 
the lesion site [350,351]. However, we can argue that the iron-induced oxidative burst at 
the onset of L.major infection may have significantly reduced the parasite numbers at the 
lesion site, thus facilitating the establishment of a protective immune response. Indeed, it 
has been described that low parasite numbers lead to the mounting of a Th1-like immune 
response to L.major irrespective of the infection route, mouse or parasite strain [402]. 
In mouse models of VL, resistance to infection also correlates with the development 
of Th1 responses, but it is not clear that Th2 responses determine susceptibility. In fact, a 
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mixed Th1/Th2 cytokine profile is detected during the course of infection with visceral 
Leishmania [122,141,142,163,377]. Although IL-10 overproduction strongly correlates with 
susceptibility to VL [122,143], other Th2 cytokines such as IL-4 [144] and IL-13 [145] 
seem to promote the control of L.donovani growth. Since the L.major model indicated that 
iron supplementation favoured the development of a Th1-like immune response [350,351], 
we also addressed whether this fact was occurring in our model. Our results suggest that 
the host’s iron overload did not significantly affect the adaptive immune response to 
L.infantum infection (chapter III). However, we cannot ignore that the absence of 
differences in the immune response profile induced by L.infantum in iron overloaded and 
untreated mice might be due to the number of parasites in the tissues. That is, although 
iron might have increased activation of a protective response, the decreased parasite 
numbers in iron overloaded mice might have elicited a lower activation of protective cells 
or production of protective cytokines than in control mice, resulting overall in a similar level 
of response. Anyhow, this result reinforces that the inhibitory effect of iron on the growth 
of L.infantum is predominantly due to its interaction with ROS and RNS. 
Earlier studies showed that iron overload adversely affected the performance of the 
host immune system, namely by (i) impairing macrophage phagocytosis, antigen 
presentation and cytokine production, (ii) depressing NK cell cytotoxic activity, (iii) 
supressing the functions of the complement system and (iv) altering lymphocyte numbers, 
proliferation and cytokine secretion, as well as T-cell subset ratios [260,403,404,405]. The 
fact that iron overload either did not affect (chapter III) or favoured [350,351] the induction 
of a protective immune response to Leishmania infection differs from what is observed in 
other infection models. Generally, the host’s iron overload correlates with the induction of 
Th2 immunity and/or the suppression of Th1 responses [260]. For instance, iron 
overloaded mice exhibit Th2 or delayed Th1 immune responses to C.albicans [376] or 
C.neoformans [375] infection, respectively, which are characterized by increased 
production of IL-4 and IL-10 and decreased production of IFNγ and IL-12. In line with this, 
the generation of NO• and secretion of TNF in response to LPS [406] or S.typhimurium 
infection [325] are impaired in iron-loaded macrophages. Decreased NO• production has 
also been observed in mice [373] and macrophages [374] treated with different iron 
sources. It should be noted, however, that the latter effect has not been consistently 
observed in all studies of iron supplementation. The treatment of rats with iron-dextran 
[371] or saccharated colloidal iron [372] potentiated the LPS-induction of hepatic NOS2 
expression and NO• production. These two studies agree with our hypothesis that iron 
supplementation favours the production or propagation of RNS that leads to inhibition of 
L.infantum growth. Lastly, a recent study showed that iron overloading of macrophages, 
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as occurs in mouse models and humans with chronic inflammatory diseases, can direct 
the polarization of these cells towards an unrestrained pro-inflammatory M1 phenotype 
[407,408]. This M1 macrophage population secretes high levels of TNF, HO• and ONOO- 
[407,408,409]. In turn, M1 macrophages retain iron due to increased expression of the 
iron storage protein FT and decreased expression of the iron exporter FPN [410]. So, it is 
left unexplored the possibility that iron accumulation in our model might have induced 
macrophage polarization into the M1 phenotype and consequently promoted oxidative 
defense mechanisms against L.infantum. 
 
1.3. Host iron overload offers resistance to re-infection with Leishmania 
Iron treatment strongly inhibited the replication of L.major and L.infantum, but did not 
lead to complete parasite elimination from the mouse tissues. In other words, sterile cure 
was not achieved by iron supplementation. It has been postulated that the long-term 
persistence of Leishmania in a host after cure is important to develop resistance in case of 
re-infection [411]. In fact, others have previously demonstrated that iron overloaded mice 
are resistant to re-infection with L.major [352]. The iron-induced oxidative burst elicited 
during both primary and secondary infections with L.major correlates with the activation of 
the transcription factor NF-κB and with an enhanced proliferation of IFNγ-secreting CD4+ 
T cells in the dLNs [352]. This is substantiated by the fact that iron and ROS/RNS can 
modulate the activation of macrophagic NF-κB signalling pathways [175,368,412], which 
are known to regulate numerous genes involved in immune and inflammatory responses 
[369]. Indeed, NF-κB regulates the development of IFNγ-secreting CD4+ T cells and 
concomitant resistance to L.major [353]. Hence, iron not only seems to synergize with the 
host’s oxidative mechanisms of defense, but also interacts with ROS and RNS in order to 
activate signalling cascades that regulate the development of protective immunity against 
Leishmania. Understanding the molecular mechanisms involved in iron-induced 
resistance to Leishmania infection and re-infection deserves further research in the future.  
 
1.4. Host iron deficiency does not correlate with susceptibility to Leishmania 
Malnutrition is associated with susceptibility to VL in humans [9,10] and mice [413]. 
Although iron deficiency is the most common micronutrient deficiency in the human 
population [414], the relationship between human iron deficiency alone and increased risk 
of acquiring VL has never been investigated. We showed that feeding mice with an iron 
deficient diet did not affect the course of infection with L.infantum (chapter III). Although 
these nutritionally iron-deprived mice had half the normal iron stores in the liver and the 
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spleen, they presented normal haematocrit and body weight (not shown). To possibly 
attain a more dramatic iron deprivation, we could eventually feed the mice with an iron-
deficient diet while simultaneously treating them with an iron chelator, such as 
desferrioxamine (DFO), deferasirox [415] or hydroxypyridinones [346,416]. Such iron 
deprivation approach has led to complete protection of mice against Trypanosoma cruzi, a 
related trypanosomatid [417].  
Prior studies concerning the impact of iron chelation on Leishmania growth have 
yielded conflicting results. First, treatment of mice with DFO significantly impaired the 
growth of L.infantum [349], but not that of L.major [350]. Second, DFO had either no effect 
[347] or an inhibitory effect on the intramacrophagic replication of L.donovani [345,348] 
and L.amazonensis [342]. Third, the multiplication of L.donovani, L.major and L.infantum 
promastigotes in culture medium was either not inhibited by DFO [348] or was modestly 
inhibited by hydroxypiridin-4-one-derived chelators [346]. Altogether, the present and 
previous studies indicate that Leishmania parasites do not seem to be particularly 
sensitive to iron deprivation. This is probably related to their high capacity to scavenge 
iron in starvation conditions [331,340,343], since Leishmania are endowed with multiple 
iron acquisition mechanisms [327,328]. Hence, we suppose that, in our model, the 
lowered levels of iron in tissue stores were enough to support the growth of L.infantum.  
Though iron chelation has been suggested as an effective therapeutic strategy 
against several infections [258,261], we feel it may be inadequate for the treatment of 
leishmaniasis, especially in areas where both this disease and malnutrition co-exist. 
Effective iron chelation could worsen the anemia that is frequently observed in VL patients 
[418] or adversely affect the proper performance of the host immune system. In fact, iron 
deficiency has been associated with (i) impaired microbicidal action of phagocytes, (ii) 
supressed NK cell cytotoxicity and (iii) reduced T lymphocyte numbers, proliferation and 
altered cytokine expression profile [404,414,419]. Of relevance, the activity of NADPH 
oxidase [355] and NOS2 [420] in response to PMA and M.tuberculosis, respectively, is 
impaired in iron-depleted macrophages. Also, the expression of the pro-inflammatory 
cytokines IL-6 and TNF in response to S.typhimurium infection is considerably attenuated 
in macrophages with low intracellular iron levels [400]. Lastly, mice fed an iron deficient 
diet produce less IFNγ upon stimulation of splenic T cells with a mitogen stimulus [421] 
and have reduced serum levels of IFNγ and IL-12 [422] in comparison to control mice.  
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1.5. Iron exerts direct toxicity towards Leishmania 
In this work, we showed that axenic cultures of L.infantum promastigotes and 
amastigotes are sensitive to the direct toxicity of iron (chapter III). In line with our results, 
the excessive production and subsequent internalization of Fe2+ by the LFR1 reductase 
and LIT1 importer, respectively, markedly reduced the viability of L.amazonensis 
amastigotes [340]. Although we have not approached how L.infantum acquired iron from 
the different added sources, some explanatory hypothesis can be suggested. Iron-dextran 
may have been internalized by L.infantum parasites through a receptor or transporter of 
carbohydrates present at the surface membrane. In fact, the uptake of several hexoses 
(glucose, mannose, fructose or galactose) by distinct carbohydrate transporters has been 
described in L.mexicana [423]. Alternatively, iron bound to dextran or citrate may have 
been released from these complexes upon reduction by a Fe3+ reductase and 
subsequently internalized by a Fe2+ importer. These iron acquisition pathways have been 
proposed to occur in L.infantum promastigotes [339,340] and have been well 
characterized in intramacrophagic amastigotes of L.amazonensis [340,343].  
Upon exposure to high iron concentrations, promastigotes exhibited impaired 
motility and morphological changes identical to those reported to occur after exposure to 
antimony (III) and arsenic (III) ([364] and data not shown). These metalloids were found to 
act through the induction of oxidative injury to L.donovani [31,32,39,364]. By analogy, iron 
may also inhibit the growth or even kill both life stages of L.infantum by catalysing the 
endogenous production of ROS. To address this hypothesis, we could try to measure 
whether iron causes direct intracellular generation of ROS [240,364] or oxidative damage 
to the parasite and/or if iron impairs the parasite’s antioxidant defense system [190,424].  
Relevantly, the concentrations of iron needed to impair the viability of both life forms 
of L.infantum were relatively high, in the millimolar range (chapter III). At lower iron 
concentrations, the parasite possibly avoided its toxicity by down-regulating the 
expression of some iron importers or by increasing the efflux of iron. In fact, decreased 
uptake and increased efflux of antimony, another heavy metal, have been proposed to 
occur in antimony-resistant Leishmania parasites [38,39]. Instead, iron may have been 
compartmentalized by the parasite in a relatively safe form. However, this hypothesis is 
unlikely, since it has been described that L.infantum promastigotes store iron in redox-
active forms, which greatly increases their susceptibility to killing by H2O2 [193,335]. 
Another hypothesis that could explain the relative resistance to iron’s toxicity is the up-
regulation of the parasites’ antioxidant defense or repair systems [94]. We envisage that 
whatever parasitic mechanisms were used for protection against the noxious effects of 
iron, they were overwhelmed by high iron concentrations (chapter III). 
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1.6. Iron potential as a therapeutic tool to fight Leishmania infections  
Iron not only enhanced or synergized with the host’s oxidative mechanisms of 
defense against Leishmania, but also exerted direct toxicity towards both life forms of the 
parasite (our results and [351]). This suggests that iron may be exploited as a therapeutic 
tool to fight infections caused by Leishmania parasites. This contention is substantiated by 
several pieces of evidence. First, an increase in intracellular iron levels directly correlates 
with the sensitivity of L.donovani promastigotes to antimony (III) [364], a drug that causes 
oxidative stress to Leishmania by interfering with the parasites’ antioxidant defense 
system [31,32,39]. Second, iron potentiates the leishmanicidal activity of artemisinin by 
inducing oxidative injury that culminates in cell death of L.donovani promastigotes [382]. 
Third, iron treatment can induce accumulation of pentamidine in the mitochondria of 
L.enriettii promastigotes, consequently increasing their sensitivity to the drug. This effect 
is probably due to the action of the multidrug resistance protein 1 (LeMDR1), a possible 
mitochondrial iron importer [425]. Fourth, the coupling of an iron-containing group 
(ferrocene) to PQ significantly enhanced its activity towards L.infantum promastigotes and 
intramacrophagic amastigotes (chapter V). Hence, the increase of intracellular iron levels 
in Leishmania overall increases their vulnerability to chemotherapy. Noteworthy, in most 
instances, such effect seems to be intertwined with the generation or propagation of ROS 
pernicious to the parasites.  
In sum, the interaction between pathogens and their hosts are complex processes 
dependent not only on the genome of both, but also on nutritional factors. It is generally 
acknowledged that iron excess increases and iron chelation decreases susceptibility to 
infection [261,262]. However, murine models of infection by Leishmania indicate that 
these parasites represent an exception to such rule. Moreover, despite several reports 
that iron supplementation (to correct nutritional iron deficiency) can significantly increase 
the risk of several infections [261,414], no correlation between iron administration and 
susceptibility to human leishmaniasis has, to our knowledge, ever been described. 
Although iron chelation has been suggested as an effective therapeutic strategy against 
several infections, in the case of leishmaniasis and especially in areas where this disease 
and malnutrition co-exist, iron chelation may be inappropriate. Iron overload decreases 
Leishmania growth, likely by promoting oxidative reactions harmful to the parasites. 
Understanding the molecular mechanisms of these effects will aid a possible exploitation 
of iron as a therapeutic tool and may also help to unravel and improve the mode of action 
of other anti-leishmanial drugs. 
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2. Role of ROS and RNS in the control of Leishmania infection 
The fact that we found that ROS and RNS seem to mediate the toxicity of iron 
towards L.infantum (chapter III), motivated us to fully characterize the relative contribution 
of these microbicidal molecules to the control of L.infantum infection in a non-iron 
overloaded mouse. Our results showed that NADPH oxidase and ROS were required to 
control the initial establishment of L.infantum in the spleen and to restrict late infection in 
the liver. In contrast, NOS2 and RNS did not afford protection against the parasite in both 
organs at any stage of the infection (chapter IV). 
 
2.1. ROS, but not RNS, mediate the in vivo control of L.infantum infection 
The oxidative burst of professional phagocytes [170,171] is prompted by 
phagocytosis of Leishmania promastigotes [186,188,189,191,195,205,206,207,209], 
leading to parasite killing by a mechanism reminiscent of apoptosis [195]. In agreement, 
we showed that ROS restrain the onset of infection by L.infantum promastigotes in the 
mouse spleen (chapter IV). We hypothesize that neutrophils and macrophages, host cells 
known to generate high amounts of toxic oxidants, are responsible for the early 
containment of L.infantum. In fact, it has been described that neutrophils contribute to the 
early restraint of L.infantum [130] and L.donovani [128,129] infection and to the 
establishment of a protective Th1 immune response [128] in the mouse spleen. Moreover, 
they can also assist infected macrophages to produce O2•- and NO• and consequently kill 
L.major [124], L.infantum and L.braziliensis [132]. Although ROS were important to 
regulate the initial extent of L.infantum replication, the infection in the mouse spleen still 
progressed (chapter IV). This means that several parasites either survive the early 
respiratory burst or barely activate the NADPH oxidase of certain phagocyte populations 
in this organ. The latter situation is supported by the fact that the levels of ROS generated 
as well as the proportion of infected cells producing detectable oxidants are reduced in 
human monocytes phagocytosing non-opsonized as opposed to opsonized L.infantum 
promastigotes [208]. Indeed, the spleen is a site of parasite persistency that becomes 
chronically infected in VL [120,121,163]. 
In contrast to what was observed in the spleen, ROS seem to control L.infantum in 
the liver at late stages of infection (chapter IV). The mouse liver permits an early and rapid 
proliferation of visceral Leishmania but spontaneously controls infection by forming 
cellular infiltrates around parasitized resident macrophages (Kupffer cells) [120,121,163]. 
Within these structures, known as granulomas, infected Kupffer cells are presumably 
activated to kill amastigotes via generation of ROS and RNS [163]. We propose that 
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Kupffer cells - which are poor producers of ROS when cultured in vitro [426] - or recruited 
blood monocytes only release ROS to eliminate L.infantum amastigotes when the 
granuloma fully matures and the required activating stimuli are present [165]. Though the 
assembly of granulomas is not a synchronized process, they become functionally and 
structurally mature during the progression from the acute to the chronic stage of infection 
with visceralizing Leishmania [163,165], which agrees with our hypothesis. Alternatively, 
neutrophils could also be recruited to granulomas at late infection stages to aid in the 
control of infection. Notably, the late influx of neutrophils into the skin lesions of 
L.amazonensis [204] and L.major [152] susceptible mice has been described as a process 
governed by IL-17 [152]. However, neutrophils do not appear to be involved in the 
containment of L.infantum in the liver [130].  
A pertinent finding was the fact that NOS2 was not critical to contain the growth of 
L.infantum in the liver and spleen. We also showed that the expression of NOS2 protein 
was not related to protection against L.infantum infection, since both wild-type and 
NADPH oxidase-deficient mice developed gradual splenic infection in the face of a 
prominent NOS2 expression (chapter IV). The latter observation has also been made in 
the spleen of mice chronically infected with L.major [214], L.infantum [121] and L.donovani 
[378] or in the lesions of mice parasitized by L.amazonensis [204]. Moreover, we detected 
higher NOS2 expression in the spleen of NADPH oxidase-deficient mice than in the wild-
type mice, probably to compensate for the deficiency in NADPH oxidase (chapter IV). In 
fact, it has been previously reported that compensatory mechanisms can arise in other 
gene-disrupted mice infected with Leishmania [165]. Overall, these results raise the 
possibility that our strain of L.infantum may be resistant to the lethal effects of RNS. 
Several NO•-resistant strains of L.infantum [227], L.amazonensis and L.braziliensis [226] 
have been isolated from infected humans. Both naturally [227] and experimentally-
induced [201] NO•-resistant L.infantum displayed enhanced infectivity and ability to 
survive or replicate inside macrophages. Although axenic amastigotes of L.infantum, 
L.amazonensis and L.mexicana are susceptible to the action of RNS [199,204], tissue 
amastigotes may exhibit enhanced antioxidant defense and resistance to RNS toxicity. In 
this respect, L.infantum possesses three cytosolic 2-cysteine peroxiredoxins, one of which 
was reported to be predominantly expressed in the amastigote stage [427], that is capable 
of detoxifying NO• and ONOO- [246]. Moreover, it has been proposed that amastigotes 
resist NO• toxicity by overexpressing metabolic enzymes that can act as NO• scavengers, 
such as aconitase and glyceraldehyde-3-phosphate dehydrogenase [428]. Interestingly, a 
NOS enzyme has also been isolated from L.donovani promastigotes, reinforcing that this 
parasite might have mechanisms to detoxify endogenously produced NO• that could also 
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offer resistance against NO• generated by the host cell [250]. Another possible 
explanation for our results may be the capacity of L.infantum to locally supress the 
expression of NOS2. Indeed, we observed a few infected cells in the liver tissue that were 
not expressing NOS2 (data not shown). Nevertheless, we cannot exclude the possibility 
that NOS2 had not yet been activated in those parasitized cells or that the infected cells 
were not macrophages and hence did not express NOS2. It is well documented that 
Leishmania can also infect cell types devoid of direct antimicrobial capacity, which 
function as safe targets particularly during late stages of infection [411]. 
 
2.2. In vivo control of other Leishmania species by ROS and RNS 
The role of ROS and RNS in the restraint of infection caused by visceralizing 
Leishmania species in mouse models is quite controversial. A prior report demonstrated 
that both NADPH oxidase and NOS2 acted in concert to control early L.donovani 
replication in the liver, whereas NOS2 alone was sufficient to resolve late infection [166]. 
In contrast, a subsequent study showed that these antimicrobial mechanisms had no 
influence on the outcome of L.donovani infection in the liver, though NOS2 exerted 
moderate protective effects in the spleen at late phases of infection [223]. Our work clearly 
establishes that NADPH oxidase, not NOS2, mediates the control of L.infantum infection 
in the mouse tissues. The incongruities between these studies might be due to several 
reasons. First, L.donovani and L.infantum might have distinct intrinsic vulnerabilities to the 
levels and type of ROS and RNS generated by the mouse cells. Second, we infected mice 
with L.infantum promastigotes, whereas the other works used the L.donovani amastigote 
life stage, known to scarcely elicit the oxidative burst of macrophages [188,191,205,209]. 
Third, the genetic background of mice differed between these studies.  
Noteworthy is the fact that resolution of cutaneous lesions caused by L.guyanensis 
also depends solely on the induction of a strong respiratory burst by NADPH oxidase 
[195,217]. This is in contrast to what is observed in most other mouse models of CL. The 
healing of lesions and long-term containment of persisting parasites correlate intimately 
with the expression of NOS2 in the L.major [196,213,214,218,219,220,221], 
L.amazonensis [204] and L.braziliensis [222] mouse models. Unlike NOS2, NADPH 
oxidase is not required to control L.amazonensis [217] or L.braziliensis [222] infections. 
However, its activity is required to clear L.major from the spleen and to prevent late 
parasite visceralization [214]. Hence, the containment of Leishmania by NOS2 and 
NADPH oxidase in vivo may be organ- and infection stage-specific. 
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2.3. Factors influencing the in vivo control of Leishmania by ROS and RNS 
Lastly, several parameters, apart from parasite species, may dictate the influence of 
NADPH oxidase and NOS2 on the control of Leishmania infections. These include the 
parasite strain, inoculum dose and administration route as well as the infected host. We 
are now planning to ascertain the sensitivities to ROS and RNS of distinct L.infantum 
strains in the mouse model. This seems a pertinent step in our research, given that 
L.infantum strains with different virulence phenotypes elicit different humoral and cellular 
immune responses in the mouse [429,430]. We cannot, however, avoid mentioning that 
the mouse model may not reflect the contribution of ROS and RNS to the control of 
L.infantum in naturally infected hosts. It has been described that neutrophils and 
monocytes derived from L.infantum-infected dogs exhibit impaired respiratory burst and 
leishmanicidal capacity in relation to non-infected dogs [431,432], effects that may be 
attributed to LPG [433] and reversed by IFNγ activation [434]. Moreover, some studies 
suggest that L.infantum may resist RNS toxicity or supress NOS2 expression by dog 
macrophages. Both high [435] and negligible [436] NOS2 expression in the tissues of 
L.infantum-infected dogs appears to correlate with disease severity and high parasite 
loads. Furthermore, co-culture of lymphocytes and macrophages derived from infected 
dogs inhibits the macrophagic production of NO• in response to re-infection with 
L.infantum [437]. Nevertheless, the NOS2-mediated leishmanicidal activity of dog 
macrophages [438,439] can be re-established in vivo through dog vaccination [216] or 
chemotherapy [440].  
To summarize, a better understanding of the host mechanisms of resistance to 
L.infantum may open novel therapeutic avenues for intervention in VL. We have found 
that ROS, but not RNS, are pivotal for the control of L.infantum in the mouse tissues. In 
this connection, improving drugs that act by inducing the production of pernicious ROS in 
target pathogens, such as PQ and other 8-AQs [79], may be a valuable strategy to 
develop new chemotherapeutics for the treatment of infections caused by L.infantum. 
 
3. VL treatment: potential of PQ-derived compounds as therapeutic agents 
The treatment of VL is particularly challenging because several of the currently 
available chemotherapeutics exhibit high toxicity, require prolonged and often painful 
treatment regiments, are expensive and their efficacy is variable and hindered by parasite 
resistance. For these reasons, alternative drugs devoid of such disadvantages are 
urgently required to treat VL [13,21,38,441]. To respond to such demands, recent efforts 
have been focused on the rational modification of pre-existing anti-parasitic drugs, such 
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as PQ. The modification of the PQ scaffold has already led to the discovery of new 8-AQs 
with potent anti-leishmanial activities, such as NPC1161B [81], tafenoquine [80] and 
sitamaquine [78,81]. However, the first two drugs have yet no applicability in the clinical 
scenario and the latter has been correlated with adverse side effects [63,64,65,66,67]. 
Moreover, the screening of several chemical libraries, using an ex vivo splenic explant 
culture system from hamsters infected with L.donovani, revealed that the most frequently 
identified leads with both anti-leishmanial activity and low toxicity were quinolinic 
compounds, including 2-, 4- and 8-AQs [442]. This highlights the importance for the 
continuous design of new PQ-derived compounds as anti-leishmanial agents.  
 
3.1. Modification of PQ side chain as a strategy to improve its anti-leishmanial 
activity: imidazolidin-4-one and ferrocene moieties 
By protecting PQ’s terminal aliphatic amine with a dipeptide, a peptidomimetic 
(imidazolidin-4-one) or an organometallic (ferrocene, Fc) moiety, we intended to possibly 
avoid the oxidative deamination of PQ and increase its anti-leishmanial activity. Increased 
anti-leishmanial and decreased in vitro hematotoxicity, has actually been accomplished by 
attaching an amino acid residue to the PQ’s side chain amino group together with the 
placement of a bulky 2-tert-butyl group at the C-2 of the quinoline ring [73]. We found that 
the conjugation of an imidazolidin-4-one (3c) and a ferrocene (7a), but not a dipeptide, 
moiety to PQ improved its activity against the intramacrophagic amastigote stage of 
L.infantum. Notably, the most active compounds, 3c and 7a, exhibited lower cytotoxicity 
towards host cells than VL reference drugs sitamaquine and miltefosine (chapter V).  
Our experimental approach to dissect the possible anti-L.infantum activity of PQ 
derivatives consisted in the selection of the most active compounds against promastigotes 
to next test them towards intramacrophagic amastigotes. Of all the dipeptide and 
peptidomimetic derivatives of PQ tested, only peptidomimetic 3c and dipeptide 4c 
revealed activity similar to the parent drug against promastigotes, whereas most other 
compounds were inactive (chapter V). Both 3c and 4c contain a valine residue at the end 
of the its side chain, which may be related to their anti-leishmanial activity against 
L.infantum promastigotes. All other amino acid residues did not seem to be beneficial for 
the activity of PQ against this stage of the parasite. Nevertheless, the behaviour of 3c and 
4c was completely different in the intramacrophagic amastigote stage. The former 
displayed activity superior to PQ and comparable to sitamaquine, whereas the latter was 
completely inactive. Several reasons may account for this fact. Firstly, the internalization, 
metabolism or efflux of both compounds might differ between the promastigote and 
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amastigote stages of L.infantum. Secondly, 3c might have been internalized to a higher 
extent than 4c by the macrophage. Thirdly, even if the entry into the macrophage 
occurred to the same extent, they might have been differently metabolized by the 
macrophage. It is possible that 4c might have been more easily degraded by proteases 
present in the PV. In fact, it has been determined that PQ-derived imidazolidin-4-ones like 
3c, but not dipeptides like 4c, display higher enzymatic stability in vitro [383]. This 
hypothesis is, however, unlikely because proteolytic digestion of 4c would cause cleavage 
of the dipeptide group to yield PQ and therefore, 4c would expectedly exhibit activity at 
least close to PQ, which was not verified (chapter V). Alternatively, 3c may have been 
transformed into a compound that is more toxic to L.infantum than PQ, and/or 4c might 
have been converted to an inactive compound. Fourthly, the absence of activity of 4c 
might be caused by its externalization by the action of macrophage efflux pumps with 
affinity for dipeptides, as is the case of peptide/histidine transporters 1 and 2 [387]. By 
contrast, 3c would be allowed to accumulate inside the macrophage because these efflux 
systems would not recognize its imidazolidin-4-one moiety. Finally, we cannot exclude the 
hypothesis that 4c is a slow-acting compound and that a longer incubation with infected 
macrophages would permit the expression of anti-leishmanial activity. 
The fact that iron potentiates the leishmanicidal activity of several drugs [364,382], 
exerts toxicity towards axenic cultures of L.infantum promastigotes and amastigotes and 
that the host’s iron overload protects mice against L.infantum visceral infection (chapter 
III), led us to investigate the activity of Fc derivatives of PQ against this parasite. Contrary 
to what was observed with the dipeptidic and peptidomimetics, we found several 
organometallics (5, 6 and 8) with better performance than PQ against promastigotes 
(chapter V). The activity of PQ was slightly improved by the attachment of a Fc group to 
its terminal aliphatic amine (5). However, the insertion of a distinct amino acid residue 
between PQ and Fc, as in 7a-h, led to loss of activity. Notably, the introduction of a 6-
carbon chain between PQ and Fc, to give 6, caused a very pronounced increase in 
activity. In fact, compound 6 was the most effective of the organometallic derivatives, 
being more active than sitamaquine and miltefosine. We hypothesize that the 6-
hydrocarbon chain might have increased the lipophilicity of 6, which in turn could have 
favored its transport across the promastigote membrane, though we have not proven this 
experimentally. It is known that the lipophilicity of sitamaquine, which possesses a 6-
carbon side chain directly attached to the heteroaromatic core of PQ, is a pivotal feature 
for crossing promastigote membranes [68,69,384]. However, compound 10, which has the 
same hexylFc group as 6, but attached to the heteroaromatic core of PQ instead of being 
linked to the PQ’s terminal aliphatic amine group, does not display activity against 
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promastigotes. Possibly, the lack of the terminal aliphatic amino group in 10, which is 
present in PQ, 6 and in sitamaquine, led to complete loss of anti-leishmanial activity. 
Finally, the attachment of an imidazolidin-4-one and a Fc group (in this order) to the PQ’s 
terminal aliphatic amino group led to compound 8, the second most active organometallic 
against L.infantum promastigotes, reinforcing that both structural modifications have a 
beneficial anti-leishmanial effect.  
The most active and non-toxic organometallic derivatives of PQ, 5 and 8, were 
further tested for activity against intramacrophagic amastigotes, except compound 6 that 
displayed high cytotoxicity towards macrophages. Compound 7a, though inactive against 
promastigotes, was also selected for such studies, since 7a represents the precursor of 
compound 8 where an additional cyclization step introduced an imidazolidin-4-one group. 
We found that the activity of 8, but not that of 5, against promastigotes was confirmed on 
the intramacrophagic amastigote stage. Moreover, we verified that 7a had significantly 
higher activity than PQ against amastigotes, contrary to what was observed in the 
promastigote stage. These results suggest that the activity of 5 and 7a is either parasite 
stage-specific or influenced by the macrophage metabolism. In addition, the fact that 7a 
was more active than 8 indicated that the imidazolidin-4-one moiety was not crucial for the 
intramacrophagic activity of the organometallic PQ derivatives. Perhaps, the presence of 
an imidazolidin-4-one together with a Fc group in 8, but not 7a, may yield an excessively 
bulky or rigid structure than does not easily enter the macrophage and/or the amastigote. 
On the other hand, the glycine residue present between PQ and the Fc moiety in 7a 
seems important for activity against amastigotes, as its absence in 5 led to a complete 
loss of activity. Hence, it is possible that other amino acid residues linking PQ to Fc, as in 
7b-h, may have potential activity against the intramacrophagic stage of the parasite, a 
subject left to explore in the future. 
 
3.2. Screening for anti-leishmanial drugs: intramacrophagic amastigote assay 
We now recognize that selecting the most effective drugs on the promastigote stage 
may not be the most adequate procedure, since the activity of a drug candidate towards 
the promastigote stage may not be reflected in the intramacrophagic amastigote stage. 
This was clearly demonstrated by the distinct behaviour of 4c, 5 and 7a between both 
parasite stages (chapter V). In support of this notion is the fact that half of the compounds 
present in a large library of kinase and phosphatase inhibitors, which were active against 
intramacrophagic amastigotes, were not active against promastigotes of L.donovani [443]. 
We performed drug screening against promastigotes growing in culture medium as it is a 
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simple, rapid and inexpensive technique that requires minute amounts of test compound. 
However, this methodology has been gradually dismissed because the metabolic 
pathways may significantly differ between both parasite stages and because it does not 
assess drug internalization, metabolism and efflux by the host cell [444,445]. Conversely, 
drug screening against amastigotes growing inside macrophages (primary or cell lines) is 
more likely to reproduce the parasite environment in an infected host. Although the latter 
methodology allows the evaluation of drug toxicity towards the parasite and the host cell, it 
holds several limitations. Drug sensitivity may vary accordingly to the species/ strain from 
which the host cell was isolated and the drug effect on parasite growth may be 
confounded by replication of the host cell line [445]. Furthermore, direct counting of 
stained intracellular amastigotes, as performed in our study (chapter V), is time 
consuming, labour intensive, incompatible with the screening of high numbers of 
compounds and requires technical expertise. Relevantly, the recent engineering of 
recombinant parasites carrying a reporter gene - either as an episomal copy or after its 
integration in a defined locus (green fluorescent protein, β-galactosidase, β-lactamase or 
luciferase) - has permitted the objective analysis of drugs in large-scale, with considerable 
sensitivity, reproducibility, rapidity and simplicity [442,444,445]. Some caution must, 
nevertheless, be taken when using these methods for several reasons. First, the antibiotic 
resistance marker may confer cross-resistance to the test drug. Second, the engineering 
procedure may disrupt the genomic architecture and interfere with ordinary biological 
processes. Third, the reporter may have variable sensitivity and be masked by the 
background activity of the host cell. Fourth, the expression of the reporter gene may 
depend on the copy number of the transfected plasmid and not on the activity of the drug 
itself [444,445]. Finally, we propose that the future evaluation of activity of PQ derivatives 
(and other classes of compounds) should be performed exclusively in the 
intramacrophagic amastigote stage, using the robust reporter gene technology described.  
 
3.3. In vivo studies on the efficacy, stability and toxicity of PQ derivatives    
Our goal for the future is to ascertain the in vivo efficacy, stability and toxicity of PQ-
derivatives 3c and 7a. In fact, we have initiated the assessment of the efficacy of 3c in a 
mouse model of VL. A pilot experiment revealed that 3c was as effective as PQ at 
decreasing the hepatic parasite burden (51.6% versus 41.8%) when administered in low 
doses (116.5 nmol/mouse/day for 21 days), without indications of toxicity (data not 
shown). Notably, we have also obtained experimental evidence that peptidomimetic 
derivatives of PQ, such as 3c, have lower tendency than PQ to undergo metabolic 
transformation mediated by rat liver enzymes [383]. Hence, these preliminary data 
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indicate that at least PQ peptidomimetics exhibit in vivo anti-L.infantum activity, low 
toxicity and superior stability than the parent drug. We now intend to explore the effect of 
escalating doses of 3c and 7a in short courses by oral administration to the mouse, as 
these compounds were developed to potentially improve the oral bioavailability (and 
hence the activity) of PQ. The testing of promising leads in animal models is important as 
it enables the determination of compound activity in relation to absorption, distribution, 
metabolism and excretion and gives an early estimation of toxicity [445]. Of note, the 
identification of compounds that act as pro-drugs or through the host’s immune system 
probably will only be clearly identified in animal models that can reproduce the 
immunological responses and pathological features of human VL [442,445].  
 
3.4. Mechanism of action of PQ and its analogues 
The mode of action of most leishmanicidal drugs is scarcely known [38,39,50]. 
Certainly, the unravelling of the mechanism of anti-leishmanial activity for peptidomimetic 
(3c) and organometallic (7a) derivatives of PQ would contribute to the rational 
optimization of their structure in order to obtain new and more potent analogues. We 
speculate that they might act in a similar way to PQ and other structurally related 8-AQs. 
Sitamaquine crosses L.donovani promastigote plasma membrane via electrostatic and 
hydrophobic interactions with phospholipids [68,69]. It was initially postulated, but recently 
discredited [70], that sitamaquine’s lethal action was related to its accumulation in and 
alkalization of the acidocalcisomes of L.donovani promastigotes [40]. More convincing is 
the fact that sitamaquine [42,71] and tafenoquine [95] inhibit the activity of mitochondrial 
succinate dehydrogenase and cytochrome c reductase, respectively. In turn, this triggers 
the generation of ROS that culminates in an apoptotic-like death of L.donovani 
promastigotes. Though the anti-leishmanial mode of action of PQ has never been 
reported, it is likely that PQ (and the derivatives tested in this work) also targets the 
mitochondrial electron transport chain and/or favours the formation of ROS, as occurs in 
Plasmodium, T.cruzi and P.jirovecii [79]. Overall, PQ and its 8-AQ analogues appear to 
act by inducing oxidative stress in Leishmania. Relevantly, we have shown that ROS are 
involved in the control of L.infantum growth in vivo (chapter IV), which reinforces that 
drugs that act by inducing oxidative stress may be valuable against L.infantum. 
Furthermore, the anti-leishmanial activity of PQ and its derivatives is probably enhanced 
by conjugation to a Fc moiety, given that the Fe2+ present in this structure catalyses the 
generation of HO• via a Fenton-like reaction in vitro [93]. In fact, iron can positively 
influence the anti-leishmanial activity of unrelated drugs. Iron potentiates the 
leishmanicidal activity of the anti-malarial drug artemisinin [382] or the metalloids arsenic 
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(III) and antimony (III) [364], by inducing oxidative injury that culminates in an apoptotic-
like cell death of L.donovani promastigotes. Thus, we can infer that strategies intended to 
augment the intracellular iron levels of Leishmania, like the inclusion of a Fc moiety into a 
drug, might increase the sensitivity of the parasite to chemotherapy. Supporting this 
contention is the fact that mice with elevated iron status are more resistant to L.major 
[350,351,352] and L.infantum (chapter III), which is related to an enhanced generation of 
ROS pernicious to the parasite. Lastly, our compounds might also display immune-
activating properties, as it has been described that macrophages secrete pro-
inflammatory cytokines in response to stimulation with imidazoquinolines via the toll-like 
receptor 7-MyD88-dependent signalling cascade [446].  
  
3.5. Improvement of PQ peptidomimetic and organometallic derivatives 
In sum, we have found one peptidomimetic (3c) and one organometallic (7a) 
derivative of PQ to be active against the intramacrophagic amastigote form of L.infantum 
that did not display apparent toxicity to the host cell. Therefore, we propose that these 
derivatives might be good scaffolds for the development of efficacious and safer PQ-
based anti-leishmanials. We envision that introduction of substituents at the quinoline ring 
of 3c or 7a may further improve their anti-leishmanial action, while keeping their safety. 
For instance, the insertion of a 2-tert-butyl group together with a 3-trifluoromethylphenoxy 
group at the C-2 and C-5 positions of the PQ quinoline ring, respectively, has greatly 
improved the activity of PQ against L.donovani promastigotes, while maintaining its safety 
[447]. It may also be worthy to explore the effect of incorporating the substituents 3-
trifluoromethylphenoxy, 3,4-dichlorophenoxy or prop-2-en-1-ol into the C-5 or C-2 
positions of the quinoline ring of our PQ derivatives. In fact, these groups are present in 
tafenoquine [80], NPC1161B [81] and 2-quinoline [448], respectively, which are oral 
agents with potent in vivo anti-leishmanial activity and limited toxicity.  
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Chapter VII | Concluding Remarks 
 
The main conclusions resulting from the work disclosed in this thesis were the 
following: 
1| While dietary iron deficiency did not affect L.infantum growth, iron overload 
inhibited its replication in the host tissues likely via interaction with ROS and RNS. 
Furthermore, iron exerted direct inhibitory action, in a dose dependent fashion, towards 
axenic cultures of L.infantum promastigotes and amastigotes (chapter III). 
2| The phagocyte NADPH oxidase, not NOS2, seems to be the critical host effector 
mechanism involved in the control of L.infantum in vivo (chapter IV). 
3| The screening of several derivatives of PQ, an 8-AQ drug with modest anti-
leishmanial activity, revealed a peptidomimetic (imidazolidin-4-one) and an organometallic 
(ferrocene) derivative which were active against the clinically relevant intramacrophagic 
amastigote stage of L.infantum, while displaying less cytotoxicity towards macrophages 
than VL reference drugs (chapter V). 
 
With this work, we intended to contribute to a better understanding of the host 
mechanisms that govern resistance to Leishmania and to the development of more 
efficacious and safer chemotherapeutics to treat infections caused by these protozoa. 
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